{"PMC7161868": [["IntroductionAcyclic analogs of nucleosides belong to the most important class of compounds showing antiviral and antitumor activities 1, 2.", [["antitumor", "ANATOMY", 113, 122], ["nucleosides", "CHEMICAL", 31, 42], ["nucleosides", "CHEMICAL", 31, 42], ["nucleosides", "SIMPLE_CHEMICAL", 31, 42], ["antitumor", "CANCER", 113, 122], ["IntroductionAcyclic analogs of nucleosides", "TREATMENT", 0, 42], ["antiviral and antitumor activities", "TREATMENT", 99, 133]]], ["Among them, acyclovir and penciclovir exhibit activity against herpes viruses including HSV\u20101, HSV\u20102, VZV, hepatitis B virus (HBV) 3, 4, 5, 6, 7, while ganciclovir 7, 8, 9, 10 and valganciclovir \u2212 its prodrug with significantly improved oral bioavailability 10, 11, 12 \u2212 are commonly used as anti\u2010cytomegalovirus agents.", [["oral", "ANATOMY", 237, 241], ["acyclovir", "CHEMICAL", 12, 21], ["penciclovir", "CHEMICAL", 26, 37], ["herpes viruses", "DISEASE", 63, 77], ["hepatitis B", "DISEASE", 107, 118], ["ganciclovir", "CHEMICAL", 152, 163], ["7, 8, 9, 10 and valganciclovir \u2212 its prodrug", "CHEMICAL", 164, 208], ["acyclovir", "CHEMICAL", 12, 21], ["penciclovir", "CHEMICAL", 26, 37], ["ganciclovir", "CHEMICAL", 152, 163], ["valganciclovir", "CHEMICAL", 180, 194], ["acyclovir", "SIMPLE_CHEMICAL", 12, 21], ["penciclovir", "SIMPLE_CHEMICAL", 26, 37], ["herpes viruses", "ORGANISM", 63, 77], ["HSV\u20101", "ORGANISM", 88, 93], ["HSV\u20102", "ORGANISM", 95, 100], ["VZV,", "ORGANISM", 102, 106], ["hepatitis B virus", "ORGANISM", 107, 124], ["HBV) 3", "ORGANISM", 126, 132], ["ganciclovir", "SIMPLE_CHEMICAL", 152, 163], ["valganciclovir", "SIMPLE_CHEMICAL", 180, 194], ["prodrug", "SIMPLE_CHEMICAL", 201, 208], ["oral", "ORGANISM_SUBDIVISION", 237, 241], ["anti\u2010cytomegalovirus agents", "SIMPLE_CHEMICAL", 292, 319], ["hepatitis B virus", "SPECIES", 107, 124], ["HSV\u20101", "SPECIES", 88, 93], ["HSV", "SPECIES", 95, 98], ["VZV", "SPECIES", 102, 105], ["hepatitis B virus", "SPECIES", 107, 124], ["HBV", "SPECIES", 126, 129], ["acyclovir", "TREATMENT", 12, 21], ["penciclovir", "TREATMENT", 26, 37], ["herpes viruses", "PROBLEM", 63, 77], ["HSV", "TEST", 88, 91], ["HSV", "TEST", 95, 98], ["VZV", "PROBLEM", 102, 105], ["hepatitis B virus (HBV)", "TREATMENT", 107, 130], ["ganciclovir", "TREATMENT", 152, 163], ["valganciclovir", "TREATMENT", 180, 194], ["anti\u2010cytomegalovirus agents", "TREATMENT", 292, 319]]], ["However, in most cases, the clinical applications of nucleosides are limited due to the observed side effects.", [["nucleosides", "CHEMICAL", 53, 64], ["nucleosides", "CHEMICAL", 53, 64], ["nucleosides", "SIMPLE_CHEMICAL", 53, 64], ["nucleosides", "TREATMENT", 53, 64], ["the observed side effects", "PROBLEM", 84, 109]]], ["In addition, an important problem in treatment of viral infections is the emergence of drug\u2010resistant mutant viruses.", [["viral infections", "DISEASE", 50, 66], ["drug\u2010resistant mutant viruses", "ORGANISM", 87, 116], ["viral infections", "PROBLEM", 50, 66], ["drug\u2010resistant mutant viruses", "PROBLEM", 87, 116], ["viral", "OBSERVATION_MODIFIER", 50, 55], ["infections", "OBSERVATION", 56, 66], ["mutant viruses", "OBSERVATION", 102, 116]]], ["For this reason, the search for new antiviral compounds with improved activity has been continuing for decades.", [["new antiviral compounds", "TREATMENT", 32, 55]]], ["This is not limited to modifications of aliphatic chains, but also includes the introduction of additional groups into the structure of nucleosides with well\u2010documented biological activity.", [["nucleosides", "CHEMICAL", 136, 147], ["nucleosides", "CHEMICAL", 136, 147], ["nucleosides", "SIMPLE_CHEMICAL", 136, 147], ["modifications of aliphatic chains", "PROBLEM", 23, 56], ["nucleosides", "TREATMENT", 136, 147], ["not limited to", "UNCERTAINTY", 8, 22], ["aliphatic chains", "OBSERVATION", 40, 56]]], ["Since the 1,2,3\u2010triazole moiety has been recognized as bioisosteric with the amide function 13, 14, the incorporation of this structural motive has been widely applied and resulted in a broad spectrum of pharmaceutically important molecules.", [["\u2010triazole", "CHEMICAL", 15, 24], ["1,2,3\u2010triazole", "CHEMICAL", 10, 24], ["amide", "CHEMICAL", 77, 82], ["1,2,3\u2010triazole moiety", "SIMPLE_CHEMICAL", 10, 31], ["the 1,2,3\u2010triazole moiety", "TREATMENT", 6, 31], ["the amide function", "TEST", 73, 91], ["pharmaceutically", "OBSERVATION_MODIFIER", 204, 220], ["important molecules", "OBSERVATION", 221, 240]]], ["Furthermore, 1,2,3\u2010triazoles are able to form hydrogen bonds, they are not protonated at the physiological pH, and are also stable to oxidation and reduction as well as to many enzymatic reactions 15.", [["\u2010triazoles", "CHEMICAL", 18, 28], ["1,2,3\u2010triazoles", "CHEMICAL", 13, 28], ["hydrogen", "CHEMICAL", 46, 54], ["1,2,3\u2010triazoles", "SIMPLE_CHEMICAL", 13, 28], ["hydrogen bonds", "SIMPLE_CHEMICAL", 46, 60], ["\u2010triazoles", "TREATMENT", 18, 28], ["many enzymatic reactions", "PROBLEM", 172, 196], ["stable", "OBSERVATION_MODIFIER", 124, 130]]], ["Several compounds of the 1,2,3\u2010triazole family have exhibited a broad spectrum of biological activities, such as anti\u2010inflammatory 16, 17, anticonvulsants 18, antiviral 19, 20, 21, 22, 23, anticancer 24, 25, 26, 27, antimicrobial agents 28, 29, 30, as well as \u03b2\u2010lactamase inhibitors 31 and dopamine D2 receptor ligands related to schizophrenia 32.", [["\u2010triazole", "CHEMICAL", 30, 39], ["dopamine", "CHEMICAL", 290, 298], ["schizophrenia", "DISEASE", 330, 343], ["1,2,3\u2010triazole", "CHEMICAL", 25, 39], ["dopamine", "CHEMICAL", 290, 298], ["1,2,3\u2010triazole", "SIMPLE_CHEMICAL", 25, 39], ["anticancer", "CANCER", 189, 199], ["\u03b2\u2010lactamase inhibitors 31", "SIMPLE_CHEMICAL", 260, 285], ["dopamine D2 receptor", "GENE_OR_GENE_PRODUCT", 290, 310], ["anti\u2010inflammatory", "TEST", 113, 130], ["anticonvulsants", "TREATMENT", 139, 154], ["antiviral", "TREATMENT", 159, 168], ["anticancer", "TEST", 189, 199], ["antimicrobial agents", "TEST", 216, 236], ["\u03b2\u2010lactamase inhibitors", "TREATMENT", 260, 282], ["dopamine D2 receptor ligands", "TREATMENT", 290, 318], ["schizophrenia", "PROBLEM", 330, 343], ["schizophrenia", "OBSERVATION", 330, 343]]], ["Since 1997, when the first acyclic 1,2,3\u2010triazolenucleosides have been obtained by Lazrek et al. 33, 34, many efforts have been made by several research groups to synthesize more potent antiviral and anticancer nucleoside analogs having both natural and modified nucleobases (Fig. 1) 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49.IntroductionAmong various heterocyclic moieties that would serve as modified nucleobase mimetics, substituted quinazoline\u20102,4\u2010diones are of special interest.", [["anticancer", "ANATOMY", 200, 210], ["\u2010triazolenucleosides", "CHEMICAL", 40, 60], ["nucleoside", "CHEMICAL", 211, 221], ["quinazoline\u20102,4\u2010diones", "CHEMICAL", 453, 475], ["acyclic 1,2,3\u2010triazolenucleosides", "CHEMICAL", 27, 60], ["nucleoside", "CHEMICAL", 211, 221], ["nucleobases", "CHEMICAL", 263, 274], ["quinazoline\u20102,4\u2010diones", "CHEMICAL", 453, 475], ["acyclic 1,2,3\u2010triazolenucleosides", "SIMPLE_CHEMICAL", 27, 60], ["anticancer nucleoside analogs", "SIMPLE_CHEMICAL", 200, 229], ["substituted quinazoline\u20102,4\u2010diones", "SIMPLE_CHEMICAL", 441, 475], ["the first acyclic 1,2,3\u2010triazolenucleosides", "TREATMENT", 17, 60], ["anticancer nucleoside analogs", "TREATMENT", 200, 229], ["various heterocyclic moieties", "TREATMENT", 361, 390], ["modified nucleobase mimetics", "TREATMENT", 411, 439], ["substituted quinazoline", "TREATMENT", 441, 464]]], ["This structural motive was successfully attached to various biologically active compounds to provide even more active hybrids (Fig. 2) 50, 51, 52, 53, 54, 55, 56.IntroductionIn continuation of our involvement in the search for new biologically active acyclic nucleoside analogs 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, a new series of 1,2,3\u2010triazole nucleosides containing the substituted quinazoline\u20102,4\u2010dione at C4 was designed (compounds 32\u201337, Scheme 1).", [["nucleoside", "CHEMICAL", 259, 269], ["1,2,3\u2010triazole nucleosides", "CHEMICAL", 334, 360], ["quinazoline\u20102,4\u2010dione", "CHEMICAL", 388, 409], ["acyclic nucleoside", "CHEMICAL", 251, 269], ["1,2,3\u2010triazole nucleosides", "CHEMICAL", 334, 360], ["quinazoline", "CHEMICAL", 388, 399], ["2,4\u2010dione", "CHEMICAL", 400, 409], ["hybrids", "CELL", 118, 125], ["acyclic nucleoside", "SIMPLE_CHEMICAL", 251, 269], ["1,2,3\u2010triazole nucleosides", "SIMPLE_CHEMICAL", 334, 360], ["quinazoline\u20102,4\u2010dione", "SIMPLE_CHEMICAL", 388, 409], ["C4", "SIMPLE_CHEMICAL", 413, 415], ["a new series", "TEST", 318, 330], ["1,2,3\u2010triazole nucleosides", "TREATMENT", 334, 360], ["the substituted quinazoline", "TREATMENT", 372, 399]]], ["Based on the previous observations on analogous heterocyclic conjugates 24\u201326 synthesized in our research group (Fig. 3) 57, 58, 67, functionalized benzyl and benzoyl groups were carefully selected as suitable substituents to be attached at C3 in the quinazolinone\u20102,4\u2010dione framework.", [["24\u201326", "CHEMICAL", 72, 77], ["benzyl", "CHEMICAL", 148, 154], ["benzoyl", "CHEMICAL", 159, 166], ["quinazolinone", "CHEMICAL", 251, 264], ["benzyl", "CHEMICAL", 148, 154], ["benzoyl", "CHEMICAL", 159, 166], ["quinazolinone", "CHEMICAL", 251, 264], ["2,4\u2010dione", "CHEMICAL", 265, 274], ["benzyl", "SIMPLE_CHEMICAL", 148, 154], ["benzoyl groups", "SIMPLE_CHEMICAL", 159, 173], ["quinazolinone\u20102,4\u2010dione", "SIMPLE_CHEMICAL", 251, 274], ["analogous heterocyclic conjugates", "TEST", 38, 71], ["functionalized benzyl and benzoyl groups", "TREATMENT", 133, 173], ["suitable substituents", "TREATMENT", 201, 222]]], ["The synthetic strategy for our new series 1,2,3\u2010triazolenucleosides is presented in Scheme 1.Chemistry ::: Results and discussionThe starting 3\u2010azidopropanol 27 was prepared from 3\u2010chloropropanol in 90% yield according to the literature procedure 68.", [["1,2,3\u2010triazolenucleosides", "CHEMICAL", 42, 67], ["3\u2010azidopropanol", "CHEMICAL", 142, 157], ["chloropropanol", "CHEMICAL", 181, 195], ["1,2,3\u2010triazolenucleosides", "CHEMICAL", 42, 67], ["3\u2010azidopropanol 27", "CHEMICAL", 142, 160], ["3\u2010chloropropanol", "CHEMICAL", 179, 195], ["1,2,3\u2010triazolenucleosides", "SIMPLE_CHEMICAL", 42, 67], ["3\u2010azidopropanol 27", "SIMPLE_CHEMICAL", 142, 160], ["3\u2010chloropropanol", "SIMPLE_CHEMICAL", 179, 195], ["our new series", "TEST", 27, 41], ["\u2010triazolenucleosides", "TREATMENT", 47, 67], ["The starting 3\u2010azidopropanol", "TREATMENT", 129, 157], ["chloropropanol", "TREATMENT", 181, 195]]], ["Reaction of 3\u2010azidopropanol 27 with benzyl bromide gave 28 in 80% yield 69, 70.", [["3\u2010azidopropanol 27", "CHEMICAL", 12, 30], ["benzyl bromide", "CHEMICAL", 36, 50], ["3\u2010azidopropanol", "CHEMICAL", 12, 27], ["benzyl bromide", "CHEMICAL", 36, 50], ["3\u2010azidopropanol 27", "SIMPLE_CHEMICAL", 12, 30], ["benzyl bromide", "SIMPLE_CHEMICAL", 36, 50], ["3\u2010azidopropanol", "TREATMENT", 12, 27], ["benzyl bromide", "TREATMENT", 36, 50]]], ["Initially, we considered the respective N3\u2010benzoylated quinazoline\u20102,4\u2010diones as convenient substrates for the preparation of N3\u2010benzoyl\u2010N1\u2010propargylquinazoline\u20102,4\u2010diones 30a (Scheme 2).", [["quinazoline", "CHEMICAL", 55, 66], ["2,4\u2010diones", "CHEMICAL", 67, 77], ["N3\u2010benzoyl\u2010N1\u2010propargylquinazoline\u20102,4\u2010diones", "CHEMICAL", 126, 171], ["N3\u2010benzoylated quinazoline\u20102,4\u2010diones", "CHEMICAL", 40, 77], ["N3\u2010benzoyl\u2010N1\u2010propargylquinazoline\u20102,4\u2010diones", "CHEMICAL", 126, 171], ["N3\u2010benzoylated quinazoline\u20102,4\u2010diones", "SIMPLE_CHEMICAL", 40, 77], ["N3\u2010benzoyl\u2010N1\u2010propargylquinazoline\u20102,4\u2010diones 30a", "SIMPLE_CHEMICAL", 126, 175], ["the respective N3\u2010benzoylated quinazoline", "TREATMENT", 25, 66], ["N3\u2010benzoyl", "TREATMENT", 126, 136], ["N1", "TREATMENT", 137, 139], ["propargylquinazoline", "TREATMENT", 140, 160]]], ["The N3\u2010benzoylquinazoline\u20102,4\u2010dione 40 was previously obtained from 2\u2010benzoylaminobenzoxazinone, although with low (less than 5%) overall yield 71 Recently, we reported 57 the synthesis of N3\u2010benzoyl\u2010N1\u2010propargylquinazoline\u20102,4\u2010diones 30a from quinazoline\u20102,4\u2010dione 38 in 19% overall yield (Scheme 2).Chemistry ::: Results and discussionHowever, this procedure suffers from several steps including benzoylation of 38 to N1,N3\u2010dibenzoylquinazoline\u20102,4\u2010dione 39, requires a selective N1\u2010debenzoylation and finally propargylation.", [["N3\u2010benzoylquinazoline\u20102,4\u2010dione", "CHEMICAL", 4, 35], ["benzoylaminobenzoxazinone", "CHEMICAL", 70, 95], ["N3\u2010benzoyl\u2010N1\u2010propargylquinazoline\u20102,4\u2010diones 30a from quinazoline\u20102,4\u2010dione", "CHEMICAL", 189, 265], ["N3\u2010dibenzoylquinazoline\u20102,4\u2010dione 39", "CHEMICAL", 423, 459], ["N3\u2010benzoylquinazoline\u20102,4\u2010dione", "CHEMICAL", 4, 35], ["2\u2010benzoylaminobenzoxazinone", "CHEMICAL", 68, 95], ["N3\u2010benzoyl\u2010N1\u2010propargylquinazoline\u20102,4\u2010diones", "CHEMICAL", 189, 234], ["quinazoline", "CHEMICAL", 244, 255], ["2,4\u2010dione", "CHEMICAL", 256, 265], ["N1", "CHEMICAL", 420, 422], ["N3", "CHEMICAL", 423, 425], ["dibenzoylquinazoline", "CHEMICAL", 426, 446], ["2,4\u2010dione", "CHEMICAL", 447, 456], ["N3\u2010benzoylquinazoline\u20102,4\u2010dione 40", "SIMPLE_CHEMICAL", 4, 38], ["2\u2010benzoylaminobenzoxazinone", "SIMPLE_CHEMICAL", 68, 95], ["N3\u2010benzoyl\u2010N1\u2010propargylquinazoline\u20102,4\u2010diones 30a", "SIMPLE_CHEMICAL", 189, 238], ["quinazoline\u20102,4\u2010dione 38", "SIMPLE_CHEMICAL", 244, 268], ["N3\u2010dibenzoylquinazoline\u20102,4\u2010dione 39", "SIMPLE_CHEMICAL", 423, 459], ["The N3\u2010benzoylquinazoline\u2010", "TREATMENT", 0, 26], ["benzoylaminobenzoxazinone", "TREATMENT", 70, 95], ["benzoyl", "TREATMENT", 192, 199], ["N1", "TREATMENT", 200, 202], ["propargylquinazoline", "TREATMENT", 203, 223], ["quinazoline", "TREATMENT", 244, 255], ["this procedure", "TREATMENT", 346, 360], ["benzoylation", "TREATMENT", 398, 410], ["dibenzoylquinazoline", "TREATMENT", 426, 446], ["a selective N1\u2010debenzoylation", "TREATMENT", 470, 499], ["finally propargylation", "TREATMENT", 504, 526]]], ["Unfortunately, in this method, the selective N1\u2010debenzoylation step appeared less effective and tedious.", [["the selective N1\u2010debenzoylation step", "TREATMENT", 31, 67]]], ["For this reason, another strategy for the synthesis of N3\u2010benzoyl\u2010N1\u2010propargylquinazoline\u20102,4\u2010diones 30a was devised (Scheme 3).", [["N3\u2010benzoyl\u2010N1\u2010propargylquinazoline\u20102,4\u2010diones 30a", "CHEMICAL", 55, 104], ["N3\u2010benzoyl\u2010N1\u2010propargylquinazoline\u20102,4\u2010diones", "CHEMICAL", 55, 100], ["N3\u2010benzoyl\u2010N1\u2010propargylquinazoline\u20102,4\u2010diones 30a", "SIMPLE_CHEMICAL", 55, 104], ["the synthesis of N3", "TREATMENT", 38, 57], ["benzoyl", "TREATMENT", 58, 65], ["N1", "TREATMENT", 66, 68], ["propargylquinazoline", "TREATMENT", 69, 89]]], ["It started from propargylation of commercially available isatoic anhydride 41 followed by the reaction of the compound 42 with urea 72 to give N1\u2010propargylquinazoline\u20102,4\u2010dione 29.", [["isatoic anhydride 41", "CHEMICAL", 57, 77], ["urea", "CHEMICAL", 127, 131], ["N1\u2010propargylquinazoline\u20102,4\u2010dione", "CHEMICAL", 143, 176], ["isatoic anhydride 41", "CHEMICAL", 57, 77], ["urea", "CHEMICAL", 127, 131], ["N1\u2010propargylquinazoline\u20102,4\u2010dione", "CHEMICAL", 143, 176], ["isatoic anhydride 41", "SIMPLE_CHEMICAL", 57, 77], ["urea 72", "SIMPLE_CHEMICAL", 127, 134], ["N1\u2010propargylquinazoline\u20102,4\u2010dione 29", "SIMPLE_CHEMICAL", 143, 179], ["isatoic anhydride", "TREATMENT", 57, 74], ["urea", "TEST", 127, 131], ["N1\u2010propargylquinazoline", "TREATMENT", 143, 166]]], ["Finally, the key compound 29 could be transformed into substituted both N3\u2010benzoyl\u2010 and N3\u2010benzyl\u2010N1\u2010propargylquinazoline\u20102,4\u2010diones 30a\u2212d and 31a\u2212d via the reaction with the respective benzoyl chlorides and benzyl bromides (Scheme 3).Chemistry ::: Results and discussionThe standard benzoylation of N1\u2010propargylquinazoline\u20102,4\u2010dione 29 with benzoyl chlorides in the presence of triethylamine led to the formation of N3\u2010benzoylated N1\u2010propargylquinazoline\u20102,4\u2010diones 30a\u2212d in moderate to good yields without formation of by\u2010products.", [["benzoyl\u2010", "CHEMICAL", 75, 83], ["N3\u2010benzyl\u2010N1\u2010propargylquinazoline\u20102,4\u2010diones 30a\u2212d and 31a\u2212d", "CHEMICAL", 88, 148], ["benzoyl chlorides", "CHEMICAL", 186, 203], ["benzyl bromides", "CHEMICAL", 208, 223], ["N1\u2010propargylquinazoline\u20102,4\u2010dione 29", "CHEMICAL", 300, 336], ["benzoyl chlorides", "CHEMICAL", 342, 359], ["triethylamine", "CHEMICAL", 379, 392], ["propargylquinazoline\u20102,4\u2010diones 30a\u2212d", "CHEMICAL", 435, 472], ["N3", "CHEMICAL", 72, 74], ["benzoyl\u2010", "CHEMICAL", 75, 83], ["N3\u2010benzyl\u2010N1\u2010propargylquinazoline\u20102,4\u2010diones", "CHEMICAL", 88, 132], ["benzoyl chlorides", "CHEMICAL", 186, 203], ["benzyl bromides", "CHEMICAL", 208, 223], ["N1\u2010propargylquinazoline", "CHEMICAL", 300, 323], ["2,4\u2010dione", "CHEMICAL", 324, 333], ["benzoyl chlorides", "CHEMICAL", 342, 359], ["triethylamine", "CHEMICAL", 379, 392], ["N3\u2010benzoylated N1\u2010propargylquinazoline\u20102,4\u2010diones", "CHEMICAL", 417, 466], ["N3\u2010benzoyl\u2010", "SIMPLE_CHEMICAL", 72, 83], ["N3\u2010benzyl\u2010N1\u2010propargylquinazoline\u20102,4\u2010diones 30a\u2212d", "SIMPLE_CHEMICAL", 88, 138], ["31a\u2212d", "SIMPLE_CHEMICAL", 143, 148], ["benzoyl chlorides", "SIMPLE_CHEMICAL", 186, 203], ["benzyl bromides", "SIMPLE_CHEMICAL", 208, 223], ["N1\u2010propargylquinazoline\u20102,4\u2010dione 29", "SIMPLE_CHEMICAL", 300, 336], ["benzoyl chlorides", "SIMPLE_CHEMICAL", 342, 359], ["triethylamine", "SIMPLE_CHEMICAL", 379, 392], ["N3\u2010benzoylated N1\u2010propargylquinazoline\u20102,4\u2010diones 30a\u2212d", "SIMPLE_CHEMICAL", 417, 472], ["benzoyl\u2010", "TREATMENT", 75, 83], ["N3", "TREATMENT", 88, 90], ["benzyl", "TREATMENT", 91, 97], ["N1", "TREATMENT", 98, 100], ["propargylquinazoline", "TREATMENT", 101, 121], ["the respective benzoyl chlorides", "TREATMENT", 171, 203], ["benzyl bromides", "TREATMENT", 208, 223], ["The standard benzoylation of N1\u2010propargylquinazoline", "TREATMENT", 271, 323], ["benzoyl chlorides", "TREATMENT", 342, 359], ["triethylamine", "TREATMENT", 379, 392], ["N3\u2010benzoylated", "TREATMENT", 417, 431], ["N1", "TREATMENT", 432, 434], ["propargylquinazoline", "TREATMENT", 435, 455]]], ["At first, attempts at benzylation of N1\u2010propargylquinazoline\u20102,4\u2010dione 29 following the strategy previously described 67 for the synthesis of N1\u2010allylated N3\u2010benzoylquinazoline\u20102,4\u2010dione were undertaken.", [["\u2010propargylquinazoline", "CHEMICAL", 39, 60], ["2,4\u2010dione", "CHEMICAL", 61, 70], ["benzoylquinazoline\u20102,4\u2010dione", "CHEMICAL", 158, 186], ["N1\u2010propargylquinazoline\u20102,4\u2010dione", "CHEMICAL", 37, 70], ["N1\u2010allylated N3\u2010benzoylquinazoline\u20102,4\u2010dione", "CHEMICAL", 142, 186], ["N1\u2010propargylquinazoline\u20102,4\u2010dione 29", "SIMPLE_CHEMICAL", 37, 73], ["N1\u2010allylated N3\u2010benzoylquinazoline\u20102,4\u2010dione", "SIMPLE_CHEMICAL", 142, 186], ["benzylation", "TREATMENT", 22, 33], ["N1\u2010propargylquinazoline", "TREATMENT", 37, 60], ["the synthesis", "TREATMENT", 125, 138], ["N1\u2010allylated N3", "TREATMENT", 142, 157], ["benzoylquinazoline", "TREATMENT", 158, 176]]], ["Treatment of 29 with benzyl bromide in the presence of potassium hydroxide at 105\u00b0C for 4 h or 60\u00b0C for 48 h led to the formation of ca. a 50:50 mixture of an alkyne 31a and an allene 43a in 79% total yield.", [["benzyl bromide", "CHEMICAL", 21, 35], ["potassium hydroxide", "CHEMICAL", 55, 74], ["105\u00b0C", "CHEMICAL", 78, 83], ["alkyne 31a", "CHEMICAL", 159, 169], ["allene 43a", "CHEMICAL", 177, 187], ["benzyl bromide", "CHEMICAL", 21, 35], ["potassium hydroxide", "CHEMICAL", 55, 74], ["alkyne", "CHEMICAL", 159, 165], ["allene 43a", "CHEMICAL", 177, 187], ["benzyl bromide", "SIMPLE_CHEMICAL", 21, 35], ["potassium hydroxide", "SIMPLE_CHEMICAL", 55, 74], ["alkyne 31a", "SIMPLE_CHEMICAL", 159, 169], ["allene 43a", "SIMPLE_CHEMICAL", 177, 187], ["Treatment", "TREATMENT", 0, 9], ["benzyl bromide", "TREATMENT", 21, 35], ["potassium hydroxide", "TREATMENT", 55, 74], ["an alkyne", "TEST", 156, 165], ["an allene", "TEST", 174, 183], ["ca", "OBSERVATION", 133, 135]]], ["Unfortunately, several attempts at elaborating the efficient procedure to separate N3\u2010benzyl\u2010N1\u2010propargylquinazoline\u20102,4\u2010diones 31a from N3\u2010benzyl\u2010N1\u2010(propa\u20101,2\u2010dien\u20101\u2010yl)quinazoline\u20102,4\u2010diones 43a on silica gel columns or by crystallization proved fruitless.", [["N3\u2010benzyl", "CHEMICAL", 83, 92], ["propargylquinazoline\u20102,4\u2010diones 31a", "CHEMICAL", 96, 131], ["N3\u2010benzyl", "CHEMICAL", 137, 146], ["propa\u20101,2\u2010dien\u20101\u2010yl)quinazoline\u20102,4\u2010diones 43a", "CHEMICAL", 151, 197], ["N3\u2010benzyl\u2010N1\u2010propargylquinazoline\u20102,4\u2010diones", "CHEMICAL", 83, 127], ["N3\u2010benzyl\u2010N1\u2010", "CHEMICAL", 137, 150], ["propa\u20101,2\u2010dien\u20101\u2010yl)quinazoline", "CHEMICAL", 151, 182], ["2,4\u2010diones", "CHEMICAL", 183, 193], ["silica gel", "CHEMICAL", 201, 211], ["N3\u2010benzyl\u2010N1\u2010propargylquinazoline\u20102,4\u2010diones 31a", "SIMPLE_CHEMICAL", 83, 131], ["N3\u2010benzyl\u2010N1\u2010(propa\u20101,2\u2010dien\u20101\u2010yl)quinazoline\u20102,4\u2010diones 43a", "SIMPLE_CHEMICAL", 137, 197], ["silica", "SIMPLE_CHEMICAL", 201, 207], ["the efficient procedure", "TREATMENT", 47, 70], ["benzyl", "TREATMENT", 86, 92], ["N1", "TREATMENT", 93, 95], ["propargylquinazoline", "TREATMENT", 96, 116], ["benzyl", "TREATMENT", 140, 146], ["propa", "TREATMENT", 151, 156], ["quinazoline", "TREATMENT", 171, 182], ["silica gel columns", "TREATMENT", 201, 219]]], ["Fortunately, we were able to chromatographically isolate a small amount of pure allene 43a.", [["allene 43a", "CHEMICAL", 80, 90], ["small", "OBSERVATION_MODIFIER", 59, 64], ["amount", "OBSERVATION_MODIFIER", 65, 71], ["pure allene", "OBSERVATION", 75, 86]]], ["Attempts to optimize a procedure for benzylation of 29, thereby avoiding formation of allenes 43 were undertaken.", [["allenes", "CHEMICAL", 86, 93], ["allenes 43", "SIMPLE_CHEMICAL", 86, 96], ["a procedure", "TREATMENT", 21, 32], ["benzylation", "TREATMENT", 37, 48], ["allenes", "TREATMENT", 86, 93]]], ["Thus, the treatment of N1\u2010propargylquinazoline\u20102,4\u2010dione 29 with benzyl bromide in the presence of potassium carbonate in DMF at room temperature for 48 h afforded pure N3\u2010benzyl\u2010N1\u2010propargylquinazoline\u20102,4\u2010dione 31a and no traces of the allene 43a were observed.Chemistry ::: Results and discussionThe H\u00fcisgen reaction of the azide 27 with the alkyne 29 could be accomplished within 21 days when the reaction mixture was heated at 45\u00b0C. However, when the reaction was performed at the same temperature under microwave irradiation, the azide was consumed in less than 30 min.", [["N1\u2010propargylquinazoline\u20102,4\u2010dione 29", "CHEMICAL", 23, 59], ["benzyl bromide", "CHEMICAL", 65, 79], ["potassium carbonate", "CHEMICAL", 99, 118], ["DMF", "CHEMICAL", 122, 125], ["N3\u2010benzyl\u2010N1\u2010propargylquinazoline\u20102,4\u2010dione 31a", "CHEMICAL", 169, 216], ["azide 27", "CHEMICAL", 327, 335], ["alkyne 29", "CHEMICAL", 345, 354], ["azide", "CHEMICAL", 536, 541], ["N1\u2010propargylquinazoline", "CHEMICAL", 23, 46], ["2,4\u2010dione", "CHEMICAL", 47, 56], ["benzyl bromide", "CHEMICAL", 65, 79], ["potassium carbonate", "CHEMICAL", 99, 118], ["DMF", "CHEMICAL", 122, 125], ["N3\u2010benzyl\u2010N1\u2010propargylquinazoline\u20102,4\u2010dione", "CHEMICAL", 169, 212], ["allene 43a", "CHEMICAL", 238, 248], ["azide", "CHEMICAL", 327, 332], ["alkyne", "CHEMICAL", 345, 351], ["azide", "CHEMICAL", 536, 541], ["N1\u2010propargylquinazoline\u20102,4\u2010dione 29", "SIMPLE_CHEMICAL", 23, 59], ["benzyl bromide", "SIMPLE_CHEMICAL", 65, 79], ["potassium carbonate", "SIMPLE_CHEMICAL", 99, 118], ["DMF", "SIMPLE_CHEMICAL", 122, 125], ["N3\u2010benzyl\u2010N1\u2010propargylquinazoline\u20102,4\u2010dione 31a", "SIMPLE_CHEMICAL", 169, 216], ["allene 43a", "SIMPLE_CHEMICAL", 238, 248], ["azide 27", "SIMPLE_CHEMICAL", 327, 335], ["alkyne 29", "SIMPLE_CHEMICAL", 345, 354], ["azide", "SIMPLE_CHEMICAL", 536, 541], ["N1\u2010propargylquinazoline", "TREATMENT", 23, 46], ["benzyl bromide", "TREATMENT", 65, 79], ["potassium carbonate", "TREATMENT", 99, 118], ["benzyl", "TREATMENT", 172, 178], ["N1", "TREATMENT", 179, 181], ["propargylquinazoline", "TREATMENT", 182, 202], ["the azide", "TREATMENT", 323, 332], ["the alkyne", "TREATMENT", 341, 351], ["the reaction mixture", "PROBLEM", 397, 417], ["the reaction", "PROBLEM", 452, 464], ["microwave irradiation", "TREATMENT", 509, 530], ["the azide", "TREATMENT", 532, 541]]], ["For this reason, all cycloadditions of azides 27 and 28 with N1\u2010propargylquinazoline\u20102,4\u2010dione 29, N3\u2010benzoylated N1\u2010propargylquinazoline\u20102,4\u2010diones 30a\u2212d, and N3\u2010benzylated N1\u2010propargylquinazoline\u20102,4\u2010diones 31a\u2212d were carried out in a microwave oven (Scheme 4) and disappearance of the starting azide was monitored by IR spectroscopy.", [["propargylquinazoline", "CHEMICAL", 64, 84], ["2,4\u2010dione", "CHEMICAL", 85, 94], ["propargylquinazoline", "CHEMICAL", 117, 137], ["\u2010propargylquinazoline", "CHEMICAL", 176, 197], ["azide", "CHEMICAL", 297, 302], ["azides", "CHEMICAL", 39, 45], ["N1\u2010propargylquinazoline\u20102,4\u2010dione", "CHEMICAL", 61, 94], ["N3\u2010benzoylated N1\u2010propargylquinazoline\u20102,4\u2010diones", "CHEMICAL", 99, 148], ["N3\u2010benzylated N1\u2010propargylquinazoline\u20102,4\u2010diones", "CHEMICAL", 160, 208], ["azide", "CHEMICAL", 297, 302], ["N1\u2010propargylquinazoline\u20102,4\u2010dione 29", "SIMPLE_CHEMICAL", 61, 97], ["N3\u2010benzoylated N1\u2010propargylquinazoline\u20102,4\u2010diones 30a\u2212d", "SIMPLE_CHEMICAL", 99, 154], ["N3\u2010benzylated N1\u2010propargylquinazoline\u20102,4\u2010diones 31a\u2212d", "SIMPLE_CHEMICAL", 160, 214], ["azide", "SIMPLE_CHEMICAL", 297, 302], ["all cycloadditions of azides", "TREATMENT", 17, 45], ["N1\u2010propargylquinazoline", "TREATMENT", 61, 84], ["benzoylated", "TREATMENT", 102, 113], ["propargylquinazoline", "TREATMENT", 117, 137], ["N3", "TREATMENT", 160, 162], ["N1\u2010propargylquinazoline", "TREATMENT", 174, 197], ["the starting azide", "TREATMENT", 284, 302]]], ["Structures and purity of all 1,2,3\u2010triazole nucleosides were established by 1H, 13C NMR, and IR techniques as well as by elemental analysis.Antiviral and cytotoxic evaluation ::: Biological evaluation ::: Results and discussionAll synthesized compounds were screened for inhibitory activity against a wide variety of DNA and RNA viruses using the following cell\u2010based assays: (i) human embryonic lung (HEL) cells: herpes simplex virus\u20101 (KOS), herpes simplex virus\u20102 (G), thymidine kinase deficient (acyclovir resistant) herpes simplex virus\u20101 (TK\u2212 KOS ACVr), vaccinia virus, adenovirus\u20102, human coronavirus (229E), cytomegalovirus (AD\u2010169 strain and Davis strain), varicella\u2010zoster virus (TK+ VZV Oka strain and TK\u2212 VZV 07\u20101 strain); (ii) HeLa cell cultures: vesicular stomatitis virus, Coxsackie virus B4 and respiratory syncytial virus; (iii) Vero cell cultures: para\u2010influenza\u20103 virus, reovirus\u20101, Sindbis virus, Coxsackie virus B4, punta toro virus, yellow fever virus; (iv) MDCK cell cultures: influenza A virus (H1N1 and H3N2 subtypes) and influenza B virus.", [["embryonic lung (HEL) cells", "ANATOMY", 386, 412], ["strain", "ANATOMY", 726, 732], ["HeLa cell cultures", "ANATOMY", 740, 758], ["Vero cell cultures", "ANATOMY", 846, 864], ["MDCK cell cultures", "ANATOMY", 980, 998], ["\u2010triazole", "CHEMICAL", 34, 43], ["herpes simplex virus\u20101", "DISEASE", 414, 436], ["herpes simplex virus\u20102", "DISEASE", 444, 466], ["thymidine", "CHEMICAL", 472, 481], ["acyclovir", "CHEMICAL", 500, 509], ["herpes simplex virus\u20101", "DISEASE", 521, 543], ["vesicular stomatitis", "DISEASE", 760, 780], ["respiratory syncytial virus", "DISEASE", 811, 838], ["yellow fever", "DISEASE", 955, 967], ["influenza A virus", "DISEASE", 1000, 1017], ["influenza B", "DISEASE", 1047, 1058], ["1,2,3\u2010triazole nucleosides", "CHEMICAL", 29, 55], ["1H", "CHEMICAL", 76, 78], ["13C", "CHEMICAL", 80, 83], ["thymidine", "CHEMICAL", 472, 481], ["acyclovir", "CHEMICAL", 500, 509], ["1,2,3\u2010triazole nucleosides", "SIMPLE_CHEMICAL", 29, 55], ["1H", "SIMPLE_CHEMICAL", 76, 78], ["13C", "SIMPLE_CHEMICAL", 80, 83], ["DNA", "CELLULAR_COMPONENT", 317, 320], ["human", "ORGANISM", 380, 385], ["embryonic lung (HEL) cells", "CELL", 386, 412], ["herpes simplex virus\u20101", "ORGANISM", 414, 436], ["KOS", "ORGANISM", 438, 441], ["herpes simplex virus\u20102", "ORGANISM", 444, 466], ["(G)", "ORGANISM", 467, 470], ["thymidine kinase", "GENE_OR_GENE_PRODUCT", 472, 488], ["acyclovir resistant)", "ORGANISM", 500, 520], ["herpes simplex virus\u20101", "ORGANISM", 521, 543], ["TK\u2212 KOS ACVr", "ORGANISM", 545, 557], ["vaccinia virus", "ORGANISM", 560, 574], ["adenovirus\u20102", "ORGANISM", 576, 588], ["human coronavirus", "ORGANISM", 590, 607], ["cytomegalovirus", "ORGANISM", 616, 631], ["AD\u2010169 strain", "ORGANISM", 633, 646], ["Davis strain", "ORGANISM", 651, 663], ["varicella\u2010zoster virus", "ORGANISM", 666, 688], ["TK+ VZV Oka strain", "ORGANISM", 690, 708], ["TK\u2212 VZV 07\u20101 strain", "ORGANISM", 713, 732], ["HeLa cell cultures", "CELL", 740, 758], ["vesicular stomatitis virus", "ORGANISM", 760, 786], ["Coxsackie virus B4", "ORGANISM", 788, 806], ["respiratory syncytial virus", "ORGANISM", 811, 838], ["Vero cell cultures", "CELL", 846, 864], ["para\u2010influenza\u20103 virus", "ORGANISM", 866, 888], ["reovirus", "ORGANISM", 890, 898], ["Sindbis virus", "ORGANISM", 902, 915], ["Coxsackie virus B4", "ORGANISM", 917, 935], ["punta toro virus", "ORGANISM", 937, 953], ["yellow fever virus", "ORGANISM", 955, 973], ["MDCK cell cultures", "ORGANISM", 980, 998], ["influenza A virus", "ORGANISM", 1000, 1017], ["H1N1 and H3N2 subtypes", "ORGANISM", 1019, 1041], ["influenza B virus", "ORGANISM", 1047, 1064], ["human embryonic lung (HEL) cells", "CELL_TYPE", 380, 412], ["thymidine kinase", "PROTEIN", 472, 488], ["HeLa cell cultures", "CELL_LINE", 740, 758], ["Vero cell cultures", "CELL_LINE", 846, 864], ["human", "SPECIES", 380, 385], ["herpes simplex virus\u20101", "SPECIES", 414, 436], ["herpes simplex virus\u20102", "SPECIES", 444, 466], ["herpes simplex virus\u20101", "SPECIES", 521, 543], ["vaccinia virus", "SPECIES", 560, 574], ["human", "SPECIES", 590, 595], ["coronavirus", "SPECIES", 596, 607], ["varicella\u2010zoster virus", "SPECIES", 666, 688], ["vesicular stomatitis virus", "SPECIES", 760, 786], ["Coxsackie virus B4", "SPECIES", 788, 806], ["respiratory syncytial virus", "SPECIES", 811, 838], ["Coxsackie virus B4", "SPECIES", 917, 935], ["punta toro virus", "SPECIES", 937, 953], ["yellow fever virus", "SPECIES", 955, 973], ["influenza A virus", "SPECIES", 1000, 1017], ["H1N1 and H3N2", "SPECIES", 1019, 1032], ["influenza B virus", "SPECIES", 1047, 1064], ["human", "SPECIES", 380, 385], ["herpes simplex virus\u20102", "SPECIES", 444, 466], ["vaccinia virus", "SPECIES", 560, 574], ["human coronavirus", "SPECIES", 590, 607], ["VZV", "SPECIES", 694, 697], ["TK\u2212 VZV 07\u20101", "SPECIES", 713, 725], ["stomatitis virus", "SPECIES", 770, 786], ["Coxsackie virus B4", "SPECIES", 788, 806], ["respiratory syncytial virus", "SPECIES", 811, 838], ["Sindbis virus", "SPECIES", 902, 915], ["Coxsackie virus B4", "SPECIES", 917, 935], ["punta toro virus", "SPECIES", 937, 953], ["yellow fever virus", "SPECIES", 955, 973], ["influenza A virus", "SPECIES", 1000, 1017], ["influenza B virus", "SPECIES", 1047, 1064], ["all 1,2,3\u2010triazole nucleosides", "TREATMENT", 25, 55], ["13C NMR", "TEST", 80, 87], ["IR techniques", "TREATMENT", 93, 106], ["elemental analysis", "TEST", 121, 139], ["Antiviral", "TREATMENT", 140, 149], ["cytotoxic evaluation", "TEST", 154, 174], ["Biological evaluation", "TEST", 179, 200], ["DNA and RNA viruses", "PROBLEM", 317, 336], ["human embryonic lung (HEL) cells", "TEST", 380, 412], ["herpes simplex virus\u20101", "TEST", 414, 436], ["herpes simplex virus\u20102", "TEST", 444, 466], ["thymidine kinase deficient", "TEST", 472, 498], ["acyclovir resistant)", "PROBLEM", 500, 520], ["herpes simplex virus\u20101", "TEST", 521, 543], ["ACVr", "TEST", 553, 557], ["vaccinia virus", "PROBLEM", 560, 574], ["human coronavirus", "TEST", 590, 607], ["cytomegalovirus", "PROBLEM", 616, 631], ["Davis strain", "TEST", 651, 663], ["varicella\u2010zoster virus", "PROBLEM", 666, 688], ["TK", "TEST", 690, 692], ["VZV Oka strain", "TEST", 694, 708], ["TK", "TEST", 713, 715], ["VZV", "TEST", 717, 720], ["HeLa cell cultures", "TEST", 740, 758], ["vesicular stomatitis virus", "PROBLEM", 760, 786], ["Coxsackie virus B4", "PROBLEM", 788, 806], ["respiratory syncytial virus", "PROBLEM", 811, 838], ["Vero cell cultures", "TEST", 846, 864], ["para\u2010influenza\u20103 virus", "PROBLEM", 866, 888], ["reovirus", "PROBLEM", 890, 898], ["Sindbis virus", "PROBLEM", 902, 915], ["Coxsackie virus B4", "TEST", 917, 935], ["punta toro virus", "PROBLEM", 937, 953], ["yellow fever virus", "PROBLEM", 955, 973], ["MDCK cell cultures", "TEST", 980, 998], ["influenza A virus", "PROBLEM", 1000, 1017], ["H1N1", "PROBLEM", 1019, 1023], ["H3N2 subtypes", "PROBLEM", 1028, 1041], ["influenza B virus", "PROBLEM", 1047, 1064], ["lung", "ANATOMY", 396, 400], ["vesicular stomatitis virus", "OBSERVATION", 760, 786], ["respiratory", "ANATOMY", 811, 822], ["syncytial virus", "OBSERVATION", 823, 838], ["Sindbis virus", "OBSERVATION", 902, 915]]], ["Ganciclovir, cidofovir, acyclovir, brivudin, zalcitabine, zanamivir, alovudine, amantadine, rimantadine, ribavirin, dextran sulfate (molecular weight 10000, DS\u201010000), mycophenolic acid, and Urtica dioica agglutinin (UDA) were used as the reference compounds.", [["Ganciclovir", "CHEMICAL", 0, 11], ["cidofovir", "CHEMICAL", 13, 22], ["acyclovir", "CHEMICAL", 24, 33], ["brivudin", "CHEMICAL", 35, 43], ["zalcitabine", "CHEMICAL", 45, 56], ["zanamivir", "CHEMICAL", 58, 67], ["alovudine", "CHEMICAL", 69, 78], ["amantadine", "CHEMICAL", 80, 90], ["rimantadine", "CHEMICAL", 92, 103], ["ribavirin", "CHEMICAL", 105, 114], ["dextran sulfate", "CHEMICAL", 116, 131], ["DS\u201010000", "CHEMICAL", 157, 165], ["mycophenolic acid", "CHEMICAL", 168, 185], ["Urtica dioica agglutinin", "CHEMICAL", 191, 215], ["UDA", "CHEMICAL", 217, 220], ["Ganciclovir", "CHEMICAL", 0, 11], ["cidofovir", "CHEMICAL", 13, 22], ["acyclovir", "CHEMICAL", 24, 33], ["brivudin", "CHEMICAL", 35, 43], ["zalcitabine", "CHEMICAL", 45, 56], ["zanamivir", "CHEMICAL", 58, 67], ["alovudine", "CHEMICAL", 69, 78], ["amantadine", "CHEMICAL", 80, 90], ["rimantadine", "CHEMICAL", 92, 103], ["ribavirin", "CHEMICAL", 105, 114], ["dextran sulfate", "CHEMICAL", 116, 131], ["mycophenolic acid", "CHEMICAL", 168, 185], ["Ganciclovir", "SIMPLE_CHEMICAL", 0, 11], ["cidofovir", "SIMPLE_CHEMICAL", 13, 22], ["acyclovir", "SIMPLE_CHEMICAL", 24, 33], ["brivudin", "SIMPLE_CHEMICAL", 35, 43], ["zalcitabine", "SIMPLE_CHEMICAL", 45, 56], ["zanamivir", "SIMPLE_CHEMICAL", 58, 67], ["alovudine", "SIMPLE_CHEMICAL", 69, 78], ["amantadine", "SIMPLE_CHEMICAL", 80, 90], ["rimantadine", "SIMPLE_CHEMICAL", 92, 103], ["ribavirin", "SIMPLE_CHEMICAL", 105, 114], ["dextran sulfate", "SIMPLE_CHEMICAL", 116, 131], ["mycophenolic acid", "SIMPLE_CHEMICAL", 168, 185], ["Urtica dioica", "ORGANISM", 191, 204], ["agglutinin", "SIMPLE_CHEMICAL", 205, 215], ["UDA", "SIMPLE_CHEMICAL", 217, 220], ["Urtica dioica", "SPECIES", 191, 204], ["Urtica dioica", "SPECIES", 191, 204], ["Ganciclovir", "TREATMENT", 0, 11], ["cidofovir", "TREATMENT", 13, 22], ["acyclovir", "TREATMENT", 24, 33], ["brivudin", "TREATMENT", 35, 43], ["zalcitabine", "TREATMENT", 45, 56], ["zanamivir", "TREATMENT", 58, 67], ["alovudine", "TREATMENT", 69, 78], ["amantadine", "TREATMENT", 80, 90], ["rimantadine", "TREATMENT", 92, 103], ["ribavirin", "TREATMENT", 105, 114], ["dextran sulfate", "TREATMENT", 116, 131], ["DS", "TEST", 157, 159], ["mycophenolic acid", "TREATMENT", 168, 185], ["Urtica dioica agglutinin (UDA)", "TREATMENT", 191, 221]]], ["The antiviral activity was expressed as the EC50: The effective concentration required to reduce virus plaque formation (VZV, HCMV) by 50% or to reduce virus\u2010induced cytopathogenicity by 50% (other viruses).", [["plaque", "ANATOMY", 103, 109], ["plaque", "DISEASE", 103, 109], ["cytopathogenicity", "DISEASE", 166, 183], ["VZV", "ORGANISM", 121, 124], ["HCMV", "ORGANISM", 126, 130], ["VZV", "SPECIES", 121, 124], ["HCMV", "SPECIES", 126, 130], ["The effective concentration", "TREATMENT", 50, 77], ["virus plaque formation", "PROBLEM", 97, 119], ["VZV", "PROBLEM", 121, 124], ["virus\u2010induced cytopathogenicity", "PROBLEM", 152, 183], ["antiviral activity", "OBSERVATION", 4, 22]]], ["Among all the tested compounds, only the alkyne 30d as well as 1,2,3\u2010triazoles 36a and 36d exhibited antiviral activity against herpes simplex viruses, adenovirus\u20102, and human corona virus (229E) in HEL cell cultures (Table 1).", [["HEL cell cultures", "ANATOMY", 199, 216], ["alkyne 30d", "CHEMICAL", 41, 51], ["1,2,3\u2010triazoles 36a and 36d", "CHEMICAL", 63, 90], ["herpes simplex viruses", "DISEASE", 128, 150], ["alkyne", "CHEMICAL", 41, 47], ["1,2,3\u2010triazoles", "CHEMICAL", 63, 78], ["alkyne 30d", "SIMPLE_CHEMICAL", 41, 51], ["1,2,3\u2010triazoles 36a", "SIMPLE_CHEMICAL", 63, 82], ["36d", "SIMPLE_CHEMICAL", 87, 90], ["herpes simplex viruses", "ORGANISM", 128, 150], ["adenovirus\u20102", "ORGANISM", 152, 164], ["human corona virus", "ORGANISM", 170, 188], ["HEL cell cultures", "CELL", 199, 216], ["HEL cell cultures", "CELL_LINE", 199, 216], ["herpes simplex viruses", "SPECIES", 128, 150], ["human", "SPECIES", 170, 175], ["corona virus", "SPECIES", 176, 188], ["herpes simplex viruses", "SPECIES", 128, 150], ["human corona virus", "SPECIES", 170, 188], ["antiviral activity", "TREATMENT", 101, 119], ["herpes simplex viruses", "PROBLEM", 128, 150], ["adenovirus\u20102", "TREATMENT", 152, 164], ["human corona virus", "PROBLEM", 170, 188], ["HEL cell cultures", "TEST", 199, 216]]], ["It should be noted that these derivatives were equally active against HSV\u20101 TK+ and TK\u2212 HSV\u20101 strains in contrast to the gold standard for therapy of HSV infections [EC50 = 6.6 \u03bcM (30d), 4.6 \u03bcM (36a), and 6.2 \u03bcM (36d) vs. 85 \u03bcM (acyclovir) for the HSV\u20101 TK\u2212 strain].", [["HSV infections", "DISEASE", 150, 164], ["acyclovir", "CHEMICAL", 229, 238], ["acyclovir", "CHEMICAL", 229, 238], ["HSV\u20101 TK", "ORGANISM", 70, 78], ["TK\u2212 HSV\u20101", "ORGANISM", 84, 93], ["HSV", "ORGANISM", 150, 153], ["acyclovir", "SIMPLE_CHEMICAL", 229, 238], ["HSV", "ORGANISM", 248, 251], ["HSV\u20101", "SPECIES", 70, 75], ["TK\u2212 HSV\u20101", "SPECIES", 84, 93], ["HSV", "SPECIES", 150, 153], ["HSV\u20101", "SPECIES", 248, 253], ["these derivatives", "TEST", 24, 41], ["HSV", "TEST", 70, 73], ["TK", "TEST", 76, 78], ["TK", "TEST", 84, 86], ["HSV", "TEST", 88, 91], ["therapy", "TREATMENT", 139, 146], ["HSV infections", "PROBLEM", 150, 164], ["EC50", "TEST", 166, 170], ["\u03bcM", "TEST", 177, 179], ["\u03bcM", "TEST", 209, 211], ["acyclovir", "TREATMENT", 229, 238], ["the HSV", "TEST", 244, 251], ["TK\u2212 strain]", "PROBLEM", 254, 265]]], ["In addition, compound 30d appeared almost as active toward adenovirus\u20102 (EC50 = 8.3 \u03bcM) as the reference compounds cidofovir (EC50 = 5.8 \u03bcM), alovudine (EC50 = 5.8 \u03bcM), and zalcitabine (EC50 = 7.2 \u03bcM).", [["30d", "CHEMICAL", 22, 25], ["cidofovir", "CHEMICAL", 115, 124], ["alovudine", "CHEMICAL", 142, 151], ["zalcitabine", "CHEMICAL", 173, 184], ["cidofovir", "CHEMICAL", 115, 124], ["alovudine", "CHEMICAL", 142, 151], ["zalcitabine", "CHEMICAL", 173, 184], ["30d", "SIMPLE_CHEMICAL", 22, 25], ["adenovirus\u20102", "SIMPLE_CHEMICAL", 59, 71], ["cidofovir", "SIMPLE_CHEMICAL", 115, 124], ["alovudine", "SIMPLE_CHEMICAL", 142, 151], ["zalcitabine", "SIMPLE_CHEMICAL", 173, 184], ["EC50", "TEST", 73, 77], ["cidofovir", "TEST", 115, 124], ["EC50", "TEST", 126, 130], ["alovudine", "TEST", 142, 151], ["EC50", "TEST", 153, 157], ["zalcitabine", "TEST", 173, 184], ["EC50", "TEST", 186, 190], ["active", "OBSERVATION_MODIFIER", 45, 51]]], ["A 10\u2010fold lower activity of 36a compared to the reference compound UDA against human corona virus was measured (EC50 of 18.5 \u03bcM and 1.8 \u03bcM, respectively).Antiviral and cytotoxic evaluation ::: Biological evaluation ::: Results and discussionMoreover, several synthesized quinazoline\u20102,4\u2010diones inhibited the replication of both TK+ and TK\u2212 VZV strains at EC50 in the 2\u201370 \u00b5M range (Table 2).", [["UDA", "CHEMICAL", 67, 70], ["quinazoline", "CHEMICAL", 271, 282], ["2,4\u2010diones", "CHEMICAL", 283, 293], ["UDA", "CHEMICAL", 67, 70], ["quinazoline", "CHEMICAL", 271, 282], ["2,4\u2010diones", "CHEMICAL", 283, 293], ["36a", "SIMPLE_CHEMICAL", 28, 31], ["UDA", "SIMPLE_CHEMICAL", 67, 70], ["human", "ORGANISM", 79, 84], ["corona virus", "ORGANISM", 85, 97], ["quinazoline\u20102,4\u2010diones", "SIMPLE_CHEMICAL", 271, 293], ["VZV", "ORGANISM", 340, 343], ["human", "SPECIES", 79, 84], ["human corona virus", "SPECIES", 79, 97], ["VZV", "SPECIES", 340, 343], ["A 10\u2010fold lower activity", "PROBLEM", 0, 24], ["human corona virus", "PROBLEM", 79, 97], ["EC50", "TEST", 112, 116], ["\u03bcM", "TEST", 125, 127], ["Antiviral", "TREATMENT", 154, 163], ["cytotoxic evaluation", "TEST", 168, 188], ["Biological evaluation", "TEST", 193, 214], ["several synthesized quinazoline", "TREATMENT", 251, 282], ["VZV strains", "PROBLEM", 340, 351], ["EC50", "TEST", 355, 359], ["corona virus", "ANATOMY", 85, 97]]], ["In particular, alkynes 30a (EC50 = 6.5 \u03bcM), 30b (EC50 = 9.5 \u03bcM), and 30d (EC50 = 5.9 \u03bcM) as well as 1,2,3\u2010triazoles 36a (EC50 = 5.9 \u03bcM), 36b (EC50 = 6.2 \u03bcM), 36c (EC50 = 8.3 \u03bcM), and 37a (EC50 = 14.2 \u03bcM), as well as 37b (EC50 = 8.2 \u03bcM) showed marked activity toward TK\u2212 VZV strain, which was higher than that of the reference drugs acyclovir and brivudin (EC50 = 40.7 and 32.0 \u00b5M, respectively).", [["30d", "CHEMICAL", 69, 72], ["acyclovir", "CHEMICAL", 332, 341], ["brivudin", "CHEMICAL", 346, 354], ["alkynes", "CHEMICAL", 15, 22], ["1,2,3\u2010triazoles", "CHEMICAL", 100, 115], ["acyclovir", "CHEMICAL", 332, 341], ["brivudin", "CHEMICAL", 346, 354], ["alkynes 30a", "SIMPLE_CHEMICAL", 15, 26], ["1,2,3\u2010triazoles 36a", "SIMPLE_CHEMICAL", 100, 119], ["VZV", "ORGANISM", 270, 273], ["acyclovir", "SIMPLE_CHEMICAL", 332, 341], ["brivudin", "SIMPLE_CHEMICAL", 346, 354], ["TK\u2212 VZV", "SPECIES", 266, 273], ["alkynes", "TEST", 15, 22], ["EC50", "TEST", 28, 32], ["EC50", "TEST", 49, 53], ["\u03bcM", "TEST", 60, 62], ["EC50", "TEST", 74, 78], ["\u03bcM", "TEST", 85, 87], ["\u2010triazoles", "TEST", 105, 115], ["EC50", "TEST", 121, 125], ["EC50", "TEST", 142, 146], ["\u03bcM", "TEST", 153, 155], ["EC50", "TEST", 163, 167], ["\u03bcM", "TEST", 174, 176], ["EC50", "TEST", 188, 192], ["\u03bcM", "TEST", 200, 202], ["EC50", "TEST", 221, 225], ["marked activity toward TK\u2212 VZV strain", "PROBLEM", 243, 280], ["acyclovir", "TREATMENT", 332, 341], ["brivudin", "TREATMENT", 346, 354], ["EC50", "TEST", 356, 360], ["marked", "OBSERVATION_MODIFIER", 243, 249], ["activity", "OBSERVATION_MODIFIER", 250, 258], ["VZV strain", "OBSERVATION", 270, 280]]], ["However, they were significantly less active than the reference anti\u2010VZV drugs against the TK+ VZV strain Oka.", [["anti\u2010VZV", "CHEMICAL", 64, 72], ["anti\u2010VZV", "SIMPLE_CHEMICAL", 64, 72], ["TK+ VZV", "ORGANISM", 91, 98], ["Oka", "ORGANISM", 106, 109], ["VZV", "SPECIES", 95, 98], ["the reference anti\u2010VZV drugs", "TREATMENT", 50, 78], ["VZV strain Oka", "PROBLEM", 95, 109], ["significantly", "OBSERVATION_MODIFIER", 19, 32], ["less", "OBSERVATION_MODIFIER", 33, 37], ["active", "OBSERVATION_MODIFIER", 38, 44], ["VZV strain", "OBSERVATION", 95, 105]]], ["Except for 36c, these derivatives had a minimum cytotoxic concentration \u2265100 \u03bcM.", [["these derivatives", "TREATMENT", 16, 33], ["a minimum cytotoxic concentration", "TREATMENT", 38, 71]]], ["However, compounds 30a (CC50 = 11.3 \u03bcM) and 30d (CC50 = 9.1 \u03bcM) as well as 36a (CC50 = 10.6 \u03bcM) and 36b (CC50 = 12.5 \u03bcM) reduced cell growth (as measured by the 50% cytostatic concentration, i.e., CC50) at lower concentrations than acyclovir and brivudin (CC50 > 350 \u00b5M), resulting in low selectivity (ratio CC50/EC50).", [["cell", "ANATOMY", 129, 133], ["30d", "CHEMICAL", 44, 47], ["acyclovir", "CHEMICAL", 232, 241], ["brivudin", "CHEMICAL", 246, 254], ["CC50", "CHEMICAL", 256, 260], ["acyclovir", "CHEMICAL", 232, 241], ["brivudin", "CHEMICAL", 246, 254], ["cell", "CELL", 129, 133], ["acyclovir", "SIMPLE_CHEMICAL", 232, 241], ["brivudin", "SIMPLE_CHEMICAL", 246, 254], ["CC50", "TEST", 24, 28], ["CC50", "TEST", 49, 53], ["CC50", "TEST", 80, 84], ["CC50", "TEST", 105, 109], ["reduced cell growth", "PROBLEM", 121, 140], ["cytostatic concentration", "TEST", 165, 189], ["acyclovir", "TREATMENT", 232, 241], ["brivudin", "TREATMENT", 246, 254], ["reduced cell", "OBSERVATION", 121, 133], ["growth", "OBSERVATION_MODIFIER", 134, 140], ["low selectivity", "OBSERVATION_MODIFIER", 285, 300]]], ["Interestingly, 30b emerged as the most selective anti\u2010VZV quinazoline\u20102,4\u2010diones since it did not inhibit growth of HEL cells up to a concentration of 100 \u03bcM.Antiviral and cytotoxic evaluation ::: Biological evaluation ::: Results and discussionAll synthesized compounds were also subjected to antiviral screening against HCMV, and among them, 36a (EC50 = 10.8\u201314.5 \u03bcM) and 36d (EC50 = 12.6 and 8.9 \u03bcM) showed some activity; however, at the same time, 36a showed cytotoxicity toward HEL cells (CC50 = 10.6 \u03bcM).Cytostatic activity ::: Biological evaluation ::: Results and discussionThe cytostatic activity of the tested compounds was defined as the 50% cytostatic inhibitory concentration (IC50) causing a 50% decrease in cell proliferation and was determined against the transformed cells murine leukemia L1210, human lymphocyte CEM, human cervix carcinoma HeLa compared to human dermal microvascular endothelial HMEC\u20101 cells.Cytostatic activity ::: Biological evaluation ::: Results and discussionIn these series, several compounds showed inhibitory activity against the proliferation of tumor cell lines (Table 3).", [["HEL cells", "ANATOMY", 116, 125], ["HEL cells", "ANATOMY", 483, 492], ["cell", "ANATOMY", 722, 726], ["cells", "ANATOMY", 784, 789], ["leukemia L1210", "ANATOMY", 797, 811], ["lymphocyte CEM", "ANATOMY", 819, 833], ["cervix carcinoma HeLa", "ANATOMY", 841, 862], ["dermal microvascular endothelial HMEC\u20101 cells", "ANATOMY", 881, 926], ["tumor cell lines", "ANATOMY", 1090, 1106], ["anti\u2010VZV quinazoline", "CHEMICAL", 49, 69], ["2,4\u2010diones", "CHEMICAL", 70, 80], ["36d", "CHEMICAL", 374, 377], ["leukemia L1210", "DISEASE", 797, 811], ["cervix carcinoma", "DISEASE", 841, 857], ["tumor", "DISEASE", 1090, 1095], ["anti\u2010VZV quinazoline", "CHEMICAL", 49, 69], ["2,4\u2010diones", "CHEMICAL", 70, 80], ["anti\u2010VZV quinazoline\u20102,4\u2010diones", "SIMPLE_CHEMICAL", 49, 80], ["HEL cells", "CELL", 116, 125], ["HCMV", "ORGANISM", 322, 326], ["36a", "SIMPLE_CHEMICAL", 452, 455], ["HEL cells", "CELL", 483, 492], ["cell", "CELL", 722, 726], ["cells", "CELL", 784, 789], ["murine", "ORGANISM", 790, 796], ["leukemia L1210", "CELL", 797, 811], ["human", "ORGANISM", 813, 818], ["lymphocyte CEM", "CELL", 819, 833], ["human", "ORGANISM", 835, 840], ["cervix carcinoma HeLa", "CELL", 841, 862], ["human", "ORGANISM", 875, 880], ["dermal microvascular endothelial HMEC\u20101 cells", "CELL", 881, 926], ["tumor cell lines", "CELL", 1090, 1106], ["Table 3", "CELL", 1108, 1115], ["HEL cells", "CELL_LINE", 116, 125], ["HEL cells", "CELL_LINE", 483, 492], ["transformed cells", "CELL_LINE", 772, 789], ["murine leukemia L1210", "CELL_LINE", 790, 811], ["human lymphocyte CEM", "CELL_LINE", 813, 833], ["human cervix carcinoma HeLa", "CELL_LINE", 835, 862], ["human dermal microvascular endothelial HMEC\u20101 cells", "CELL_LINE", 875, 926], ["tumor cell lines", "CELL_LINE", 1090, 1106], ["murine", "SPECIES", 790, 796], ["human", "SPECIES", 813, 818], ["human", "SPECIES", 835, 840], ["human", "SPECIES", 875, 880], ["HCMV", "SPECIES", 322, 326], ["human", "SPECIES", 813, 818], ["human", "SPECIES", 835, 840], ["human", "SPECIES", 875, 880], ["the most selective anti\u2010VZV quinazoline", "TREATMENT", 30, 69], ["HEL cells", "PROBLEM", 116, 125], ["Antiviral", "TREATMENT", 158, 167], ["cytotoxic evaluation", "TEST", 172, 192], ["Biological evaluation", "TEST", 197, 218], ["antiviral screening", "TEST", 294, 313], ["HCMV", "PROBLEM", 322, 326], ["EC50", "TEST", 349, 353], ["\u03bcM", "TEST", 366, 368], ["EC50", "TEST", 379, 383], ["some activity", "PROBLEM", 410, 423], ["cytotoxicity toward HEL cells", "PROBLEM", 463, 492], ["CC50", "TEST", 494, 498], ["Biological evaluation", "TEST", 534, 555], ["a 50% decrease in cell proliferation", "PROBLEM", 704, 740], ["the transformed cells murine leukemia L1210", "PROBLEM", 768, 811], ["human lymphocyte CEM", "TEST", 813, 833], ["human cervix carcinoma HeLa", "PROBLEM", 835, 862], ["human dermal microvascular endothelial HMEC", "TEST", 875, 918], ["Biological evaluation", "TEST", 951, 972], ["these series", "TEST", 1002, 1014], ["the proliferation of tumor cell lines", "PROBLEM", 1069, 1106], ["cytostatic", "OBSERVATION_MODIFIER", 586, 596], ["activity", "OBSERVATION_MODIFIER", 597, 605], ["decrease", "OBSERVATION_MODIFIER", 710, 718], ["cell proliferation", "OBSERVATION", 722, 740], ["cells murine leukemia L1210", "OBSERVATION", 784, 811], ["lymphocyte CEM", "OBSERVATION", 819, 833], ["cervix carcinoma", "OBSERVATION", 841, 857], ["dermal", "ANATOMY_MODIFIER", 881, 887], ["microvascular endothelial", "ANATOMY", 888, 913], ["tumor cell lines", "OBSERVATION", 1090, 1106]]], ["From the entire library of compounds, 36a and 36d appeared to be the most inhibitory toward the growth of human T\u2010lymphocyte (CEM) cell line with an inhibitory effect of 21 \u03bcM and 22 \u03bcM, respectively, comparable to that of the reference drug 5\u2010fluorouracil (IC50 = 18 \u00b1 5 \u03bcM).", [["T\u2010lymphocyte (CEM) cell line", "ANATOMY", 112, 140], ["5\u2010fluorouracil", "CHEMICAL", 242, 256], ["5\u2010fluorouracil", "CHEMICAL", 242, 256], ["36a", "SIMPLE_CHEMICAL", 38, 41], ["36d", "SIMPLE_CHEMICAL", 46, 49], ["human", "ORGANISM", 106, 111], ["T\u2010lymphocyte (CEM) cell line", "CELL", 112, 140], ["5\u2010fluorouracil", "SIMPLE_CHEMICAL", 242, 256], ["human T\u2010lymphocyte (CEM) cell line", "CELL_LINE", 106, 140], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 106, 111], ["fluorouracil (IC50", "TREATMENT", 244, 262], ["compounds", "OBSERVATION_MODIFIER", 27, 36], ["cell line", "OBSERVATION", 131, 140], ["inhibitory effect", "OBSERVATION", 149, 166], ["21 \u03bcM", "OBSERVATION_MODIFIER", 170, 175]]], ["36a and 36d weakly inhibited the proliferation of L1210, HeLa, and HMEC\u20101 cells with IC50 values in the range of 83\u2013136 \u03bcM and 106\u2013113 \u03bcM, respectively.", [["L1210", "ANATOMY", 50, 55], ["HeLa", "ANATOMY", 57, 61], ["HMEC\u20101 cells", "ANATOMY", 67, 79], ["36a", "SIMPLE_CHEMICAL", 0, 3], ["36d", "SIMPLE_CHEMICAL", 8, 11], ["L1210", "CELL", 50, 55], ["HeLa", "CELL", 57, 61], ["HMEC\u20101 cells", "CELL", 67, 79], ["L1210", "CELL_LINE", 50, 55], ["HeLa", "CELL_LINE", 57, 61], ["HMEC\u20101 cells", "CELL_LINE", 67, 79], ["the proliferation of L1210", "PROBLEM", 29, 55], ["HeLa", "TEST", 57, 61], ["IC50 values", "TEST", 85, 96], ["proliferation", "OBSERVATION", 33, 46]]], ["Among all tested compounds, only 35 exhibited cytostatic activity (IC50: 28 \u00b1 2 \u03bcM) toward HMEC\u20101 cell line.ConclusionThe N3\u2010benzoylated\u2010 and N3\u2010benzylated N1\u2010propargylquinazoline\u20102,4\u2010diones 30a\u2013d and 31a\u2212d were efficiently synthesized from isatoic anhydride 41.ConclusionThe copper(I)\u2010catalyzed 1,3\u2010dipolar cycloadditions of the azides 27 and 28 with the selected N3\u2010benzoylated\u2010 and N3\u2010benzylated N1\u2010propargylquinazoline\u20102,4\u2010diones 30a\u2212d and 31a\u2212d under microwave irradiation led to the formation of 1,2,3\u2010triazole acyclonucleosides 32, 35 and 33\u201334a\u2212d as well as 36\u201337a\u2212d in good yields.ConclusionAll synthesized compounds were tested for their antiviral activities against DNA and RNA viruses as well as cytostatic activity and cytotoxicity.", [["HMEC\u20101 cell line", "ANATOMY", 91, 107], ["\u2010propargylquinazoline\u20102,4\u2010diones 30a\u2013d and 31a\u2212d", "CHEMICAL", 158, 206], ["isatoic anhydride", "CHEMICAL", 241, 258], ["copper", "CHEMICAL", 276, 282], ["\u2010propargylquinazoline", "CHEMICAL", 401, 422], ["2,4\u2010diones 30a\u2212d and 31a\u2212d", "CHEMICAL", 423, 449], ["1,2,3\u2010triazole acyclonucleosides 32, 35 and 33\u201334a\u2212d", "CHEMICAL", 502, 554], ["N3\u2010benzoylated\u2010 and N3\u2010benzylated N1\u2010propargylquinazoline\u20102,4\u2010diones", "CHEMICAL", 122, 190], ["isatoic anhydride", "CHEMICAL", 241, 258], ["copper(I)", "CHEMICAL", 276, 285], ["azides", "CHEMICAL", 330, 336], ["N3\u2010benzoylated\u2010 and N3\u2010benzylated N1\u2010propargylquinazoline", "CHEMICAL", 365, 422], ["2,4\u2010diones", "CHEMICAL", 423, 433], ["1,2,3\u2010triazole acyclonucleosides", "CHEMICAL", 502, 534], ["HMEC\u20101 cell line", "CELL", 91, 107], ["N3\u2010benzoylated\u2010", "SIMPLE_CHEMICAL", 122, 137], ["N3\u2010benzylated N1\u2010propargylquinazoline\u20102,4\u2010diones 30a\u2013d", "SIMPLE_CHEMICAL", 142, 196], ["31a\u2212d", "SIMPLE_CHEMICAL", 201, 206], ["isatoic anhydride 41", "SIMPLE_CHEMICAL", 241, 261], ["copper(I)\u2010catalyzed 1,3\u2010dipolar", "SIMPLE_CHEMICAL", 276, 307], ["N3\u2010benzoylated\u2010", "SIMPLE_CHEMICAL", 365, 380], ["N3\u2010benzylated N1\u2010propargylquinazoline\u20102,4\u2010diones 30a\u2212d", "SIMPLE_CHEMICAL", 385, 439], ["31a\u2212d", "SIMPLE_CHEMICAL", 444, 449], ["1,2,3\u2010triazole acyclonucleosides 32, 35", "SIMPLE_CHEMICAL", 502, 541], ["33\u201334a\u2212d", "SIMPLE_CHEMICAL", 546, 554], ["36\u201337a\u2212d", "SIMPLE_CHEMICAL", 566, 574], ["DNA", "CELLULAR_COMPONENT", 677, 680], ["HMEC\u20101 cell line", "CELL_LINE", 91, 107], ["cytostatic activity", "TEST", 46, 65], ["IC50", "TEST", 67, 71], ["HMEC", "TEST", 91, 95], ["The N3\u2010benzoylated\u2010", "TREATMENT", 118, 137], ["N3\u2010benzylated N1\u2010propargylquinazoline", "TREATMENT", 142, 179], ["isatoic anhydride", "TREATMENT", 241, 258], ["dipolar cycloadditions of the azides", "TREATMENT", 300, 336], ["the selected N3\u2010benzoylated\u2010", "TREATMENT", 352, 380], ["N3", "TREATMENT", 385, 387], ["N1\u2010propargylquinazoline", "TREATMENT", 399, 422], ["microwave irradiation", "TREATMENT", 456, 477], ["their antiviral activities", "TREATMENT", 642, 668], ["DNA", "PROBLEM", 677, 680], ["RNA viruses", "PROBLEM", 685, 696], ["cytostatic activity", "PROBLEM", 708, 727], ["cytotoxicity", "PROBLEM", 732, 744], ["cell line", "OBSERVATION", 98, 107], ["cytostatic activity", "OBSERVATION", 708, 727]]], ["Among all tested compounds, 30d (EC50 = 7.6 \u03bcM) showed activity against adenovirus\u20102 comparable to that of the reference compounds cidofovir, alovudine, and zalcitabine.", [["30d", "CHEMICAL", 28, 31], ["cidofovir", "CHEMICAL", 131, 140], ["alovudine", "CHEMICAL", 142, 151], ["zalcitabine", "CHEMICAL", 157, 168], ["cidofovir", "CHEMICAL", 131, 140], ["alovudine", "CHEMICAL", 142, 151], ["zalcitabine", "CHEMICAL", 157, 168], ["30d", "SIMPLE_CHEMICAL", 28, 31], ["adenovirus\u20102", "SIMPLE_CHEMICAL", 72, 84], ["cidofovir", "SIMPLE_CHEMICAL", 131, 140], ["alovudine", "SIMPLE_CHEMICAL", 142, 151], ["zalcitabine", "SIMPLE_CHEMICAL", 157, 168], ["EC50", "TEST", 33, 37], ["activity against adenovirus\u20102", "PROBLEM", 55, 84], ["cidofovir", "TREATMENT", 131, 140], ["alovudine", "TREATMENT", 142, 151], ["zalcitabine", "TREATMENT", 157, 168]]], ["Compounds 30d, 36a, and 36d proved equally active against HSV\u20101 and VZV TK+ and TK\u2212 strains.", [["30d, 36a, and 36d", "CHEMICAL", 10, 27], ["36a", "GENE_OR_GENE_PRODUCT", 15, 18], ["36d", "SIMPLE_CHEMICAL", 24, 27], ["HSV\u20101", "ORGANISM", 58, 63], ["VZV TK+", "ORGANISM", 68, 75], ["TK\u2212 strains", "ORGANISM", 80, 91], ["HSV\u20101", "SPECIES", 58, 63], ["VZV", "SPECIES", 68, 71], ["HSV", "TEST", 58, 61], ["VZV TK", "TEST", 68, 74], ["TK\u2212 strains", "PROBLEM", 80, 91]]], ["In addition, the derivatives 30a, 30b, and 36b were also inhibitory for TK+ and TK\u2212 VZV strains.", [["30a, 30b, and 36b", "CHEMICAL", 29, 46], ["30a", "GENE_OR_GENE_PRODUCT", 29, 32], ["30b", "GENE_OR_GENE_PRODUCT", 34, 37], ["36b", "GENE_OR_GENE_PRODUCT", 43, 46], ["TK+", "SIMPLE_CHEMICAL", 72, 75], ["VZV", "ORGANISM", 84, 87], ["VZV", "SPECIES", 84, 87], ["the derivatives", "TEST", 13, 28], ["TK", "TEST", 72, 74], ["VZV strains", "PROBLEM", 84, 95]]], ["The highest selectivity (ratio cytostatic effect [CC50]/antiviral activity [EC50]) was found for the compound 30b (CC50 \u2265 100 \u03bcM and MCC = 100).", [["30b", "SIMPLE_CHEMICAL", 110, 113], ["The highest selectivity (ratio cytostatic effect", "TREATMENT", 0, 48], ["antiviral activity", "TREATMENT", 56, 74], ["CC50", "TEST", 115, 119], ["MCC", "TEST", 133, 136]]], ["The selectivity for the compounds 30a, 30d, 36a, and 36b was low as they reduced cell growth (CC50) at concentrations of 9\u201312.5 \u00b5M.", [["cell", "ANATOMY", 81, 85], ["30a, 30d, 36a, and 36b", "CHEMICAL", 34, 56], ["36a", "GENE_OR_GENE_PRODUCT", 44, 47], ["36b", "GENE_OR_GENE_PRODUCT", 53, 56], ["cell", "CELL", 81, 85]]], ["Furthermore, several compounds (30c [EC50 = 48.12 \u03bcM], 33a [EC50 = 49.45 \u03bcM], 33c [EC50 = 46.31 \u03bcM], and 33d [EC50 = 48.34 \u03bcM]) exhibited marginal activity against VZV strains and at the same time, they were not cytotoxic to uninfected HEL cells (MCC \u2265 100 \u03bcM).ConclusionAmong all tested quinazoline\u20102,4\u2010diones, compounds 36a and 36d were the most inhibitory toward the human T\u2010lymphocyte (CEM) cell line and they showed inhibitory effects (IC50 = 21 \u00b1 7 and 22 \u00b1 1 \u03bcM, respectively) comparable to that of the reference compound 5\u2010fluorouracil (IC50 = 18 \u00b1 5 \u03bcM).", [["HEL cells", "ANATOMY", 236, 245], ["T\u2010lymphocyte (CEM) cell line", "ANATOMY", 376, 404], ["quinazoline\u20102,4\u2010diones", "CHEMICAL", 288, 310], ["compounds 36a and 36d", "CHEMICAL", 312, 333], ["5\u2010fluorouracil", "CHEMICAL", 529, 543], ["quinazoline\u20102,4\u2010diones", "CHEMICAL", 288, 310], ["5\u2010fluorouracil", "CHEMICAL", 529, 543], ["VZV", "ORGANISM", 164, 167], ["HEL cells", "CELL", 236, 245], ["MCC", "CELL", 247, 250], ["quinazoline\u20102,4\u2010diones", "SIMPLE_CHEMICAL", 288, 310], ["compounds 36a", "SIMPLE_CHEMICAL", 312, 325], ["36d", "SIMPLE_CHEMICAL", 330, 333], ["human", "ORGANISM", 370, 375], ["T\u2010lymphocyte (CEM) cell line", "CELL", 376, 404], ["5\u2010fluorouracil", "SIMPLE_CHEMICAL", 529, 543], ["uninfected HEL cells", "CELL_LINE", 225, 245], ["human T\u2010lymphocyte (CEM) cell line", "CELL_LINE", 370, 404], ["human", "SPECIES", 370, 375], ["VZV", "SPECIES", 164, 167], ["human", "SPECIES", 370, 375], ["EC50", "TEST", 37, 41], ["EC50", "TEST", 60, 64], ["\u03bcM", "TEST", 73, 75], ["EC50", "TEST", 83, 87], ["M", "TEST", 97, 98], ["EC50", "TEST", 110, 114], ["M", "TEST", 124, 125], ["VZV strains", "PROBLEM", 164, 175], ["MCC", "TEST", 247, 250], ["quinazoline", "TREATMENT", 288, 299], ["cell line", "TEST", 395, 404], ["inhibitory effects", "PROBLEM", 421, 439], ["IC50", "TEST", 441, 445], ["IC50", "TEST", 545, 549], ["marginal activity", "OBSERVATION", 138, 155], ["cell line", "OBSERVATION", 395, 404]]], ["The compound 35 exhibited also cytostatic activity (IC50: 28 \u00b1 2 \u03bcM) toward HMEC\u20101 cell line.General ::: Chemistry ::: Experimental", [["HMEC\u20101 cell line", "ANATOMY", 76, 92], ["HMEC\u20101 cell line", "CELL", 76, 92], ["HMEC\u20101 cell line", "CELL_LINE", 76, 92], ["cytostatic activity", "TEST", 31, 50], ["IC50", "TEST", 52, 56], ["HMEC", "TEST", 76, 80], ["35 exhibited", "OBSERVATION_MODIFIER", 13, 25], ["cytostatic activity", "OBSERVATION", 31, 50], ["cell line", "OBSERVATION", 83, 92]]]], "PMC7259899": [["In response to the evolving COVID-19 pandemic, most governments and professional bodies recommended cancellation of elective surgery.", [["the evolving COVID", "TEST", 15, 33], ["pandemic", "PROBLEM", 37, 45], ["professional bodies", "TREATMENT", 68, 87], ["elective surgery", "TREATMENT", 116, 132]]], ["This action was important to free up hospital bed capacity and ensure supplies of personal protective equipment (PPE), as well as to protect patients and health-care workers.", [["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 141, 149]]], ["In The Lancet, The COVIDSurg Collaborative1 report 30-day results of an international cohort study assessing postoperative outcomes in 1128 adults with COVID-19 who were undergoing a broad range of surgeries (605 [53\u00b76%] men and 523 [46\u00b74%] women; 214 [19\u00b70%] aged <50 years, 353 [31\u00b73%] aged 50\u201369 years, and 558 [49\u00b75%] aged \u226570 years).", [["men", "ORGANISM", 221, 224], ["women", "ORGANISM", 241, 246], ["men", "SPECIES", 221, 224], ["women", "SPECIES", 241, 246], ["an international cohort study", "TEST", 69, 98]]], ["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was diagnosed postoperatively in more than two-thirds of the patients (806 [71\u00b75%]).", [["acute respiratory syndrome coronavirus", "DISEASE", 7, 45], ["infection", "DISEASE", 61, 70], ["SARS-CoV-2", "ORGANISM", 49, 59], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 0, 45], ["SARS-CoV-2", "SPECIES", 49, 59], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 0, 45], ["SARS", "TEST", 49, 53], ["CoV", "TEST", 54, 57], ["infection", "PROBLEM", 61, 70], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome", "OBSERVATION", 13, 33], ["infection", "OBSERVATION", 61, 70]]], ["The primary outcome was overall postoperative mortality at 30 days and the rate was high at 23\u00b78% (268 of 1128 patients).", [["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["the rate", "TEST", 71, 79]]], ["Pulmonary complications occurred in 577 (51\u00b72%) patients and 30-day mortality in these patients was 38\u00b70% (219 of 577), accounting for 82\u00b76% (219 of 265) of all deaths.", [["Pulmonary", "ANATOMY", 0, 9], ["Pulmonary complications", "DISEASE", 0, 23], ["deaths", "DISEASE", 161, 167], ["Pulmonary", "ORGAN", 0, 9], ["patients", "ORGANISM", 48, 56], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 48, 56], ["patients", "SPECIES", 87, 95], ["Pulmonary complications", "PROBLEM", 0, 23], ["complications", "OBSERVATION", 10, 23]]], ["Risk factors for mortality were patient age of 70 years or older, male sex, poor preoperative physical health status, emergency versus elective surgery, malignant versus benign or obstetric diagnosis, and more extensive (major vs minor) surgery.", [["patient", "ORGANISM", 32, 39], ["patient", "SPECIES", 32, 39], ["elective surgery", "TREATMENT", 135, 151], ["malignant versus benign or obstetric diagnosis", "PROBLEM", 153, 199], ["minor) surgery", "TREATMENT", 230, 244], ["malignant", "OBSERVATION_MODIFIER", 153, 162], ["extensive", "OBSERVATION_MODIFIER", 210, 219], ["surgery", "OBSERVATION", 237, 244]]], ["The high proportion of these patients who were diagnosed with SARS-CoV-2 infection in the postoperative period is of interest.", [["SARS-CoV-2 infection", "DISEASE", 62, 82], ["patients", "ORGANISM", 29, 37], ["SARS-CoV-2", "ORGANISM", 62, 72], ["patients", "SPECIES", 29, 37], ["SARS", "PROBLEM", 62, 66], ["CoV-2 infection", "PROBLEM", 67, 82], ["infection", "OBSERVATION", 73, 82], ["postoperative period", "OBSERVATION_MODIFIER", 90, 110]]], ["These patients probably acquired their infection before being admitted to hospital, thus reflecting the high prevalence of SARS-CoV-2 in the community.", [["infection", "DISEASE", 39, 48], ["SARS", "DISEASE", 123, 127], ["patients", "ORGANISM", 6, 14], ["SARS-CoV-2", "ORGANISM", 123, 133], ["patients", "SPECIES", 6, 14], ["SARS-CoV", "SPECIES", 123, 131], ["their infection", "PROBLEM", 33, 48], ["infection", "OBSERVATION", 39, 48]]]], "PMC1751549": [["Querying MMDB with text terms, e.g. one may identify structures of interest based on a protein name.", [["MMDB", "DNA", 9, 13]]], ["The agreement between atomic coordinate and sequence data is verified, and sequence data are obtained from PDB coordinate records, if necessary, to resolve ambiguities(3).", [["sequence data", "TEST", 44, 57], ["sequence data", "TEST", 75, 88]]], ["This validation and encoding supports the interoperable display of sequence, structure and alignment.", [["This validation", "TEST", 0, 15], ["alignment", "OBSERVATION_MODIFIER", 91, 100]]], ["Uniformly defined secondary-structure and 3D-domain features are added to support structure neighbor calculations.", [["Uniformly defined secondary-structure and 3D-domain features", "PROBLEM", 0, 60], ["secondary", "OBSERVATION_MODIFIER", 18, 27], ["structure", "OBSERVATION", 28, 37]]], ["MMDB currently contains \u223c39 000 structure entries, corresponding to \u223c90 000 chains and 170 000 3D domains.Summary, links, neighbors and visualization ::: CONTENTThe MMDB web server generates structure summary pages, which provide a concise description of an MMDB entry's content and the available annotation (4).", [["MMDB", "PROTEIN", 0, 4], ["170 000 3D domains", "PROTEIN", 87, 105], ["MMDB", "PROTEIN", 165, 169]]], ["Sequences derived from MMDB are entered into Entrez's protein or nucleic acid sequence database, preserving links to the corresponding 3D structures.", [["nucleic acid", "CHEMICAL", 65, 77], ["MMDB", "CANCER", 23, 27], ["MMDB", "DNA", 23, 27], ["nucleic acid sequence database", "TEST", 65, 95]]], ["Links to Entrez's organism taxonomy database are generated by semi-automatic processing of \u2018source records' and other descriptive text provided by PDB.", [["Entrez's organism taxonomy database", "TEST", 9, 44], ["PDB", "ANATOMY", 147, 150]]], ["Ligands and other small molecules are identified and added to the PubChem resource, accessible at , also preserving reciprocal links to 3D structure.", [["other small molecules", "PROBLEM", 12, 33], ["small", "OBSERVATION_MODIFIER", 18, 23], ["molecules", "OBSERVATION", 24, 33]]], ["Sequence neighbors are identified by BLAST (5), and links to the Conserved Domain Database (CDD) (6) by the RPS-BLAST algorithm (5).", [["the RPS", "TEST", 104, 111], ["BLAST algorithm", "TEST", 112, 127]]], ["The 3D structure viewer supported by Entrez, Cn3D (8), provides molecular-graphics visualization.The \u2018Related Structure\u2019 service ::: ANNOTATING SEQUENCE WITH STRUCTUREIn the Entrez database system, protein sequences are neighbored to each other by comparing each newly entered sequence to all other database entries.", [["protein sequences", "TEST", 198, 215]]], ["These database scans are run with the BLAST (5) engine, which identifies sequence neighbors with significant similarity, and the resulting sequence identifiers and taxonomy indices are stored, so that Entrez can provide \u2018Related Sequences\u2019 links for all protein records in the collection.", [["These database scans", "TEST", 0, 20], ["the resulting sequence identifiers", "TEST", 125, 159], ["taxonomy indices", "TEST", 164, 180]]], ["Sequence neighbors directly linked to MMDB are identified and alignments are re-computed by employing the \u2018BlastTwoSequences\u2019 tool (9) to restore alignment footprints.", [["MMDB", "GENE_OR_GENE_PRODUCT", 38, 42], ["MMDB", "DNA", 38, 42]]], ["The \u2018Related Structure\u2019 web interface provides direct access to this information.", [["web interface", "OBSERVATION", 24, 37]]], ["Identification of structure-linked neighbors and the visualization of sequence-structure alignment is also possible using Entrez and the Cn3D alignment viewer/editor, but \u2018Related Structures\u2019 provides a convenient new summary and \u2018one click\u2019 shortcuts to 3D visualization.", [["the visualization of sequence", "TEST", 49, 78], ["Entrez", "TREATMENT", 122, 128], ["3D visualization", "TEST", 255, 271]]], ["These 3D views may be used to identify conserved residues and map site-specific features derived from the 3D structure.", [["These 3D views", "TEST", 0, 14], ["conserved residues and map site", "PROBLEM", 39, 70]]], ["Currently \u223c48% of non-identical protein sequences in Entrez have been linked to at least one related structure, employing a conservative threshold for alignment length (50 aligned residues or more) and similarity (30% or more identical residues in the aligned footprint); see Figure 1 for details.An example ::: ANNOTATING SEQUENCE WITH STRUCTUREA search with the term \u2018Angiotensin converting enzyme\u2019 in Entrez's protein database retrieves >400 hits.", [["Angiotensin", "CHEMICAL", 370, 381], ["Angiotensin converting enzyme\u2019", "GENE_OR_GENE_PRODUCT", 370, 400], ["non-identical protein sequences", "DNA", 18, 49], ["Angiotensin converting enzyme\u2019", "PROTEIN", 370, 400], ["non-identical protein sequences", "TEST", 18, 49], ["a conservative threshold for alignment length", "TREATMENT", 122, 167], ["Angiotensin converting enzyme\u2019", "TREATMENT", 370, 400], ["Entrez's protein database", "TEST", 404, 429], ["at least", "OBSERVATION_MODIFIER", 80, 88]]], ["One may configure the Entrez browser to filter search results by various criteria, and one pre-configured filter selects those protein sequences with \u2018Related Structures\u2019 (configuration of Entrez can be achieved by following links to \u2018My NCBI\u2019, or by clicking on the \u2018toolbox\u2019 icon shown at the top of Entrez document summaries.).", [["one pre-configured filter", "TREATMENT", 87, 112], ["those protein sequences", "TEST", 121, 144]]], ["In this example, the \u2018Related Structures\u2019 filter shows that >240 of the identified sequence records have links to related structures.An example ::: ANNOTATING SEQUENCE WITH STRUCTUREOne such protein sequence is the ACE protein from Rattus norvegicus (accession no.", [["ACE", "GENE_OR_GENE_PRODUCT", 215, 218], ["Rattus norvegicus", "ORGANISM", 232, 249], ["ACE protein", "PROTEIN", 215, 226], ["Rattus norvegicus", "SPECIES", 232, 249], ["Rattus norvegicus", "SPECIES", 232, 249], ["STRUCTUREOne such protein sequence", "TEST", 173, 207], ["the ACE protein", "TEST", 211, 226], ["filter", "OBSERVATION", 42, 48]]], ["The display also supports sorting by a variety of alignment parameters such as score or length and selection of sequence-dissimilar \u2018non redundant\u2019 subsets.", [["\u2018non redundant\u2019 subsets", "CELL_TYPE", 132, 155], ["selection of sequence", "TEST", 99, 120]]], ["A \u2018Table\u2019 option switches to a text view, listing descriptions of each structure as well as alignment scores.An example ::: ANNOTATING SEQUENCE WITH STRUCTUREUsing the table view with this example, one may notice that several related structures are complexes of the same protein with different drugs/inhibitors, e.g. structures with PDB codes 1O86 (11), 1UZF (12) and 1UZE (12).", [["1UZF", "CHEMICAL", 354, 358], ["1UZE", "CHEMICAL", 368, 372], ["a text view", "TEST", 29, 40], ["the table view", "TEST", 164, 178], ["different drugs/inhibitors", "TREATMENT", 284, 310], ["PDB codes", "TEST", 333, 342], ["1UZF", "TEST", 354, 358], ["PDB", "ANATOMY", 333, 336]]], ["Clicking on the graphical alignment footprint of 1O86, a human ACE enzyme in complex with lisinopril, one can see a text representation of the corresponding BLAST alignment, and a Cn3D view of the alignment can be launched by clicking on \u2018Get 3D Structure data\u2019 (Figure 3).", [["1O86", "CHEMICAL", 49, 53], ["lisinopril", "CHEMICAL", 90, 100], ["lisinopril", "CHEMICAL", 90, 100], ["1O86", "SIMPLE_CHEMICAL", 49, 53], ["human", "ORGANISM", 57, 62], ["ACE", "GENE_OR_GENE_PRODUCT", 63, 66], ["lisinopril", "SIMPLE_CHEMICAL", 90, 100], ["1O86", "DNA", 49, 53], ["human ACE enzyme", "PROTEIN", 57, 73], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["the graphical alignment footprint", "TEST", 12, 45], ["a human ACE enzyme", "TREATMENT", 55, 73], ["lisinopril", "TREATMENT", 90, 100], ["a Cn3D view", "TEST", 178, 189], ["BLAST alignment", "OBSERVATION", 157, 172]]], ["One may see that the query protein is highly similar in sequence to the human ACE enzyme, as identical residue pairs are colored red by default.", [["human", "ORGANISM", 72, 77], ["ACE", "GENE_OR_GENE_PRODUCT", 78, 81], ["human ACE enzyme", "PROTEIN", 72, 88], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 72, 77], ["the query protein", "TEST", 17, 34], ["the human ACE enzyme", "TEST", 68, 88]]], ["The sequence identity across the aligned region is 82%, and it appears that the core of the structure is mostly formed by residues conserved between the two aligned rows, while non-conserved residues are mainly located on the structure's surface.An example ::: ANNOTATING SEQUENCE WITH STRUCTUREOne may further identify the catalytic center by identifying residues that contact the catalytic Zinc ion.", [["surface", "ANATOMY", 238, 245], ["Zinc", "CHEMICAL", 392, 396], ["Zinc", "CHEMICAL", 392, 396], ["surface", "CELLULAR_COMPONENT", 238, 245], ["the catalytic Zinc ion", "TREATMENT", 378, 400], ["core", "OBSERVATION_MODIFIER", 80, 84], ["structure", "OBSERVATION", 92, 101], ["mostly", "OBSERVATION_MODIFIER", 105, 111], ["formed", "OBSERVATION", 112, 118], ["residues", "OBSERVATION", 122, 130], ["two", "OBSERVATION_MODIFIER", 153, 156], ["aligned", "OBSERVATION_MODIFIER", 157, 164], ["rows", "OBSERVATION_MODIFIER", 165, 169], ["non-conserved residues", "OBSERVATION", 177, 199], ["surface", "OBSERVATION_MODIFIER", 238, 245]]], ["Those sites can then be mapped from the structure to aligned regions in the sequence window using Cn3D's highlighting functionality.", [["Cn3D", "SIMPLE_CHEMICAL", 98, 102], ["Cn3D", "DNA", 98, 102]]], ["One may also examine the sequence-structure alignments with related structures 1UZE and 1UZF, human ACE binding to enalaprilat and captopril, respectively, drugs with chemical structures similar to that of lisinopril.", [["enalaprilat", "CHEMICAL", 115, 126], ["captopril", "CHEMICAL", 131, 140], ["lisinopril", "CHEMICAL", 206, 216], ["enalaprilat", "CHEMICAL", 115, 126], ["captopril", "CHEMICAL", 131, 140], ["lisinopril", "CHEMICAL", 206, 216], ["1UZE", "SIMPLE_CHEMICAL", 79, 83], ["1UZF", "SIMPLE_CHEMICAL", 88, 92], ["human", "ORGANISM", 94, 99], ["ACE", "GENE_OR_GENE_PRODUCT", 100, 103], ["enalaprilat", "SIMPLE_CHEMICAL", 115, 126], ["captopril", "SIMPLE_CHEMICAL", 131, 140], ["lisinopril", "SIMPLE_CHEMICAL", 206, 216], ["human ACE", "PROTEIN", 94, 103], ["human", "SPECIES", 94, 99], ["human", "SPECIES", 94, 99], ["the sequence", "TEST", 21, 33], ["related structures 1UZE", "PROBLEM", 60, 83], ["1UZF", "TREATMENT", 88, 92], ["human ACE binding", "TREATMENT", 94, 111], ["enalaprilat", "TREATMENT", 115, 126], ["captopril", "TREATMENT", 131, 140], ["drugs", "TREATMENT", 156, 161], ["chemical structures", "TREATMENT", 167, 186], ["lisinopril", "TREATMENT", 206, 216]]], ["This allows one to identify conserved interactions between the ACE enzyme and this series of antihypertensive drugs.", [["ACE enzyme", "GENE_OR_GENE_PRODUCT", 63, 73], ["ACE enzyme", "PROTEIN", 63, 73], ["the ACE enzyme", "TREATMENT", 59, 73], ["antihypertensive drugs", "TREATMENT", 93, 115]]], ["Similarly, by examining the related structure 2AJF (13), one may be able to identify residues critical for cross-species infection by studying the protein\u2013protein interactions between the receptor binding domain from SARS Coronavirus Spike and human versus rat angiotensin-converting enzyme 2.An example ::: ANNOTATING SEQUENCE WITH STRUCTUREThe \u2018Related Structure\u2019 service is also integrated with NCBI's protein BLAST service.", [["infection", "DISEASE", 121, 130], ["angiotensin", "CHEMICAL", 261, 272], ["human", "ORGANISM", 244, 249], ["rat", "ORGANISM", 257, 260], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 261, 292], ["receptor binding domain", "PROTEIN", 188, 211], ["SARS Coronavirus Spike and human versus rat angiotensin-converting enzyme 2", "PROTEIN", 217, 292], ["human", "SPECIES", 244, 249], ["rat", "SPECIES", 257, 260], ["human", "SPECIES", 244, 249], ["cross-species infection", "PROBLEM", 107, 130], ["the protein\u2013protein interactions", "PROBLEM", 143, 175], ["the receptor binding domain", "PROBLEM", 184, 211], ["SARS Coronavirus Spike", "PROBLEM", 217, 239], ["human versus rat angiotensin", "TREATMENT", 244, 272]]], ["A \u2018Related Structures\u2019 link is provided when one or more similar proteins with known 3D structures have been identified by BLAST.", [["BLAST", "OBSERVATION", 123, 128]]], ["The NCBI single-nucleotide polymorphism resource (SNP) also links to the \u2018Related Structure\u2019 service, which in this context provides a mapping of both synonymous and non-synonymous coding SNPs onto experimentally determined 3D structures.", [["SNP", "CHEMICAL", 50, 53], ["non-synonymous coding SNPs", "DNA", 166, 192], ["The NCBI single-nucleotide polymorphism resource", "TREATMENT", 0, 48], ["a mapping", "TEST", 133, 142], ["both synonymous and non-synonymous coding SNPs", "TREATMENT", 146, 192]]], ["\u2018Related Structure\u2019 may be expanded further in the future, to provide visualization for other NCBI resources and to support additional filtering and selection among related structures, e.g. to highlight those annotated with conserved domain footprints by the CDD resource or those linked to small molecules in the PubChem database.", [["additional filtering", "TREATMENT", 124, 144], ["may be", "UNCERTAINTY", 20, 26], ["expanded", "OBSERVATION", 27, 35], ["small", "OBSERVATION_MODIFIER", 291, 296], ["molecules", "OBSERVATION", 297, 306], ["PubChem", "ANATOMY", 314, 321]]]], "2cc58b10f08e136c7482384c8dc0e52cc67f189b": [["Operating 12-Hour Staff Shifts on Coronavirus Disease-2019 Patients: A Harmful and Unwanted ProposalTo the Editor W e read with great interest Dexter et al's 1 evidence-based approach for optimization of infection control and operating room management, as well as their proposed 12-hour work shifts.", [["infection", "DISEASE", 204, 213], ["Patients", "ORGANISM", 59, 67], ["Patients", "SPECIES", 59, 67], ["infection control", "TREATMENT", 204, 221], ["operating room management", "TREATMENT", 226, 251], ["infection", "OBSERVATION", 204, 213]]], ["We must respectfully caution against the latter, as they could negatively impact anesthesiologists' neurobehavioral performance when caring for coronavirus disease 2019 (COVID-19) patients due to multiple factors (thereby increasing the likelihood of medical error).Operating 12-Hour Staff Shifts on Coronavirus Disease-2019 Patients: A Harmful and Unwanted ProposalFirst, working in close proximity to infected or at-risk COVID-19 patients requires the use of personal protective equipment (PPE), coupled with strict adherence to universal infection precautions.", [["coronavirus disease", "DISEASE", 144, 163], ["infection", "DISEASE", 541, 550], ["patients", "ORGANISM", 180, 188], ["Patients", "ORGANISM", 325, 333], ["patients", "ORGANISM", 432, 440], ["patients", "SPECIES", 180, 188], ["Patients", "SPECIES", 325, 333], ["patients", "SPECIES", 432, 440], ["coronavirus disease", "PROBLEM", 144, 163], ["COVID", "TEST", 170, 175], ["multiple factors", "PROBLEM", 196, 212], ["personal protective equipment", "TREATMENT", 461, 490], ["universal infection precautions", "TREATMENT", 531, 562], ["infected", "OBSERVATION", 403, 411], ["infection", "OBSERVATION", 541, 550]]], ["These protocols can result in a physically uncomfortable experience, as fluid-repellent PPE hinders the transfer of heat and moisture between human and environment.", [["human", "ORGANISM", 142, 147], ["human", "SPECIES", 142, 147], ["human", "SPECIES", 142, 147], ["a physically uncomfortable experience", "PROBLEM", 30, 67], ["fluid-repellent PPE", "TREATMENT", 72, 91]]], ["2, 3 In turn, heat stress is associated with decreased cognitive and psychomotor performance across multiple tasks.", [["decreased cognitive and psychomotor performance", "DISEASE", 45, 92], ["heat stress", "PROBLEM", 14, 25], ["decreased cognitive and psychomotor performance", "PROBLEM", 45, 92]]], ["3 In fact, during the Ebola outbreak in West Africa (2014), health care workers wearing impermeable PPE were limited to 40 minutes of working time before requiring a break for rest and cooling to remedy disrupted thermoregulatory homeostasis.", [["Ebola", "DISEASE", 22, 27], ["impermeable PPE", "TREATMENT", 88, 103], ["a break for rest", "TREATMENT", 164, 180], ["cooling", "TREATMENT", 185, 192], ["disrupted thermoregulatory homeostasis", "PROBLEM", 203, 241]]], ["4, 5 Second, anesthesiologists may be required to stay in the operating room for longer periods, with extra time needed for preparation, decontamination, and recovery of the patient in the operating room.", [["patient", "ORGANISM", 174, 181], ["patient", "SPECIES", 174, 181], ["decontamination", "TREATMENT", 137, 152]]], ["Consequently, COVID-19 patients can be difficult to care for, especially if they suffer from severe coughing, vomiting, or diarrhea, thereby producing significant viral loads with the attendant risk for cross-infection.", [["coughing", "DISEASE", 100, 108], ["vomiting", "DISEASE", 110, 118], ["diarrhea", "DISEASE", 123, 131], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["severe coughing", "PROBLEM", 93, 108], ["vomiting", "PROBLEM", 110, 118], ["diarrhea", "PROBLEM", 123, 131], ["significant viral loads", "PROBLEM", 151, 174], ["cross-infection", "PROBLEM", 203, 218], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["coughing", "OBSERVATION", 100, 108], ["viral loads", "OBSERVATION", 163, 174], ["cross-infection", "OBSERVATION", 203, 218]]], ["The resultant feelings of emotional stress, uncertainty, and fear, as well as concerns about passing infections to families and friends, may contribute to mental fatigue among health care workers.", [["infections", "DISEASE", 101, 111], ["fatigue", "DISEASE", 162, 169], ["emotional stress", "PROBLEM", 26, 42], ["mental fatigue", "PROBLEM", 155, 169]]], ["5, 6 Third, effective use of PPE constitutes a laborious process that requires guidance and training and, although essential, constricts mobility, which may hinder medical actions during lifesaving medical procedures, such as cardiopulmonary resuscitation.", [["cardiopulmonary", "ANATOMY", 226, 241], ["PPE", "TREATMENT", 29, 32], ["a laborious process", "PROBLEM", 45, 64], ["lifesaving medical procedures", "TREATMENT", 187, 216], ["cardiopulmonary resuscitation", "TREATMENT", 226, 255], ["constricts mobility", "OBSERVATION", 126, 145]]], ["2 Fourth, double gloving may not be favored by many medical staff due to loss of grip control, as well as a decrease in dexterity and tactile sensitivity.", [["double gloving", "TREATMENT", 10, 24], ["loss of grip control", "PROBLEM", 73, 93], ["a decrease in dexterity and tactile sensitivity", "PROBLEM", 106, 153], ["may not be", "UNCERTAINTY", 25, 35], ["decrease", "OBSERVATION_MODIFIER", 108, 116]]], ["2, 3, 5, 7 Anesthesiologists may experience a reduction in fine motor skills (eg, those required by intravenous/arterial cannulation), thereby exposing themselves to the added risk for needlestick injuries.", [["intravenous", "ANATOMY", 100, 111], ["arterial", "ANATOMY", 112, 120], ["needlestick injuries", "DISEASE", 185, 205], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 100, 111], ["arterial", "MULTI-TISSUE_STRUCTURE", 112, 120], ["a reduction in fine motor skills", "PROBLEM", 44, 76], ["intravenous/arterial cannulation", "TREATMENT", 100, 132], ["needlestick injuries", "PROBLEM", 185, 205], ["reduction", "OBSERVATION_MODIFIER", 46, 55]]], ["Similarly, regional anesthesia blocks may be more difficult to execute due to the use of multiple gloves and decreased finger dexterity.Operating 12-Hour Staff Shifts on Coronavirus Disease-2019 Patients: A Harmful and Unwanted ProposalIn a recent study, Parush et al 8 surveyed health care workers regarding the effect of wearing full level 1 PPE.", [["finger", "ANATOMY", 119, 125], ["decreased finger dexterity", "DISEASE", 109, 135], ["finger", "ORGANISM_SUBDIVISION", 119, 125], ["Patients", "ORGANISM", 195, 203], ["Patients", "SPECIES", 195, 203], ["regional anesthesia blocks", "TREATMENT", 11, 37], ["multiple gloves", "TREATMENT", 89, 104], ["decreased finger dexterity", "PROBLEM", 109, 135], ["a recent study", "TEST", 239, 253], ["decreased", "OBSERVATION_MODIFIER", 109, 118], ["finger dexterity", "OBSERVATION", 119, 135]]], ["Although all respondents recognized its importance, the survey uncovered limitations of PPE ergonomics (ie, physical discomfort, difficulties in seeing, hearing, speech comprehension, impaired communication, and situational awareness), as well as contamination problems during donning and doffing procedures.", [["PPE ergonomics", "PROBLEM", 88, 102], ["physical discomfort", "PROBLEM", 108, 127], ["difficulties in seeing, hearing, speech comprehension", "PROBLEM", 129, 182], ["impaired communication", "PROBLEM", 184, 206], ["contamination problems", "PROBLEM", 247, 269], ["doffing procedures", "TREATMENT", 289, 307]]], ["Wearing PPE negatively affects physical performance and individual well-being and influences concentration and error rates.", [["error rates", "TEST", 111, 122]]], ["2, 3, 5 Despite these setbacks, anesthesiologists and intensivists, taking care of COVID-19 patients, are required to wear even higher levels of PPE (ie, type 2 or 3) during aerosolgenerating procedures.", [["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["aerosolgenerating procedures", "TREATMENT", 174, 202]]], ["Such precautions include a long-sleeved, fluid-repellent gown or a completely encapsulated coverall, tight-fit filtering face piece (FFP3/N95) respirators, and sturdy face shield, visor, or hood.", [["Such precautions", "TREATMENT", 0, 16], ["a long-sleeved, fluid-repellent gown", "TREATMENT", 25, 61], ["filtering face piece", "TREATMENT", 111, 131], ["FFP3/N95", "TREATMENT", 133, 141], ["respirators", "TREATMENT", 143, 154]]], ["In these situations, the use of personal cooling devices may be advantageous to mitigate increases in body temperature and weight loss.", [["body", "ANATOMY", 102, 106], ["weight loss", "DISEASE", 123, 134], ["body", "ORGANISM_SUBDIVISION", 102, 106], ["personal cooling devices", "TREATMENT", 32, 56], ["body temperature", "PROBLEM", 102, 118], ["weight loss", "PROBLEM", 123, 134], ["weight loss", "OBSERVATION", 123, 134]]], ["4 In summary, 12-hour work shifts in the current context of physically and psychologically demanding workloads may contribute to impairment of cognitive function.", [["impairment of cognitive function", "DISEASE", 129, 161], ["impairment of cognitive function", "PROBLEM", 129, 161]]], ["In turn, this could result in lapses in attention, altered clinical judgment, and inaccurate decisionmaking and could contribute to health care provider fatigue and burnout.", [["fatigue", "DISEASE", 153, 160], ["burnout", "DISEASE", 165, 172], ["fatigue", "PROBLEM", 153, 160], ["burnout", "PROBLEM", 165, 172]]], ["Thus, psychological support for medical well-being and shorter shift times become essential.", [["psychological support", "TREATMENT", 6, 27]]], ["2 In fact, physicians and nurses working with COVID-19 patients have already provided identical feedback on ideal work times (ie, 4-to 6-hour shifts) and longer recovery periods, thus underpinning the importance of adequate sleep restoration.", [["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["adequate sleep restoration", "TREATMENT", 215, 241], ["sleep restoration", "OBSERVATION", 224, 241]]]], "PMC7115640": [["Gastroenteritis agudaLa diarrea aguda es uno de los diagn\u00f3sticos m\u00e1s frecuentes en la pr\u00e1ctica cl\u00ednica, tanto en adultos como en ni\u00f1os, variando su prevalencia y su etiolog\u00eda en funci\u00f3n del \u00e1rea geogr\u00e1fica, las condiciones socioecon\u00f3micas y la edad1.", [["Gastroenteritis", "PROBLEM", 0, 15]]], ["Los datos recogidos infraestiman esta entidad ya que no todos los pacientes reclaman asistencia m\u00e9dica (tan s\u00f3lo el 22% consultan al m\u00e9dico) y las pruebas no siempre se realizan en el momento de acudir al especialista (tan s\u00f3lo en un 5% se efect\u00faa coprocultivo)2.", [["acudir al especialista (tan s\u00f3lo en un", "TREATMENT", 195, 233]]], ["A pesar de todas estas dificultades metodol\u00f3gicas se estima que en los pa\u00edses desarrollados la incidencia es de 0,5-2 episodios por persona y a\u00f1o, siendo esta cifra mucho mayor en pa\u00edses en v\u00edas de desarrollo.", [["A pesar de todas estas", "TREATMENT", 0, 22], ["metodol\u00f3gicas", "TEST", 36, 49]]], ["As\u00ed, en Europa occidental se calcula una incidencia de un episodio por persona al a\u00f1o3.", [["As\u00ed", "TEST", 0, 3]]], ["En Espa\u00f1a no existen estudios en poblaci\u00f3n adulta.Gastroenteritis agudaLas causas m\u00e1s frecuentes de diarrea aguda son los agentes infecciosos: virus, bacterias y par\u00e1sitos.", [["Gastroenteritis", "PROBLEM", 50, 65], ["virus", "PROBLEM", 143, 148]]], ["Entre otras causas se encuentran la toma de f\u00e1rmacos (especialmente los antibi\u00f3ticos), la intoxicaci\u00f3n alimentaria, la colitis isqu\u00e9mica, etc. En la mayor\u00eda de pa\u00edses desarrollados los agentes m\u00e1s frecuentes que producen diarrea aguda son los Rotavirus y Norovirus; pr\u00e1cticamente todos los ni\u00f1os menores de 5 a\u00f1os han sido infectados por Rotavirus.", [["colitis isqu\u00e9mica", "DISEASE", 119, 136], ["Rotavirus y Norovirus", "DISEASE", 243, 264], ["Rotavirus", "DISEASE", 338, 347], ["la intoxicaci\u00f3n alimentaria", "PROBLEM", 87, 114], ["la colitis isqu\u00e9mica", "PROBLEM", 116, 136], ["Rotavirus y Norovirus", "PROBLEM", 243, 264], ["Rotavirus", "PROBLEM", 338, 347], ["la colitis", "OBSERVATION", 116, 126]]], ["Otros virus ent\u00e9ricos menos prevalentes incluyen Sapovirus, Coronavirus, Torovirus y Enterovirus.", [["Enterovirus", "DISEASE", 85, 96], ["Otros virus", "ORGANISM", 0, 11], ["Torovirus y Enterovirus", "ORGANISM", 73, 96], ["virus ent\u00e9ricos menos", "SPECIES", 6, 27], ["Otros virus ent\u00e9ricos", "SPECIES", 0, 21], ["Otros virus ent\u00e9ricos menos", "TEST", 0, 27], ["Sapovirus", "PROBLEM", 49, 58], ["Coronavirus", "PROBLEM", 60, 71], ["Torovirus y Enterovirus", "PROBLEM", 73, 96]]], ["Entre las causas bacterianas m\u00e1s frecuentes est\u00e1n Campylobacter, Salmonella no tifoidea, Shigella y Escherichia coli (E. coli) enterohemorr\u00e1gica.", [["Escherichia coli", "ORGANISM", 100, 116], ["E. coli", "ORGANISM", 118, 125], ["Escherichia coli", "SPECIES", 100, 116], ["E. coli", "SPECIES", 118, 125], ["Salmonella no tifoidea", "SPECIES", 65, 87], ["Escherichia coli", "SPECIES", 100, 116], ["E. coli", "SPECIES", 118, 125], ["Entre las causas bacterianas m\u00e1s", "TEST", 0, 32], ["Campylobacter", "PROBLEM", 50, 63], ["Salmonella", "PROBLEM", 65, 75], ["tifoidea", "PROBLEM", 79, 87], ["Shigella y Escherichia coli (E. coli)", "PROBLEM", 89, 126], ["enterohemorr\u00e1gica", "PROBLEM", 127, 144], ["Escherichia coli", "OBSERVATION", 100, 116], ["E. coli", "OBSERVATION", 118, 125]]], ["Clostridium difficile, antes considerado como exclusivamente nosocomial, es tambi\u00e9n una causa frecuente de diarrea adquirida en la comunidad.", [["Clostridium difficile", "DISEASE", 0, 21], ["nosocomial", "DISEASE", 61, 71], ["Clostridium difficile", "SPECIES", 0, 21], ["Clostridium difficile", "SPECIES", 0, 21], ["Clostridium difficile", "PROBLEM", 0, 21], ["nosocomial", "PROBLEM", 61, 71], ["difficile", "OBSERVATION", 12, 21]]]], "PMC7263488": [["IntroductionCoronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic affecting millions of people worldwide.", [["IntroductionCoronavirus disease", "DISEASE", 0, 31], ["COVID-19", "CHEMICAL", 38, 46], ["acute respiratory syndrome coronavirus", "DISEASE", 65, 103], ["SARS-CoV-2", "CHEMICAL", 107, 117], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 58, 105], ["SARS-CoV-2", "ORGANISM", 107, 117], ["people", "ORGANISM", 163, 169], ["people", "SPECIES", 163, 169], ["IntroductionCoronavirus disease 2019 (COVID-19", "SPECIES", 0, 46], ["severe acute respiratory syndrome coronavirus", "SPECIES", 58, 103], ["SARS-CoV-2", "SPECIES", 107, 117], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31], ["COVID", "TEST", 38, 43], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 58, 103], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["respiratory syndrome", "OBSERVATION", 71, 91], ["pandemic", "OBSERVATION", 132, 140]]], ["Limited understanding of the disease pathophysiology has impeded our ability to develop effective preventative and therapeutic strategies.", [["the disease pathophysiology", "PROBLEM", 25, 52], ["therapeutic strategies", "TREATMENT", 115, 137]]], ["Multi-organ failure is the most lethal complication of SARS-CoV-2 infection1.", [["Multi-organ", "ANATOMY", 0, 11], ["Multi-organ failure", "DISEASE", 0, 19], ["SARS", "DISEASE", 55, 59], ["Multi-organ failure", "PROBLEM", 0, 19], ["SARS", "PROBLEM", 55, 59], ["CoV-2 infection1", "PROBLEM", 60, 76], ["failure", "OBSERVATION", 12, 19], ["most lethal", "OBSERVATION_MODIFIER", 27, 38], ["SARS", "OBSERVATION", 55, 59]]], ["Early reports from China show higher mortality rates in patients that develop myocardial injury, as measured by the elevation of serum troponin T levels2,3.", [["myocardial", "ANATOMY", 78, 88], ["serum", "ANATOMY", 129, 134], ["myocardial injury", "DISEASE", 78, 95], ["patients", "ORGANISM", 56, 64], ["myocardial", "MULTI-TISSUE_STRUCTURE", 78, 88], ["serum", "ORGANISM_SUBSTANCE", 129, 134], ["troponin T", "GENE_OR_GENE_PRODUCT", 135, 145], ["patients", "SPECIES", 56, 64], ["myocardial injury", "PROBLEM", 78, 95], ["serum troponin T levels", "TEST", 129, 152], ["myocardial", "ANATOMY", 78, 88], ["injury", "OBSERVATION", 89, 95], ["elevation", "OBSERVATION_MODIFIER", 116, 125]]], ["Furthermore, COVID-19 patients presenting with cardiac injury were more likely to have a baseline cardiovascular disease such as hypertensive disorders or heart failure2.IntroductionIt has been well documented that organ involvement and disease manifestation are correlated with the expression of SARS-CoV receptor and co-receptors on the membrane of target cells4.", [["cardiac", "ANATOMY", 47, 54], ["cardiovascular", "ANATOMY", 98, 112], ["heart", "ANATOMY", 155, 160], ["organ", "ANATOMY", 215, 220], ["membrane", "ANATOMY", 339, 347], ["cells4", "ANATOMY", 358, 364], ["cardiac injury", "DISEASE", 47, 61], ["cardiovascular disease", "DISEASE", 98, 120], ["hypertensive disorders", "DISEASE", 129, 151], ["heart failure2", "DISEASE", 155, 169], ["patients", "ORGANISM", 22, 30], ["cardiac", "ORGAN", 47, 54], ["heart", "ORGAN", 155, 160], ["organ", "ORGAN", 215, 220], ["SARS-CoV receptor", "GENE_OR_GENE_PRODUCT", 297, 314], ["membrane", "CELLULAR_COMPONENT", 339, 347], ["cells4", "CELL", 358, 364], ["SARS-CoV receptor", "PROTEIN", 297, 314], ["co-receptors", "PROTEIN", 319, 331], ["target cells4", "CELL_TYPE", 351, 364], ["patients", "SPECIES", 22, 30], ["SARS-CoV", "SPECIES", 297, 305], ["cardiac injury", "PROBLEM", 47, 61], ["a baseline cardiovascular disease", "PROBLEM", 87, 120], ["hypertensive disorders", "PROBLEM", 129, 151], ["heart failure2", "PROBLEM", 155, 169], ["organ involvement", "PROBLEM", 215, 232], ["disease manifestation", "PROBLEM", 237, 258], ["SARS", "PROBLEM", 297, 301], ["cardiac", "ANATOMY", 47, 54], ["injury", "OBSERVATION", 55, 61], ["cardiovascular", "ANATOMY", 98, 112], ["disease", "OBSERVATION", 113, 120], ["heart", "ANATOMY", 155, 160], ["failure2", "OBSERVATION", 161, 169]]], ["The spike (S) protein, which is responsible for the characteristic crown-like shape of coronaviruses, facilitates the binding of the virus to its receptors on the cell membrane5,6.", [["cell membrane", "ANATOMY", 163, 176], ["spike (S)", "GENE_OR_GENE_PRODUCT", 4, 13], ["cell membrane", "CELLULAR_COMPONENT", 163, 176], ["spike (S) protein", "PROTEIN", 4, 21], ["The spike (S) protein", "TEST", 0, 21], ["the characteristic crown-like shape of coronaviruses", "PROBLEM", 48, 100], ["the cell membrane", "TEST", 159, 176], ["crown", "OBSERVATION_MODIFIER", 67, 72], ["like shape", "OBSERVATION_MODIFIER", 73, 83], ["coronaviruses", "OBSERVATION", 87, 100]]], ["ACE2 has been identified as the main receptor utilized by SARS-CoV-2 and SARS-CoV-1 to enter cells7.", [["cells7", "ANATOMY", 93, 99], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["SARS-CoV-2", "ORGANISM", 58, 68], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 73, 83], ["cells7", "CELL", 93, 99], ["ACE2", "PROTEIN", 0, 4], ["cells7", "DNA", 93, 99], ["SARS-CoV-1", "SPECIES", 73, 83], ["ACE2", "TREATMENT", 0, 4], ["CoV", "TEST", 63, 66], ["SARS", "TEST", 73, 77], ["CoV", "TEST", 78, 81]]], ["Additionally, recent findings using human and animal cell lines have demonstrated that SARS-CoV-2 relies on the serine protease TMPRSS2 for S protein priming prior to ACE2 facilitated internalization6.", [["cell lines", "ANATOMY", 53, 63], ["serine", "CHEMICAL", 112, 118], ["human", "ORGANISM", 36, 41], ["cell lines", "CELL", 53, 63], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 87, 97], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 128, 135], ["S protein", "GENE_OR_GENE_PRODUCT", 140, 149], ["ACE2", "GENE_OR_GENE_PRODUCT", 167, 171], ["human and animal cell lines", "CELL_LINE", 36, 63], ["serine protease", "PROTEIN", 112, 127], ["TMPRSS2", "PROTEIN", 128, 135], ["S protein", "PROTEIN", 140, 149], ["ACE2", "PROTEIN", 167, 171], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["human and animal cell lines", "TREATMENT", 36, 63], ["SARS", "PROBLEM", 87, 91], ["CoV", "TEST", 92, 95], ["the serine protease TMPRSS2", "TREATMENT", 108, 135], ["S protein priming", "TREATMENT", 140, 157], ["ACE2 facilitated internalization6", "TREATMENT", 167, 200], ["cell lines", "OBSERVATION", 53, 63]]], ["Research after the SARS-CoV-1 epidemic shows that knockingout ACE2 results in markedly decreased viral entry in lungs of mice infected with the virus8.", [["lungs", "ANATOMY", 112, 117], ["SARS", "DISEASE", 19, 23], ["SARS-CoV-1", "ORGANISM", 19, 29], ["ACE2", "GENE_OR_GENE_PRODUCT", 62, 66], ["lungs", "ORGAN", 112, 117], ["mice", "ORGANISM", 121, 125], ["virus8", "GENE_OR_GENE_PRODUCT", 144, 150], ["knockingout ACE2", "PROTEIN", 50, 66], ["mice", "SPECIES", 121, 125], ["mice", "SPECIES", 121, 125], ["the SARS", "TEST", 15, 23], ["CoV", "TEST", 24, 27], ["epidemic", "PROBLEM", 30, 38], ["markedly decreased viral entry", "PROBLEM", 78, 108], ["markedly", "OBSERVATION_MODIFIER", 78, 86], ["decreased", "OBSERVATION_MODIFIER", 87, 96], ["viral entry", "OBSERVATION", 97, 108], ["lungs", "ANATOMY", 112, 117]]], ["Recently, Tucker et. al. showed expression of ACE2 in human adult cardiac cells, such as cardiomyocytes, fibroblasts, pericytes, and vascular smooth muscle.", [["adult cardiac cells", "ANATOMY", 60, 79], ["cardiomyocytes", "ANATOMY", 89, 103], ["fibroblasts", "ANATOMY", 105, 116], ["pericytes", "ANATOMY", 118, 127], ["vascular smooth muscle", "ANATOMY", 133, 155], ["ACE2", "GENE_OR_GENE_PRODUCT", 46, 50], ["human", "ORGANISM", 54, 59], ["adult cardiac cells", "CELL", 60, 79], ["cardiomyocytes", "CELL", 89, 103], ["fibroblasts", "CELL", 105, 116], ["pericytes", "CELL", 118, 127], ["vascular smooth muscle", "TISSUE", 133, 155], ["ACE2", "PROTEIN", 46, 50], ["human adult cardiac cells", "CELL_TYPE", 54, 79], ["cardiomyocytes", "CELL_TYPE", 89, 103], ["fibroblasts", "CELL_TYPE", 105, 116], ["pericytes", "CELL_TYPE", 118, 127], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 54, 59], ["ACE2 in human adult cardiac cells", "PROBLEM", 46, 79], ["cardiomyocytes", "PROBLEM", 89, 103], ["fibroblasts, pericytes, and vascular smooth muscle", "PROBLEM", 105, 155], ["cardiac cells", "ANATOMY", 66, 79], ["cardiomyocytes", "ANATOMY", 89, 103], ["fibroblasts", "OBSERVATION", 105, 116], ["pericytes", "OBSERVATION", 118, 127], ["vascular", "ANATOMY", 133, 141], ["smooth muscle", "ANATOMY", 142, 155]]], ["Interestingly, ACE2 levels in cardiomyocytes are found to be increased in patients with failing hearts, further linking the expression profile of ACE2 to clinical findings in COVID-19 patients9.", [["cardiomyocytes", "ANATOMY", 30, 44], ["hearts", "ANATOMY", 96, 102], ["ACE2", "GENE_OR_GENE_PRODUCT", 15, 19], ["cardiomyocytes", "CELL", 30, 44], ["patients", "ORGANISM", 74, 82], ["hearts", "ORGAN", 96, 102], ["ACE2", "GENE_OR_GENE_PRODUCT", 146, 150], ["ACE2", "PROTEIN", 15, 19], ["cardiomyocytes", "CELL_TYPE", 30, 44], ["ACE2", "PROTEIN", 146, 150], ["patients", "SPECIES", 74, 82], ["ACE2 levels", "TEST", 15, 26], ["failing hearts", "PROBLEM", 88, 102], ["COVID", "TEST", 175, 180], ["cardiomyocytes", "ANATOMY", 30, 44], ["increased", "OBSERVATION_MODIFIER", 61, 70]]], ["In this study, we identified pharmacological strategies to reduce the levels of ACE2 in human embryonic stem cell (hESC) derived cardiac cells in order to facilitate therapeutic interventions aimed at reducing viral entry, thereby mitigating the multi-organ complications induced by SARS-CoV-2 infection.IntroductionTo identify candidate drugs capable of modulating ACE2 protein levels, we took advantage of our previously established methods to generate cardiac cells from human embryonic stem cells at large scale10\u201312 and performed a high content screen with a library of 1443 FDA-approved drugs and a subsequent in silico screen with the ZINC15 library of over 9 million drug-like compounds.", [["embryonic stem cell", "ANATOMY", 94, 113], ["hESC", "ANATOMY", 115, 119], ["cardiac cells", "ANATOMY", 129, 142], ["multi-organ", "ANATOMY", 246, 257], ["cardiac cells", "ANATOMY", 455, 468], ["embryonic stem cells", "ANATOMY", 480, 500], ["infection", "DISEASE", 294, 303], ["ACE2", "GENE_OR_GENE_PRODUCT", 80, 84], ["human", "ORGANISM", 88, 93], ["embryonic stem cell (hESC) derived cardiac cells", "CELL", 94, 142], ["SARS-CoV-2", "ORGANISM", 283, 293], ["ACE2", "GENE_OR_GENE_PRODUCT", 366, 370], ["cardiac cells", "CELL", 455, 468], ["human", "ORGANISM", 474, 479], ["embryonic stem cells", "CELL", 480, 500], ["ACE2", "PROTEIN", 80, 84], ["human embryonic stem cell (hESC) derived cardiac cells", "CELL_LINE", 88, 142], ["ACE2", "PROTEIN", 366, 370], ["cardiac cells", "CELL_TYPE", 455, 468], ["human embryonic stem cells", "CELL_TYPE", 474, 500], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 474, 479], ["human", "SPECIES", 88, 93], ["SARS-CoV-2", "SPECIES", 283, 293], ["human", "SPECIES", 474, 479], ["this study", "TEST", 3, 13], ["pharmacological strategies", "TREATMENT", 29, 55], ["ACE2 in human embryonic stem cell", "TREATMENT", 80, 113], ["cardiac cells", "TREATMENT", 129, 142], ["therapeutic interventions", "TREATMENT", 166, 191], ["the multi-organ complications", "PROBLEM", 242, 271], ["SARS", "PROBLEM", 283, 287], ["CoV-2 infection", "PROBLEM", 288, 303], ["drugs", "TREATMENT", 338, 343], ["modulating ACE2 protein levels", "PROBLEM", 355, 385], ["human embryonic stem cells", "TREATMENT", 474, 500], ["drugs", "TREATMENT", 593, 598], ["silico screen", "TEST", 619, 632], ["embryonic stem cell", "OBSERVATION", 94, 113], ["multi-organ", "ANATOMY", 246, 257], ["complications", "OBSERVATION", 258, 271], ["infection", "OBSERVATION", 294, 303], ["cardiac", "ANATOMY", 455, 462], ["embryonic stem cells", "OBSERVATION", 480, 500]]], ["We discovered that drugs most effective in reducing ACE2 protein levels converge on androgen receptor (AR) signaling inhibition as a common mechanism of action.", [["androgen", "CHEMICAL", 84, 92], ["ACE2", "GENE_OR_GENE_PRODUCT", 52, 56], ["androgen receptor", "GENE_OR_GENE_PRODUCT", 84, 101], ["AR", "GENE_OR_GENE_PRODUCT", 103, 105], ["ACE2", "PROTEIN", 52, 56], ["androgen receptor", "PROTEIN", 84, 101], ["AR", "PROTEIN", 103, 105], ["drugs", "TREATMENT", 19, 24], ["reducing ACE2 protein levels", "PROBLEM", 43, 71], ["androgen receptor (AR) signaling inhibition", "TREATMENT", 84, 127]]], ["These drugs were effective in reducing ACE2 and TMPRSS2 levels on the cellular membrane and resulted in reduced internalization of SARS-CoV-2 spike-RBD in hESC-derived cardiac cells and human primary alveolar epithelial cells.IntroductionClinical case studies have identified male sex as a major risk factor for SARS-CoV-2 complications.", [["cellular membrane", "ANATOMY", 70, 87], ["hESC-derived cardiac cells", "ANATOMY", 155, 181], ["alveolar epithelial cells", "ANATOMY", 200, 225], ["SARS", "DISEASE", 312, 316], ["ACE2", "GENE_OR_GENE_PRODUCT", 39, 43], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 48, 55], ["cellular membrane", "CELLULAR_COMPONENT", 70, 87], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 131, 141], ["hESC-derived cardiac cells", "CELL", 155, 181], ["human", "ORGANISM", 186, 191], ["alveolar epithelial cells", "CELL", 200, 225], ["ACE2", "PROTEIN", 39, 43], ["TMPRSS2", "PROTEIN", 48, 55], ["RBD", "PROTEIN", 148, 151], ["hESC", "CELL_LINE", 155, 159], ["cardiac cells", "CELL_TYPE", 168, 181], ["human primary alveolar epithelial cells", "CELL_TYPE", 186, 225], ["human", "SPECIES", 186, 191], ["human", "SPECIES", 186, 191], ["SARS-CoV", "SPECIES", 312, 320], ["These drugs", "TREATMENT", 0, 11], ["TMPRSS2 levels", "TEST", 48, 62], ["the cellular membrane", "TREATMENT", 66, 87], ["reduced internalization of SARS", "PROBLEM", 104, 135], ["CoV", "TEST", 136, 139], ["RBD", "PROBLEM", 148, 151], ["human primary alveolar epithelial cells", "PROBLEM", 186, 225], ["SARS", "PROBLEM", 312, 316], ["CoV-2 complications", "PROBLEM", 317, 336], ["cellular membrane", "ANATOMY", 70, 87], ["reduced", "OBSERVATION_MODIFIER", 104, 111], ["cardiac cells", "ANATOMY", 168, 181], ["primary", "OBSERVATION_MODIFIER", 192, 199], ["alveolar epithelial cells", "OBSERVATION", 200, 225]]], ["In fact, 70% of the patients on ventilators in the ICU were found to be males1.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["ventilators", "TREATMENT", 32, 43]]], ["To explore the possible role of androgen signaling on poor disease outcomes in male COVID-19 patients, we conducted a study on two independent cohorts of patients tested for SARS-CoV-2.", [["androgen", "CHEMICAL", 32, 40], ["androgen", "GENE_OR_GENE_PRODUCT", 32, 40], ["patients", "ORGANISM", 93, 101], ["patients", "ORGANISM", 154, 162], ["SARS-CoV-2", "ORGANISM", 174, 184], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 154, 162], ["SARS-CoV", "SPECIES", 174, 182], ["androgen signaling", "PROBLEM", 32, 50], ["poor disease outcomes", "PROBLEM", 54, 75], ["a study", "TEST", 116, 123], ["SARS", "PROBLEM", 174, 178], ["CoV", "TEST", 179, 182]]], ["Among males, we found a significant positive association between free androgen index and the risk of severe COVID-19 and between prostatic disease as a surrogate for androgen dysregulation and abnormal blood troponin T levels.", [["prostatic", "ANATOMY", 129, 138], ["blood", "ANATOMY", 202, 207], ["prostatic disease", "DISEASE", 129, 146], ["androgen", "CHEMICAL", 70, 78], ["androgen", "CHEMICAL", 166, 174], ["androgen", "SIMPLE_CHEMICAL", 70, 78], ["prostatic", "ORGAN", 129, 138], ["androgen", "SIMPLE_CHEMICAL", 166, 174], ["blood", "ORGANISM_SUBSTANCE", 202, 207], ["troponin T", "GENE_OR_GENE_PRODUCT", 208, 218], ["a significant positive association between free androgen index", "PROBLEM", 22, 84], ["severe COVID", "PROBLEM", 101, 113], ["prostatic disease", "PROBLEM", 129, 146], ["androgen dysregulation", "PROBLEM", 166, 188], ["abnormal blood troponin T levels", "PROBLEM", 193, 225], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["positive", "OBSERVATION", 36, 44], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["prostatic", "ANATOMY", 129, 138], ["disease", "OBSERVATION", 139, 146]]], ["Our data provide a potential mechanistic link between clinical observations and pathways involved in COVID-19 pathogenesis.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 101, 109]]], ["The results identify AR signaling inhibition as a potential therapeutic strategy to reduce SARS-CoV-2 viral entry and mitigate severe manifestations in COVID-19 patients.High-throughput drug screen identifies ACE2 modulators in human cardiac cellsOur analysis of previously published single cell RNA sequencing datasets13\u201315 showed abundant expression of SARS-CoV-2 receptor, ACE2, and co-receptors, TMPRSS2 and FURIN in adult cardiac, esophageal, lung and colon tissues (Supplementary Figure 1A).", [["cardiac cells", "ANATOMY", 234, 247], ["adult cardiac", "ANATOMY", 421, 434], ["esophageal", "ANATOMY", 436, 446], ["lung", "ANATOMY", 448, 452], ["colon tissues", "ANATOMY", 457, 470], ["AR", "GENE_OR_GENE_PRODUCT", 21, 23], ["SARS-CoV-2", "ORGANISM", 91, 101], ["patients", "ORGANISM", 161, 169], ["ACE2", "GENE_OR_GENE_PRODUCT", 209, 213], ["human", "ORGANISM", 228, 233], ["cardiac cells", "CELL", 234, 247], ["cell", "CELL", 291, 295], ["SARS-CoV-2 receptor", "GENE_OR_GENE_PRODUCT", 355, 374], ["ACE2", "GENE_OR_GENE_PRODUCT", 376, 380], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 400, 407], ["FURIN", "GENE_OR_GENE_PRODUCT", 412, 417], ["cardiac", "ORGAN", 427, 434], ["esophageal", "MULTI-TISSUE_STRUCTURE", 436, 446], ["lung", "ORGAN", 448, 452], ["colon tissues", "TISSUE", 457, 470], ["AR", "PROTEIN", 21, 23], ["ACE2", "PROTEIN", 209, 213], ["human cardiac cells", "CELL_TYPE", 228, 247], ["SARS-CoV-2 receptor", "PROTEIN", 355, 374], ["ACE2", "PROTEIN", 376, 380], ["co-receptors", "PROTEIN", 386, 398], ["TMPRSS2", "PROTEIN", 400, 407], ["FURIN", "PROTEIN", 412, 417], ["patients", "SPECIES", 161, 169], ["human", "SPECIES", 228, 233], ["SARS-CoV", "SPECIES", 91, 99], ["human", "SPECIES", 228, 233], ["a potential therapeutic strategy", "TREATMENT", 48, 80], ["SARS", "TEST", 91, 95], ["CoV", "TEST", 96, 99], ["severe manifestations", "PROBLEM", 127, 148], ["COVID", "TEST", 152, 157], ["drug screen", "TEST", 186, 197], ["ACE2 modulators in human cardiac cells", "PROBLEM", 209, 247], ["Our analysis", "TEST", 247, 259], ["single cell RNA sequencing datasets", "TEST", 284, 319], ["SARS", "PROBLEM", 355, 359], ["CoV", "TEST", 360, 363], ["ACE2", "TEST", 376, 380], ["co-receptors", "TREATMENT", 386, 398], ["TMPRSS2", "PROBLEM", 400, 407], ["FURIN in adult cardiac, esophageal, lung and colon tissues", "PROBLEM", 412, 470], ["cardiac cells", "ANATOMY", 234, 247], ["cardiac", "ANATOMY", 427, 434], ["esophageal", "ANATOMY", 436, 446], ["lung", "ANATOMY", 448, 452], ["colon tissues", "ANATOMY", 457, 470]]], ["Given the highly significant association of poor outcomes in COVID-19 patients with cardiovascular complications2,3 and the significant role of ACE2 in cardiac physiology16, we chose to focus on the regulation of ACE2 levels in cardiac cells.", [["cardiovascular", "ANATOMY", 84, 98], ["cardiac", "ANATOMY", 152, 159], ["cardiac cells", "ANATOMY", 228, 241], ["cardiovascular complications", "DISEASE", 84, 112], ["patients", "ORGANISM", 70, 78], ["cardiovascular", "ANATOMICAL_SYSTEM", 84, 98], ["ACE2", "GENE_OR_GENE_PRODUCT", 144, 148], ["cardiac", "ORGAN", 152, 159], ["ACE2", "GENE_OR_GENE_PRODUCT", 213, 217], ["cardiac cells", "CELL", 228, 241], ["ACE2", "PROTEIN", 144, 148], ["ACE2", "PROTEIN", 213, 217], ["cardiac cells", "CELL_TYPE", 228, 241], ["patients", "SPECIES", 70, 78], ["cardiovascular complications", "PROBLEM", 84, 112], ["ACE2 levels", "TEST", 213, 224], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["significant", "OBSERVATION_MODIFIER", 124, 135], ["cardiac", "ANATOMY", 152, 159], ["cardiac cells", "ANATOMY", 228, 241]]], ["Due to limitations associated with isolation and maintenance of human cells from primary tissue, we used our previously established hESC differentiation method as an alternative strategy to generate cardiac cells (Supplementary Figure 1B)12 Previously published transcriptomics data on hESC-derived cells generated using this method12 confirmed the expression of SARS-CoV-2 receptor and co-receptors mRNAs in cardiomyocytes and non-cardiomyocyte (Supplementary Figure 1C).", [["cells", "ANATOMY", 70, 75], ["primary tissue", "ANATOMY", 81, 95], ["hESC", "ANATOMY", 132, 136], ["cardiac cells", "ANATOMY", 199, 212], ["hESC-derived cells", "ANATOMY", 286, 304], ["cardiomyocytes", "ANATOMY", 409, 423], ["non-cardiomyocyte", "ANATOMY", 428, 445], ["human", "ORGANISM", 64, 69], ["cells", "CELL", 70, 75], ["tissue", "TISSUE", 89, 95], ["hESC", "CELL", 132, 136], ["cardiac cells", "CELL", 199, 212], ["hESC-derived cells", "CELL", 286, 304], ["method12", "GENE_OR_GENE_PRODUCT", 326, 334], ["SARS-CoV-2 receptor", "GENE_OR_GENE_PRODUCT", 363, 382], ["cardiomyocytes", "CELL", 409, 423], ["non-cardiomyocyte", "CELL", 428, 445], ["human cells", "CELL_TYPE", 64, 75], ["cardiac cells", "CELL_TYPE", 199, 212], ["hESC-derived cells", "CELL_LINE", 286, 304], ["method12", "DNA", 326, 334], ["SARS-CoV-2 receptor and co-receptors mRNAs", "RNA", 363, 405], ["cardiomyocytes", "CELL_TYPE", 409, 423], ["non-cardiomyocyte", "CELL_TYPE", 428, 445], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["isolation", "TREATMENT", 35, 44], ["human cells", "PROBLEM", 64, 75], ["primary tissue", "PROBLEM", 81, 95], ["an alternative strategy", "TREATMENT", 163, 186], ["this method12", "TEST", 321, 334], ["SARS", "TEST", 363, 367], ["CoV", "TEST", 368, 371], ["cardiomyocytes", "PROBLEM", 409, 423], ["non-cardiomyocyte", "TEST", 428, 445], ["human cells", "OBSERVATION", 64, 75], ["cardiac", "ANATOMY", 199, 206], ["cardiomyocytes", "ANATOMY", 409, 423]]], ["The differentiated cells also stained positive for ACE2 as assessed by immunofluorescence imaging (Supplementary Figure 1D).High-throughput drug screen identifies ACE2 modulators in human cardiac cellsSearching for modulators of ACE2 levels in hESC-derived cardiac cells, we screened a Selleckchem small molecule library composed of 1443 FDA-approved drugs (Figure 1A).", [["cells", "ANATOMY", 19, 24], ["cardiac cells", "ANATOMY", 188, 201], ["hESC-derived cardiac cells", "ANATOMY", 244, 270], ["cells", "CELL", 19, 24], ["ACE2", "GENE_OR_GENE_PRODUCT", 51, 55], ["ACE2", "GENE_OR_GENE_PRODUCT", 163, 167], ["human", "ORGANISM", 182, 187], ["cardiac cells", "CELL", 188, 201], ["ACE2", "GENE_OR_GENE_PRODUCT", 229, 233], ["hESC-derived cardiac cells", "CELL", 244, 270], ["differentiated cells", "CELL_TYPE", 4, 24], ["ACE2", "PROTEIN", 51, 55], ["ACE2", "PROTEIN", 163, 167], ["human cardiac cells", "CELL_TYPE", 182, 201], ["ACE2", "PROTEIN", 229, 233], ["hESC", "CELL_LINE", 244, 248], ["cardiac cells", "CELL_TYPE", 257, 270], ["human", "SPECIES", 182, 187], ["human", "SPECIES", 182, 187], ["The differentiated cells", "PROBLEM", 0, 24], ["ACE2", "TEST", 51, 55], ["immunofluorescence imaging", "TEST", 71, 97], ["drug screen", "TEST", 140, 151], ["ACE2 modulators in human cardiac cells", "PROBLEM", 163, 201], ["modulators of ACE2 levels", "TEST", 215, 240], ["differentiated cells", "OBSERVATION", 4, 24], ["cardiac cells", "ANATOMY", 188, 201], ["cardiac cells", "ANATOMY", 257, 270]]], ["ACE2 levels were measured in drug-treated cells using high content imaging and a list of drugs that significantly down-regulate or up-regulate ACE2 were identified based on their normalized ACE2 expression z-scores (Figure 1B, Supplementary Table 1).", [["cells", "ANATOMY", 42, 47], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["cells", "CELL", 42, 47], ["ACE2", "GENE_OR_GENE_PRODUCT", 143, 147], ["ACE2", "GENE_OR_GENE_PRODUCT", 190, 194], ["ACE2", "PROTEIN", 0, 4], ["drug-treated cells", "CELL_LINE", 29, 47], ["ACE2", "PROTEIN", 143, 147], ["ACE2", "PROTEIN", 190, 194], ["ACE2 levels", "TEST", 0, 11], ["high content imaging", "TEST", 54, 74], ["drugs", "TREATMENT", 89, 94], ["ACE2", "TEST", 143, 147]]], ["We confirmed the effect of a compound with a high positive z-score (vincristine) and a compound with a low negative z-score (dronedarone) on ACE2 fluorescence intensity (Figure 1C), and subsequently selected several hit compounds with low and high z-scores (Supplementary Figure 1 E&,F) for further analysis and validation at 1 \u03bcM and 2 \u03bcM concentrations (Figure 1D\u2013E).", [["vincristine", "CHEMICAL", 68, 79], ["dronedarone", "CHEMICAL", 125, 136], ["vincristine", "CHEMICAL", 68, 79], ["dronedarone", "CHEMICAL", 125, 136], ["vincristine", "SIMPLE_CHEMICAL", 68, 79], ["dronedarone", "SIMPLE_CHEMICAL", 125, 136], ["ACE2", "GENE_OR_GENE_PRODUCT", 141, 145], ["ACE2", "PROTEIN", 141, 145], ["a high positive z-score (vincristine", "PROBLEM", 43, 79], ["dronedarone", "TREATMENT", 125, 136], ["ACE2 fluorescence intensity", "TEST", 141, 168], ["several hit compounds", "PROBLEM", 208, 229], ["further analysis", "TEST", 291, 307], ["validation", "TEST", 312, 322]]], ["The high-quality cell-based measurements and the inherent diversity of the FDA library provided a unique opportunity to develop a virtual high-throughput screening (vHTS) approach that allowed for rapid in silico screening and cost-effective identification of compounds that can elicit the desired biological response.", [["cell", "ANATOMY", 17, 21], ["cell", "CELL", 17, 21], ["silico screening", "TEST", 206, 222], ["high", "OBSERVATION_MODIFIER", 4, 8], ["quality cell", "OBSERVATION_MODIFIER", 9, 21]]], ["Combined analysis of these in vitro measurements and in silico predictions allows us to nominate molecular entities that can effectively modulate the signaling pathways responsible for ACE regulation.High-throughput drug screen identifies ACE2 modulators in human cardiac cellsTo achieve this goal, we first randomly split our in vitro screening results into three datasets as training, validation and test inputs (Supplementary Figure 2A\u2013C).", [["cardiac cells", "ANATOMY", 264, 277], ["ACE", "GENE_OR_GENE_PRODUCT", 185, 188], ["ACE2", "GENE_OR_GENE_PRODUCT", 239, 243], ["human", "ORGANISM", 258, 263], ["cardiac cells", "CELL", 264, 277], ["ACE", "PROTEIN", 185, 188], ["ACE2", "PROTEIN", 239, 243], ["human cardiac cells", "CELL_TYPE", 258, 277], ["human", "SPECIES", 258, 263], ["human", "SPECIES", 258, 263], ["these in vitro measurements", "TEST", 21, 48], ["ACE regulation", "TREATMENT", 185, 199], ["drug screen", "TEST", 216, 227], ["ACE2 modulators in human cardiac cells", "PROBLEM", 239, 277], ["vitro screening", "TEST", 330, 345], ["validation and test inputs", "TEST", 387, 413], ["cardiac cells", "ANATOMY", 264, 277]]], ["We used the model trained on the in vitro screening data to predict changes in ACE2 expression in response to treatments with the in silico library.", [["ACE2", "GENE_OR_GENE_PRODUCT", 79, 83], ["ACE2", "PROTEIN", 79, 83], ["ACE2 expression", "TREATMENT", 79, 94], ["treatments", "TREATMENT", 110, 120]]], ["We then variance normalized the model predictions to determine their associated z-scores.", [["their associated z-scores", "PROBLEM", 63, 88]]], ["To visualize these hits, we used Morgan fingerprints to generate molecular features for all in vitro and in silico tested compounds and visualized their relationship in a 2-dimensional space using Uniform Manifold Approximation and Projection (UMAP) (Figure 1F).", [["Morgan fingerprints", "TEST", 33, 52], ["Uniform Manifold Approximation", "TREATMENT", 197, 227], ["hits", "OBSERVATION", 19, 23]]], ["We observed a consistent coclustering of the FDA-approved drugs that are known to have structural similarities, such as the cluster containing finasteride and dutasteride, confirming the utility of these clustering representations.", [["finasteride", "CHEMICAL", 143, 154], ["dutasteride", "CHEMICAL", 159, 170], ["finasteride", "CHEMICAL", 143, 154], ["dutasteride", "CHEMICAL", 159, 170], ["finasteride", "SIMPLE_CHEMICAL", 143, 154], ["dutasteride", "SIMPLE_CHEMICAL", 159, 170], ["drugs", "TREATMENT", 58, 63], ["the cluster containing finasteride", "TREATMENT", 120, 154], ["dutasteride", "TREATMENT", 159, 170], ["these clustering representations", "PROBLEM", 198, 230]]], ["Taken together, this integrative cell-based and in silico screening strategy enabled the identification and nomination of novel drug-like compounds with similar structure and potentially higher potency as compared to the FDA-approved drugs utilized in the in vitro screen.Drugs that reduce ACE-2 regulate steroid signaling and peptidase activitiesWe explored if a potential shared pathway exists among the candidates that decrease ACE2 levels on the membrane of cardiac cells.", [["cell", "ANATOMY", 33, 37], ["membrane", "ANATOMY", 450, 458], ["cardiac cells", "ANATOMY", 462, 475], ["steroid", "CHEMICAL", 305, 312], ["steroid", "CHEMICAL", 305, 312], ["cell", "CELL", 33, 37], ["ACE-2", "GENE_OR_GENE_PRODUCT", 290, 295], ["steroid", "SIMPLE_CHEMICAL", 305, 312], ["ACE2", "GENE_OR_GENE_PRODUCT", 431, 435], ["membrane", "CELLULAR_COMPONENT", 450, 458], ["cardiac cells", "CELL", 462, 475], ["ACE", "PROTEIN", 290, 293], ["ACE2", "PROTEIN", 431, 435], ["cardiac cells", "CELL_TYPE", 462, 475], ["silico screening strategy", "TEST", 51, 76], ["the identification", "TEST", 85, 103], ["novel drug-like compounds", "PROBLEM", 122, 147], ["drugs", "TREATMENT", 234, 239], ["the in vitro screen", "TEST", 252, 271], ["Drugs", "TREATMENT", 272, 277], ["ACE", "TREATMENT", 290, 293], ["steroid signaling", "TREATMENT", 305, 322], ["peptidase activities", "TEST", 327, 347], ["a potential shared pathway", "PROBLEM", 362, 388], ["ACE2 levels", "TEST", 431, 442], ["higher potency", "OBSERVATION_MODIFIER", 187, 201], ["cardiac cells", "ANATOMY", 462, 475]]], ["We acquired isometric simplified molecular-input line-entry system (SMILES) for each drug in the FDA-approved library from Selleckchem and used them to predict drug-protein interactions via the similarity ensemble approach (SEA) computational tool17.", [["SEA", "PROTEIN", 224, 227], ["Selleckchem", "TREATMENT", 123, 134]]], ["The SEA-predicted drug-protein pairs were filtered, selecting human proteins and predicted interaction p-values <0.05, which yielded 2150 predicted proteins targeted by the drug library.Drugs that reduce ACE-2 regulate steroid signaling and peptidase activitiesWeighted combined z-scores were then calculated by adding normalized z-scores across all compounds that target each target protein18.", [["steroid", "CHEMICAL", 219, 226], ["steroid", "CHEMICAL", 219, 226], ["human", "ORGANISM", 62, 67], ["ACE-2", "GENE_OR_GENE_PRODUCT", 204, 209], ["steroid", "SIMPLE_CHEMICAL", 219, 226], ["protein18", "GENE_OR_GENE_PRODUCT", 384, 393], ["SEA", "PROTEIN", 4, 7], ["human proteins", "PROTEIN", 62, 76], ["ACE", "PROTEIN", 204, 207], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 62, 67], ["The SEA", "TEST", 0, 7], ["Drugs", "TREATMENT", 186, 191], ["ACE", "TREATMENT", 204, 207], ["steroid signaling", "TREATMENT", 219, 236], ["peptidase activities", "TEST", 241, 261], ["Weighted combined z-scores", "TEST", 261, 287]]], ["The p-values were then calculated based on the combined z-scores and adjusted using p.adjust (method=false discovery rate(FDR)).", [["The p-values", "TEST", 0, 12], ["the combined z-scores", "TEST", 43, 64], ["p.adjust (method", "TREATMENT", 84, 100]]], ["Using the sum of counts for all other targets and drugs, we performed a Fisher\u2019s exact test to evaluate the degree to which negative z-scores were enriched among the drugs likely to target a protein of interest.", [["drugs", "TREATMENT", 50, 55], ["the drugs", "TREATMENT", 162, 171]]], ["As expected, the two p-values, i.e. combined z-score and Fisher\u2019s, are generally correlated (R=0.6, p<1e-200).", [["Fisher\u2019s", "TEST", 57, 65], ["R", "TEST", 93, 94]]], ["In Figure 2A, we have specifically compared these p-values across the genes with negative average z-scores.", [["these p-values", "TEST", 44, 58]]], ["Finally, we selected the likely target genes using the following criteria: average z-score<0, FDR<0.25 based on combined z-score analysis, and Fisher\u2019s p<0.05.", [["target genes", "DNA", 32, 44], ["average z-score", "TEST", 75, 90], ["FDR", "TEST", 94, 97], ["combined z-score analysis", "TEST", 112, 137]]], ["This selection process resulted in 30 proteins nominated as significant drug targets (Figure 2B,C, Supplementary Table 2).Drugs that reduce ACE-2 regulate steroid signaling and peptidase activitiesThe previously published bulk transcriptomics data12 confirmed that 28 of these 30 proteins were expressed by the in vitro generated cardiomyocytes and/or non-cardiomyocytes supporting their potential as drug targets (Supplementary Figure 3A).", [["cardiomyocytes", "ANATOMY", 330, 344], ["non-cardiomyocytes", "ANATOMY", 352, 370], ["steroid", "CHEMICAL", 155, 162], ["steroid", "CHEMICAL", 155, 162], ["ACE-2", "GENE_OR_GENE_PRODUCT", 140, 145], ["steroid", "SIMPLE_CHEMICAL", 155, 162], ["cardiomyocytes", "CELL", 330, 344], ["non-cardiomyocytes", "CELL", 352, 370], ["ACE", "PROTEIN", 140, 143], ["data12", "DNA", 243, 249], ["in vitro generated cardiomyocytes", "CELL_TYPE", 311, 344], ["non-cardiomyocytes", "CELL_TYPE", 352, 370], ["30 proteins", "PROBLEM", 35, 46], ["significant drug targets", "PROBLEM", 60, 84], ["Drugs", "TREATMENT", 122, 127], ["ACE", "TREATMENT", 140, 143], ["steroid signaling", "TREATMENT", 155, 172], ["peptidase activities", "TEST", 177, 197], ["The previously published bulk transcriptomics data12", "TEST", 197, 249], ["non-cardiomyocytes", "PROBLEM", 352, 370], ["cardiomyocytes", "ANATOMY", 330, 344]]], ["Analysis of the collective expression of all 30 predicted targets using module scoring revealed that some ACE2 expressing cell types, such as cardiac fibroblasts and ciliated cells in the lung, express high levels of multiple predicted drug targets (Supplementary Figure 3B).", [["cell", "ANATOMY", 122, 126], ["cardiac fibroblasts", "ANATOMY", 142, 161], ["ciliated cells", "ANATOMY", 166, 180], ["lung", "ANATOMY", 188, 192], ["ACE2", "GENE_OR_GENE_PRODUCT", 106, 110], ["cell", "CELL", 122, 126], ["cardiac fibroblasts", "CELL", 142, 161], ["ciliated cells", "CELL", 166, 180], ["lung", "ORGAN", 188, 192], ["ACE2", "PROTEIN", 106, 110], ["cardiac fibroblasts", "CELL_TYPE", 142, 161], ["ciliated cells", "CELL_TYPE", 166, 180], ["module scoring", "TEST", 72, 86], ["some ACE2 expressing cell types", "PROBLEM", 101, 132], ["cardiac fibroblasts", "PROBLEM", 142, 161], ["ciliated cells in the lung", "PROBLEM", 166, 192], ["expressing cell types", "OBSERVATION", 111, 132], ["cardiac", "ANATOMY", 142, 149], ["fibroblasts", "OBSERVATION", 150, 161], ["ciliated cells", "OBSERVATION", 166, 180], ["lung", "ANATOMY", 188, 192], ["high", "OBSERVATION_MODIFIER", 202, 206], ["levels", "OBSERVATION_MODIFIER", 207, 213]]], ["Additionally, expression of the predicted targets was detected in ACE2 expressing cell types of the adult human heart, and the majority were also detected in ACE2 expressing cell types of other commonly affected organs (Supplementary Figure 4).", [["cell", "ANATOMY", 82, 86], ["heart", "ANATOMY", 112, 117], ["cell", "ANATOMY", 174, 178], ["organs", "ANATOMY", 212, 218], ["ACE2", "GENE_OR_GENE_PRODUCT", 66, 70], ["cell", "CELL", 82, 86], ["human", "ORGANISM", 106, 111], ["heart", "ORGAN", 112, 117], ["ACE2", "GENE_OR_GENE_PRODUCT", 158, 162], ["cell", "CELL", 174, 178], ["organs", "ORGAN", 212, 218], ["ACE2", "PROTEIN", 66, 70], ["ACE2", "PROTEIN", 158, 162], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 106, 111], ["expressing cell types", "OBSERVATION", 71, 92], ["adult", "ANATOMY_MODIFIER", 100, 105], ["human heart", "ANATOMY", 106, 117]]], ["This analysis also provides insight into non-ACE2 expressing cell types that may be affected by treatment with the hit compounds.", [["cell", "ANATOMY", 61, 65], ["non-ACE2", "GENE_OR_GENE_PRODUCT", 41, 49], ["cell", "CELL", 61, 65], ["non-ACE2 expressing cell types", "CELL_LINE", 41, 71], ["This analysis", "TEST", 0, 13], ["non-ACE2 expressing cell types", "TREATMENT", 41, 71], ["the hit compounds", "PROBLEM", 111, 128], ["cell types", "OBSERVATION", 61, 71], ["may be", "UNCERTAINTY", 77, 83]]], ["In particular, tissue resident immune populations of the myeloid lineage in the heart, esophagus and lung also collectively express many of the predicted target genes (Supplementary Figure 3B,4).", [["tissue", "ANATOMY", 15, 21], ["myeloid lineage", "ANATOMY", 57, 72], ["heart", "ANATOMY", 80, 85], ["esophagus", "ANATOMY", 87, 96], ["lung", "ANATOMY", 101, 105], ["tissue", "TISSUE", 15, 21], ["immune populations", "CELL", 31, 49], ["myeloid lineage", "CELL", 57, 72], ["heart", "ORGAN", 80, 85], ["esophagus", "ORGAN", 87, 96], ["lung", "ORGAN", 101, 105], ["myeloid lineage", "CELL_TYPE", 57, 72], ["target genes", "DNA", 154, 166], ["myeloid lineage", "OBSERVATION", 57, 72], ["heart", "ANATOMY", 80, 85], ["esophagus", "ANATOMY", 87, 96], ["lung", "ANATOMY", 101, 105]]], ["This is particularly interesting given the recent reports that myeloid lineage and epithelial cells are affected in severe SARS-CoV-2 infection cases19.Drugs that reduce ACE-2 regulate steroid signaling and peptidase activitiesTo identify biological pathways associated with changes in ACE2 expression, we used the combined z-scores across all proteins using iPAGE gene ontology (GO) analysis (Supplementary Figure 5).", [["myeloid lineage", "ANATOMY", 63, 78], ["epithelial cells", "ANATOMY", 83, 99], ["SARS-CoV-2 infection", "DISEASE", 123, 143], ["steroid", "CHEMICAL", 185, 192], ["steroid", "CHEMICAL", 185, 192], ["myeloid lineage", "CELL", 63, 78], ["epithelial cells", "CELL", 83, 99], ["SARS-CoV-2", "ORGANISM", 123, 133], ["ACE-2", "GENE_OR_GENE_PRODUCT", 170, 175], ["steroid", "SIMPLE_CHEMICAL", 185, 192], ["ACE2", "GENE_OR_GENE_PRODUCT", 286, 290], ["myeloid lineage", "CELL_TYPE", 63, 78], ["epithelial cells", "CELL_TYPE", 83, 99], ["ACE", "PROTEIN", 170, 173], ["ACE2", "PROTEIN", 286, 290], ["iPAGE gene ontology", "DNA", 359, 378], ["SARS-CoV-2", "SPECIES", 123, 133], ["myeloid lineage and epithelial cells", "PROBLEM", 63, 99], ["severe SARS", "PROBLEM", 116, 127], ["CoV-2 infection cases", "PROBLEM", 128, 149], ["Drugs", "TREATMENT", 152, 157], ["ACE", "TREATMENT", 170, 173], ["steroid signaling", "TREATMENT", 185, 202], ["peptidase activities", "TEST", 207, 227], ["changes in ACE2 expression", "PROBLEM", 275, 301], ["the combined z-scores across all proteins", "TREATMENT", 311, 352], ["myeloid lineage", "OBSERVATION", 63, 78], ["epithelial cells", "OBSERVATION", 83, 99], ["severe", "OBSERVATION_MODIFIER", 116, 122], ["SARS", "OBSERVATION", 123, 127]]], ["Interestingly, target proteins associated with compounds that reduce ACE2 expression were associated with various GO terms related to peptidase activity and steroid metabolic processes (Figure 2D).", [["steroid", "CHEMICAL", 157, 164], ["steroid", "CHEMICAL", 157, 164], ["ACE2", "GENE_OR_GENE_PRODUCT", 69, 73], ["steroid", "SIMPLE_CHEMICAL", 157, 164], ["ACE2", "PROTEIN", 69, 73], ["peptidase", "PROTEIN", 134, 143], ["target proteins", "PROBLEM", 15, 30], ["ACE2 expression", "PROBLEM", 69, 84], ["various GO terms", "PROBLEM", 106, 122], ["peptidase activity", "PROBLEM", 134, 152], ["steroid metabolic processes", "PROBLEM", 157, 184]]], ["These pathways were then validated with the SEA predicted protein targets from the in silico library screen.", [["SEA predicted protein targets", "DNA", 44, 73]]], ["Interestingly, hit compounds identified in the in silico screen also showed enrichment for targets involved in steroid hormone activity, steroid metabolic processes, and peptidase activity (Figure 2E).", [["steroid", "CHEMICAL", 111, 118], ["steroid", "CHEMICAL", 137, 144], ["steroid", "CHEMICAL", 111, 118], ["steroid", "CHEMICAL", 137, 144], ["steroid hormone", "GENE_OR_GENE_PRODUCT", 111, 126], ["steroid", "SIMPLE_CHEMICAL", 137, 144], ["peptidase", "PROTEIN", 170, 179], ["hit compounds", "PROBLEM", 15, 28], ["the in silico screen", "TEST", 43, 63], ["steroid hormone activity", "TREATMENT", 111, 135], ["steroid metabolic processes", "TREATMENT", 137, 164], ["peptidase activity", "TEST", 170, 188], ["hit compounds", "OBSERVATION", 15, 28]]], ["Given the strong clinical evidence on COVID-19 disproportionately affecting men, the well-established role of peptidase in modulating ACE2 and SARS-Co-V-2 co-receptors, and the possible link between ACE2 expression and sex hormones, we sought to uncover the specific drug-protein interactions driving enrichment of steroid and peptidase pathways.", [["steroid", "CHEMICAL", 315, 322], ["steroid", "CHEMICAL", 315, 322], ["COVID-19", "GENE_OR_GENE_PRODUCT", 38, 46], ["men", "ORGANISM", 76, 79], ["peptidase", "GENE_OR_GENE_PRODUCT", 110, 119], ["ACE2", "GENE_OR_GENE_PRODUCT", 134, 138], ["SARS-Co-V-2", "GENE_OR_GENE_PRODUCT", 143, 154], ["ACE2", "GENE_OR_GENE_PRODUCT", 199, 203], ["steroid", "SIMPLE_CHEMICAL", 315, 322], ["peptidase", "GENE_OR_GENE_PRODUCT", 327, 336], ["COVID-19", "DNA", 38, 46], ["peptidase", "PROTEIN", 110, 119], ["ACE2", "PROTEIN", 134, 138], ["SARS-Co-V-2 co-receptors", "PROTEIN", 143, 167], ["ACE2", "PROTEIN", 199, 203], ["men", "SPECIES", 76, 79], ["COVID", "TEST", 38, 43], ["peptidase", "TEST", 110, 119], ["ACE2", "TEST", 134, 138], ["SARS", "TEST", 143, 147], ["steroid and peptidase pathways", "TREATMENT", 315, 345]]], ["We first mapped the drug-protein interactions for the full list of predicted targets and compounds with z-score<\u22121.5 (Figure 3A).", [["z-score", "TEST", 104, 111]]], ["This revealed a list of 48 compounds with significant interactions with target proteins (Supplementary Figure 6).", [["target proteins", "PROTEIN", 72, 87]]], ["Next we created drug-protein matrices on proteins in \u201csteroid metabolic process\u201d and \u201cserine-type peptidase\u201d activity GO terms to map the interaction of drugs with corresponding targets (Supplementary Figure 7A,B).", [["steroid", "CHEMICAL", 54, 61], ["steroid", "CHEMICAL", 54, 61], ["serine", "CHEMICAL", 86, 92], ["steroid", "SIMPLE_CHEMICAL", 54, 61], ["drug-protein matrices", "TREATMENT", 16, 37], ["proteins", "TREATMENT", 41, 49], ["steroid metabolic process", "TREATMENT", 54, 79], ["drugs", "TREATMENT", 153, 158]]], ["This analysis highlighted the interaction of several drugs including ketoconazole, spironolactone, finasteride and dutasteride with androgen signaling modulators such as SRD5A1 and SHBG (Figure 3A, Supplementary Figure 7A,B) whereas other drugs from the in vitro screen, such as camostat mesilate, sotagliflozin, and guanabenz acetate, are specific to the serine-type peptidase activity pathway (Supplementary Figure 7B).Drugs that reduce ACE-2 regulate steroid signaling and peptidase activitiesTo build a working model of the drug-protein interactions in ACE2 regulation, we conducted a protein-protein interaction (PPI) network analysis to identify interactions between our list of significant predicted targets (Figure 2C), androgen signaling pathway components (AR and SRD5A2), and proteins implicated in ACE2 function regulation (ACE, ADAM10, ADAM17, FURIN, REN, TMPRSS2).", [["ketoconazole", "CHEMICAL", 69, 81], ["spironolactone", "CHEMICAL", 83, 97], ["finasteride", "CHEMICAL", 99, 110], ["dutasteride", "CHEMICAL", 115, 126], ["camostat mesilate", "CHEMICAL", 279, 296], ["sotagliflozin", "CHEMICAL", 298, 311], ["guanabenz acetate", "CHEMICAL", 317, 334], ["steroid", "CHEMICAL", 454, 461], ["ketoconazole", "CHEMICAL", 69, 81], ["spironolactone", "CHEMICAL", 83, 97], ["finasteride", "CHEMICAL", 99, 110], ["dutasteride", "CHEMICAL", 115, 126], ["androgen", "CHEMICAL", 132, 140], ["camostat mesilate", "CHEMICAL", 279, 296], ["sotagliflozin", "CHEMICAL", 298, 311], ["guanabenz acetate", "CHEMICAL", 317, 334], ["serine", "CHEMICAL", 356, 362], ["steroid", "CHEMICAL", 454, 461], ["androgen", "CHEMICAL", 728, 736], ["ketoconazole", "SIMPLE_CHEMICAL", 69, 81], ["spironolactone", "SIMPLE_CHEMICAL", 83, 97], ["finasteride", "SIMPLE_CHEMICAL", 99, 110], ["dutasteride", "SIMPLE_CHEMICAL", 115, 126], ["androgen", "SIMPLE_CHEMICAL", 132, 140], ["SRD5A1", "SIMPLE_CHEMICAL", 170, 176], ["SHBG", "GENE_OR_GENE_PRODUCT", 181, 185], ["B", "GENE_OR_GENE_PRODUCT", 222, 223], ["camostat mesilate", "SIMPLE_CHEMICAL", 279, 296], ["sotagliflozin", "SIMPLE_CHEMICAL", 298, 311], ["guanabenz acetate", "SIMPLE_CHEMICAL", 317, 334], ["ACE-2", "GENE_OR_GENE_PRODUCT", 439, 444], ["steroid", "SIMPLE_CHEMICAL", 454, 461], ["ACE2", "GENE_OR_GENE_PRODUCT", 557, 561], ["Figure 2C", "GENE_OR_GENE_PRODUCT", 716, 725], ["androgen signaling pathway components", "GENE_OR_GENE_PRODUCT", 728, 765], ["AR", "GENE_OR_GENE_PRODUCT", 767, 769], ["SRD5A2", "GENE_OR_GENE_PRODUCT", 774, 780], ["ACE2", "GENE_OR_GENE_PRODUCT", 810, 814], ["ACE", "GENE_OR_GENE_PRODUCT", 836, 839], ["ADAM10", "GENE_OR_GENE_PRODUCT", 841, 847], ["ADAM17", "GENE_OR_GENE_PRODUCT", 849, 855], ["FURIN", "GENE_OR_GENE_PRODUCT", 857, 862], ["REN", "GENE_OR_GENE_PRODUCT", 864, 867], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 869, 876], ["SRD5A1", "PROTEIN", 170, 176], ["SHBG", "PROTEIN", 181, 185], ["ACE", "PROTEIN", 439, 442], ["ACE2", "PROTEIN", 557, 561], ["androgen signaling pathway components", "PROTEIN", 728, 765], ["AR", "PROTEIN", 767, 769], ["SRD5A2", "PROTEIN", 774, 780], ["ACE2", "PROTEIN", 810, 814], ["ACE", "PROTEIN", 836, 839], ["ADAM10", "PROTEIN", 841, 847], ["ADAM17", "PROTEIN", 849, 855], ["FURIN", "PROTEIN", 857, 862], ["REN", "PROTEIN", 864, 867], ["TMPRSS2", "PROTEIN", 869, 876], ["This analysis", "TEST", 0, 13], ["several drugs", "TREATMENT", 45, 58], ["ketoconazole", "TREATMENT", 69, 81], ["spironolactone", "TREATMENT", 83, 97], ["finasteride", "TREATMENT", 99, 110], ["dutasteride", "TREATMENT", 115, 126], ["androgen signaling modulators", "TREATMENT", 132, 161], ["SRD5A1", "TEST", 170, 176], ["SHBG", "TEST", 181, 185], ["other drugs", "TREATMENT", 233, 244], ["the in vitro screen", "TEST", 250, 269], ["camostat mesilate", "TREATMENT", 279, 296], ["sotagliflozin", "TREATMENT", 298, 311], ["guanabenz acetate", "TREATMENT", 317, 334], ["the serine-type peptidase activity pathway", "TREATMENT", 352, 394], ["Drugs", "TREATMENT", 421, 426], ["ACE", "TREATMENT", 439, 442], ["steroid signaling", "TREATMENT", 454, 471], ["peptidase activities", "TEST", 476, 496], ["the drug-protein interactions", "TREATMENT", 524, 553], ["ACE2 regulation", "TREATMENT", 557, 572], ["a protein-protein interaction (PPI", "TREATMENT", 587, 621], ["network analysis", "TEST", 623, 639], ["androgen signaling pathway components", "PROBLEM", 728, 765], ["SRD5A2", "TEST", 774, 780], ["ACE2 function regulation", "TREATMENT", 810, 834], ["ACE, ADAM10, ADAM17", "TREATMENT", 836, 855], ["FURIN", "TREATMENT", 857, 862]]], ["We used the STRING physical interaction database to draw a high confidence network of associating proteins (Figure 3B).", [["associating proteins", "PROTEIN", 86, 106], ["Figure 3B", "PROTEIN", 108, 117]]], ["In the resulting network, AR and IL6 have the highest degree centrality, connecting to seven other nodes in the network.", [["AR", "GENE_OR_GENE_PRODUCT", 26, 28], ["IL6", "GENE_OR_GENE_PRODUCT", 33, 36], ["AR", "PROTEIN", 26, 28], ["IL6", "PROTEIN", 33, 36], ["AR", "PROBLEM", 26, 28], ["highest degree", "OBSERVATION_MODIFIER", 46, 60], ["nodes", "OBSERVATION", 99, 104]]], ["Furthermore, AR and IL6 share high betweenness centrality, connecting the androgen pathway module to the peptidases.", [["androgen", "CHEMICAL", 74, 82], ["AR", "GENE_OR_GENE_PRODUCT", 13, 15], ["IL6", "GENE_OR_GENE_PRODUCT", 20, 23], ["androgen", "GENE_OR_GENE_PRODUCT", 74, 82], ["AR", "PROTEIN", 13, 15], ["IL6", "PROTEIN", 20, 23], ["peptidases", "PROTEIN", 105, 115], ["AR and IL6 share high betweenness centrality", "PROBLEM", 13, 57]]], ["The observed link between AR and IL6 is clinically important given the elevated IL6 response in severe cases of COVID-19 infection20.Drugs that reduce ACE-2 regulate steroid signaling and peptidase activitiesThe remarkable convergence of the gene set enrichment analysis and the PPI network on steroid hormone related genes and pathways prompted us to hypothesize that the drug candidates may be reducing ACE2 expression via inhibition of AR signaling and peptidase pathways (Figure 3C\u2013D).", [["COVID-19 infection20", "CHEMICAL", 112, 132], ["steroid", "CHEMICAL", 166, 173], ["steroid", "CHEMICAL", 294, 301], ["steroid", "CHEMICAL", 166, 173], ["steroid", "CHEMICAL", 294, 301], ["AR", "GENE_OR_GENE_PRODUCT", 26, 28], ["IL6", "GENE_OR_GENE_PRODUCT", 33, 36], ["IL6", "GENE_OR_GENE_PRODUCT", 80, 83], ["ACE-2", "GENE_OR_GENE_PRODUCT", 151, 156], ["steroid", "SIMPLE_CHEMICAL", 166, 173], ["steroid hormone", "GENE_OR_GENE_PRODUCT", 294, 309], ["ACE2", "GENE_OR_GENE_PRODUCT", 405, 409], ["AR", "GENE_OR_GENE_PRODUCT", 439, 441], ["AR", "PROTEIN", 26, 28], ["IL6", "PROTEIN", 33, 36], ["IL6", "PROTEIN", 80, 83], ["ACE", "PROTEIN", 151, 154], ["ACE2", "PROTEIN", 405, 409], ["AR", "PROTEIN", 439, 441], ["the elevated IL6 response", "PROBLEM", 67, 92], ["COVID-19 infection20", "PROBLEM", 112, 132], ["Drugs", "TREATMENT", 133, 138], ["ACE", "TREATMENT", 151, 154], ["steroid signaling", "TREATMENT", 166, 183], ["peptidase activities", "TEST", 188, 208], ["the gene set enrichment analysis", "TEST", 238, 270], ["the PPI network", "TREATMENT", 275, 290], ["steroid hormone", "TREATMENT", 294, 309], ["ACE2 expression", "TREATMENT", 405, 420], ["AR signaling", "TREATMENT", 439, 451], ["peptidase pathways", "TEST", 456, 474], ["severe", "OBSERVATION_MODIFIER", 96, 102]]], ["Seven of the predicted drug targets are upstream regulators of AR signaling and are targeted by multiple drug candidates that reduce ACE2 (Figure 3C).", [["AR", "GENE_OR_GENE_PRODUCT", 63, 65], ["ACE2", "GENE_OR_GENE_PRODUCT", 133, 137], ["Figure 3C", "GENE_OR_GENE_PRODUCT", 139, 148], ["AR", "PROTEIN", 63, 65], ["ACE2", "PROTEIN", 133, 137], ["Figure 3C", "PROTEIN", 139, 148], ["AR signaling", "PROBLEM", 63, 75], ["ACE2", "TEST", 133, 137]]], ["Furthermore, peptidases such as FURIN and TMPRSS2 which are important players in ACE2 regulation and thereby SARS-CoV-2 viral entry21,22, are amongst the downstream targets of AR.", [["FURIN", "GENE_OR_GENE_PRODUCT", 32, 37], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 42, 49], ["ACE2", "GENE_OR_GENE_PRODUCT", 81, 85], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 109, 119], ["entry21,22", "GENE_OR_GENE_PRODUCT", 126, 136], ["AR", "GENE_OR_GENE_PRODUCT", 176, 178], ["FURIN", "PROTEIN", 32, 37], ["TMPRSS2", "PROTEIN", 42, 49], ["ACE2", "PROTEIN", 81, 85], ["SARS-CoV-2 viral entry21,22", "DNA", 109, 136], ["AR", "PROTEIN", 176, 178], ["peptidases", "PROBLEM", 13, 23], ["FURIN and TMPRSS2", "TEST", 32, 49], ["ACE2 regulation", "TEST", 81, 96], ["SARS", "TEST", 109, 113], ["CoV", "TEST", 114, 117], ["AR", "PROBLEM", 176, 178]]], ["These receptors and their upstream regulators are also predicted to be targeted by the drug candidates (Figure 3D).Androgen receptor signaling modulates ACE2 and TMPRSS2Although most highly expressed in male reproductive organs, AR mediates hormone signaling in many male and female tissues23.", [["reproductive organs", "ANATOMY", 208, 227], ["tissues", "ANATOMY", 283, 290], ["Androgen", "CHEMICAL", 115, 123], ["Androgen receptor", "GENE_OR_GENE_PRODUCT", 115, 132], ["ACE2", "GENE_OR_GENE_PRODUCT", 153, 157], ["TMPRSS2Although", "GENE_OR_GENE_PRODUCT", 162, 177], ["reproductive organs", "ORGAN", 208, 227], ["AR", "GENE_OR_GENE_PRODUCT", 229, 231], ["tissues", "TISSUE", 283, 290], ["upstream regulators", "PROTEIN", 26, 45], ["Androgen receptor", "PROTEIN", 115, 132], ["ACE2", "PROTEIN", 153, 157], ["TMPRSS2Although", "PROTEIN", 162, 177], ["AR", "PROTEIN", 229, 231], ["ACE2", "TEST", 153, 157], ["AR mediates hormone signaling", "PROBLEM", 229, 258], ["female tissues", "ANATOMY", 276, 290]]], ["In agreement, expression of AR and testosterone converting enzymes SRD5A1 and SRD5A2 are detected in ACE2 expressing cell types in the adult heart, lung, esophagus and colon (Supplementary Figure 8).", [["cell", "ANATOMY", 117, 121], ["adult heart", "ANATOMY", 135, 146], ["lung", "ANATOMY", 148, 152], ["esophagus", "ANATOMY", 154, 163], ["colon", "ANATOMY", 168, 173], ["testosterone", "CHEMICAL", 35, 47], ["testosterone", "CHEMICAL", 35, 47], ["AR", "GENE_OR_GENE_PRODUCT", 28, 30], ["testosterone converting enzymes", "GENE_OR_GENE_PRODUCT", 35, 66], ["SRD5A1", "GENE_OR_GENE_PRODUCT", 67, 73], ["SRD5A2", "GENE_OR_GENE_PRODUCT", 78, 84], ["ACE2", "GENE_OR_GENE_PRODUCT", 101, 105], ["cell", "CELL", 117, 121], ["heart", "ORGAN", 141, 146], ["lung", "ORGAN", 148, 152], ["esophagus", "ORGAN", 154, 163], ["colon", "ORGAN", 168, 173], ["AR", "PROTEIN", 28, 30], ["testosterone converting enzymes", "PROTEIN", 35, 66], ["SRD5A1", "PROTEIN", 67, 73], ["SRD5A2", "PROTEIN", 78, 84], ["ACE2", "PROTEIN", 101, 105], ["AR", "PROBLEM", 28, 30], ["testosterone converting enzymes", "TEST", 35, 66], ["SRD5A2", "TEST", 78, 84], ["lung, esophagus and colon", "PROBLEM", 148, 173], ["expressing cell types", "OBSERVATION", 106, 127], ["adult", "ANATOMY_MODIFIER", 135, 140], ["heart", "ANATOMY", 141, 146], ["lung", "ANATOMY", 148, 152], ["esophagus", "ANATOMY", 154, 163], ["colon", "ANATOMY", 168, 173]]], ["Additionally, collective expression of genes involved in AR signaling (GO:0030521), common receptors upstream of AR activation24\u201327, and common gene targets of AR transcription factor activity28, reveals potential organ and cell type specific differences in AR signaling regulation (Supplementary Figure 8).", [["organ", "ANATOMY", 214, 219], ["cell", "ANATOMY", 224, 228], ["AR", "GENE_OR_GENE_PRODUCT", 57, 59], ["AR", "GENE_OR_GENE_PRODUCT", 113, 115], ["AR", "GENE_OR_GENE_PRODUCT", 160, 162], ["activity28", "GENE_OR_GENE_PRODUCT", 184, 194], ["organ", "ORGAN", 214, 219], ["cell type", "CELL", 224, 233], ["AR", "GENE_OR_GENE_PRODUCT", 258, 260], ["AR", "PROTEIN", 57, 59], ["AR activation24\u201327", "DNA", 113, 131], ["AR transcription factor activity28", "PROTEIN", 160, 194], ["AR", "PROTEIN", 258, 260], ["AR signaling", "PROBLEM", 57, 69], ["AR transcription factor activity28", "TEST", 160, 194], ["potential organ and cell type specific differences in AR signaling regulation", "PROBLEM", 204, 281], ["cell type", "OBSERVATION", 224, 233]]], ["A list of genes included in each module is provided in Supplementary Table 3.Androgen receptor signaling modulates ACE2 and TMPRSS2To determine whether AR regulates the expression of SARS-CoV-2 receptors directly, we used an existing AR ChIP-seq dataset generated in LNCaP cells29 to identify direct transcriptional targets.", [["LNCaP cells29", "ANATOMY", 267, 280], ["Androgen", "CHEMICAL", 77, 85], ["Androgen receptor", "GENE_OR_GENE_PRODUCT", 77, 94], ["ACE2", "GENE_OR_GENE_PRODUCT", 115, 119], ["TMPRSS2To", "GENE_OR_GENE_PRODUCT", 124, 133], ["AR", "GENE_OR_GENE_PRODUCT", 152, 154], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 183, 193], ["AR", "GENE_OR_GENE_PRODUCT", 234, 236], ["LNCaP cells29", "CELL", 267, 280], ["Androgen receptor", "PROTEIN", 77, 94], ["ACE2", "PROTEIN", 115, 119], ["TMPRSS2To", "PROTEIN", 124, 133], ["AR", "PROTEIN", 152, 154], ["SARS-CoV-2 receptors", "PROTEIN", 183, 203], ["AR ChIP-seq dataset", "DNA", 234, 253], ["LNCaP cells29", "CELL_LINE", 267, 280], ["Androgen receptor signaling", "TEST", 77, 104], ["ACE2", "TEST", 115, 119], ["TMPRSS2To", "TEST", 124, 133], ["AR", "PROBLEM", 152, 154], ["SARS", "TEST", 183, 187], ["an existing AR ChIP", "TREATMENT", 222, 241], ["LNCaP cells29", "TEST", 267, 280]]], ["The genes with AR binding to this 5kb downstream or upstream of transcription start sites (TSS) were selected as direct AR-bound targets.", [["AR", "GENE_OR_GENE_PRODUCT", 15, 17], ["AR", "GENE_OR_GENE_PRODUCT", 120, 122], ["AR", "PROTEIN", 15, 17], ["5kb downstream", "DNA", 34, 48], ["transcription start sites", "DNA", 64, 89], ["TSS", "DNA", 91, 94], ["AR", "PROTEIN", 120, 122], ["AR binding", "PROBLEM", 15, 25]]], ["We next used a transcriptomics dataset generated using RNAi-mediated knockdown of AR30 and compared gene expression changes in response to AR knockdown.", [["AR30", "GENE_OR_GENE_PRODUCT", 82, 86], ["AR", "GENE_OR_GENE_PRODUCT", 139, 141], ["AR30", "PROTEIN", 82, 86], ["AR", "PROTEIN", 139, 141], ["RNAi-mediated knockdown of AR30", "TREATMENT", 55, 86], ["gene expression changes", "PROBLEM", 100, 123], ["AR knockdown", "TREATMENT", 139, 151]]], ["We divided log-fold expression changes into nine equally populated bins, which were also shown along with the patterns of AR enrichment and depletion at the corresponding TSS across the data (Figure 4A).", [["AR", "GENE_OR_GENE_PRODUCT", 122, 124], ["AR", "PROTEIN", 122, 124], ["TSS", "DNA", 171, 174], ["log-fold expression changes", "TREATMENT", 11, 38], ["AR enrichment", "PROBLEM", 122, 135], ["depletion", "PROBLEM", 140, 149], ["log-fold expression", "OBSERVATION_MODIFIER", 11, 30], ["enrichment", "OBSERVATION", 125, 135]]], ["This analysis identified ACE2, and other SARS-CoV-2 co-receptors TMPRSS2 and Furin as direct transcriptional targets that are downregulated in response to AR knockdown (Figure 4A).", [["ACE2", "GENE_OR_GENE_PRODUCT", 25, 29], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 41, 51], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 65, 72], ["Furin", "GENE_OR_GENE_PRODUCT", 77, 82], ["AR", "GENE_OR_GENE_PRODUCT", 155, 157], ["ACE2", "PROTEIN", 25, 29], ["SARS-CoV-2 co-receptors", "PROTEIN", 41, 64], ["TMPRSS2", "PROTEIN", 65, 72], ["Furin", "PROTEIN", 77, 82], ["AR", "PROTEIN", 155, 157], ["This analysis", "TEST", 0, 13], ["ACE2", "TEST", 25, 29], ["other SARS", "TEST", 35, 45], ["CoV", "TEST", 46, 49], ["TMPRSS2", "TEST", 65, 72], ["Furin", "TREATMENT", 77, 82]]], ["Furthermore, after exposing hESC-derived cardiac cells to the drug candidates that are known to inhibit AR signaling, we observed significant reductions in ACE2 and TMPRSS2 protein levels (Figure 4B,C).", [["hESC-derived cardiac cells", "ANATOMY", 28, 54], ["hESC-derived cardiac cells", "CELL", 28, 54], ["AR", "GENE_OR_GENE_PRODUCT", 104, 106], ["ACE2", "GENE_OR_GENE_PRODUCT", 156, 160], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 165, 172], ["hESC", "CELL_LINE", 28, 32], ["cardiac cells", "CELL_TYPE", 41, 54], ["AR", "PROTEIN", 104, 106], ["ACE2", "PROTEIN", 156, 160], ["TMPRSS2", "PROTEIN", 165, 172], ["AR signaling", "PROBLEM", 104, 116], ["significant reductions", "PROBLEM", 130, 152], ["ACE2", "TEST", 156, 160], ["TMPRSS2 protein levels", "TEST", 165, 187], ["Figure 4B", "TEST", 189, 198], ["cardiac", "ANATOMY", 41, 48], ["significant", "OBSERVATION_MODIFIER", 130, 141], ["reductions", "OBSERVATION_MODIFIER", 142, 152]]], ["Dutasteride and spironolactone, the top candidates that modulate AR signaling, were both able to reduce ACE2 levels in a dose-dependent manner (Supplementary Figure 9 A,B).", [["Dutasteride", "CHEMICAL", 0, 11], ["spironolactone", "CHEMICAL", 16, 30], ["Dutasteride", "CHEMICAL", 0, 11], ["spironolactone", "CHEMICAL", 16, 30], ["Dutasteride", "SIMPLE_CHEMICAL", 0, 11], ["spironolactone", "SIMPLE_CHEMICAL", 16, 30], ["AR", "GENE_OR_GENE_PRODUCT", 65, 67], ["ACE2", "GENE_OR_GENE_PRODUCT", 104, 108], ["AR", "PROTEIN", 65, 67], ["ACE2", "PROTEIN", 104, 108], ["Dutasteride", "TREATMENT", 0, 11], ["spironolactone", "TREATMENT", 16, 30], ["modulate AR signaling", "PROBLEM", 56, 77], ["ACE2 levels", "TEST", 104, 115]]], ["Together, these results indicate that AR signaling regulates expression of SARS-CoV-2 receptors.Androgen receptor signaling modulates ACE2 and TMPRSS2To assess whether pharmacologic inhibition of AR signaling can reduce viral entry, hESC-derived cardiac cells were exposed to recombinant spike-RBD protein.", [["hESC", "ANATOMY", 233, 237], ["cardiac cells", "ANATOMY", 246, 259], ["Androgen", "CHEMICAL", 96, 104], ["AR", "GENE_OR_GENE_PRODUCT", 38, 40], ["SARS-CoV-2 receptors", "GENE_OR_GENE_PRODUCT", 75, 95], ["Androgen receptor", "GENE_OR_GENE_PRODUCT", 96, 113], ["ACE2", "GENE_OR_GENE_PRODUCT", 134, 138], ["TMPRSS2To", "GENE_OR_GENE_PRODUCT", 143, 152], ["AR", "GENE_OR_GENE_PRODUCT", 196, 198], ["hESC", "CELL", 233, 237], ["cardiac cells", "CELL", 246, 259], ["spike-RBD", "GENE_OR_GENE_PRODUCT", 288, 297], ["AR", "PROTEIN", 38, 40], ["SARS-CoV-2 receptors", "PROTEIN", 75, 95], ["Androgen receptor", "PROTEIN", 96, 113], ["ACE2", "PROTEIN", 134, 138], ["TMPRSS2To", "PROTEIN", 143, 152], ["AR", "PROTEIN", 196, 198], ["hESC", "CELL_LINE", 233, 237], ["cardiac cells", "CELL_TYPE", 246, 259], ["recombinant spike-RBD protein", "PROTEIN", 276, 305], ["AR signaling", "PROBLEM", 38, 50], ["SARS", "PROBLEM", 75, 79], ["Androgen receptor signaling", "TEST", 96, 123], ["ACE2", "TEST", 134, 138], ["TMPRSS2To assess", "TEST", 143, 159], ["pharmacologic inhibition", "PROBLEM", 168, 192], ["AR signaling", "PROBLEM", 196, 208], ["viral entry", "PROBLEM", 220, 231], ["derived cardiac cells", "PROBLEM", 238, 259], ["RBD protein", "TEST", 294, 305], ["cardiac", "ANATOMY", 246, 253]]], ["After a 24 hour exposure, immunofluorescence imaging showed co-localization of spike-RBD protein with cells expressing ACE2 protein (Figure 4D\u2013E).", [["cells", "ANATOMY", 102, 107], ["spike-RBD", "GENE_OR_GENE_PRODUCT", 79, 88], ["cells", "CELL", 102, 107], ["ACE2", "GENE_OR_GENE_PRODUCT", 119, 123], ["RBD protein", "PROTEIN", 85, 96], ["ACE2 protein", "PROTEIN", 119, 131], ["Figure 4D\u2013E", "PROTEIN", 133, 144], ["immunofluorescence imaging", "TEST", 26, 52], ["spike", "PROBLEM", 79, 84], ["RBD protein", "TEST", 85, 96], ["ACE2 protein", "TEST", 119, 131]]], ["This supports the findings by Sharma et al. that hPSC-derived cardiomyocytes can be infected with SARS-CoV-2 virus31.", [["hPSC", "ANATOMY", 49, 53], ["cardiomyocytes", "ANATOMY", 62, 76], ["hPSC", "CELL", 49, 53], ["cardiomyocytes", "CELL", 62, 76], ["SARS-CoV-2 virus31", "ORGANISM", 98, 116], ["hPSC", "CELL_TYPE", 49, 53], ["cardiomyocytes", "CELL_TYPE", 62, 76], ["SARS-CoV-2 virus31", "SPECIES", 98, 116], ["SARS", "PROBLEM", 98, 102], ["CoV", "TEST", 103, 106], ["cardiomyocytes", "ANATOMY", 62, 76]]], ["Remarkably, pre-incubation with the AR signaling inhibitor, dutasteride, significantly reduced the levels of ACE2 and internalized spike-RBD, whereas, pre-incubation with the AR ligand and agonist, 5a-dihydrotestosterone (DHT), had the opposite effect.", [["dutasteride", "CHEMICAL", 60, 71], ["5a-dihydrotestosterone", "CHEMICAL", 198, 220], ["DHT", "CHEMICAL", 222, 225], ["dutasteride", "CHEMICAL", 60, 71], ["5a-dihydrotestosterone", "CHEMICAL", 198, 220], ["DHT", "CHEMICAL", 222, 225], ["AR", "GENE_OR_GENE_PRODUCT", 36, 38], ["dutasteride", "SIMPLE_CHEMICAL", 60, 71], ["ACE2", "GENE_OR_GENE_PRODUCT", 109, 113], ["AR ligand", "GENE_OR_GENE_PRODUCT", 175, 184], ["5a-dihydrotestosterone", "SIMPLE_CHEMICAL", 198, 220], ["DHT", "SIMPLE_CHEMICAL", 222, 225], ["AR", "PROTEIN", 36, 38], ["ACE2", "PROTEIN", 109, 113], ["RBD", "PROTEIN", 137, 140], ["pre-incubation", "TREATMENT", 12, 26], ["the AR signaling inhibitor", "TREATMENT", 32, 58], ["dutasteride", "TREATMENT", 60, 71], ["ACE2", "TEST", 109, 113], ["internalized spike", "PROBLEM", 118, 136], ["RBD", "PROBLEM", 137, 140], ["the AR ligand", "TREATMENT", 171, 184], ["agonist", "TEST", 189, 196], ["5a-dihydrotestosterone (DHT", "TREATMENT", 198, 225]]], ["The effect of dutasteride on reducing ACE2 and spike-RBD internalization was further confirmed in human primary alveolar epithelial cells (Figure 4F\u2013G).Androgen imbalance states are associated with COVID-19 complications in male patientsOur results suggest that androgen regulation can increase viral receptor and co-receptor expression leading to increased Spike-RBD entry.", [["primary alveolar epithelial cells", "ANATOMY", 104, 137], ["dutasteride", "CHEMICAL", 14, 25], ["dutasteride", "CHEMICAL", 14, 25], ["Androgen", "CHEMICAL", 152, 160], ["androgen", "CHEMICAL", 262, 270], ["dutasteride", "SIMPLE_CHEMICAL", 14, 25], ["ACE2", "GENE_OR_GENE_PRODUCT", 38, 42], ["human", "ORGANISM", 98, 103], ["alveolar epithelial cells", "CELL", 112, 137], ["Figure 4F\u2013G", "CELL", 139, 150], ["Androgen", "SIMPLE_CHEMICAL", 152, 160], ["patients", "ORGANISM", 229, 237], ["androgen", "SIMPLE_CHEMICAL", 262, 270], ["Spike-RBD", "GENE_OR_GENE_PRODUCT", 358, 367], ["ACE2", "PROTEIN", 38, 42], ["RBD", "PROTEIN", 53, 56], ["human primary alveolar epithelial cells", "CELL_TYPE", 98, 137], ["Figure 4F\u2013G", "CELL_LINE", 139, 150], ["viral receptor", "PROTEIN", 295, 309], ["Spike", "PROTEIN", 358, 363], ["RBD", "PROTEIN", 364, 367], ["human", "SPECIES", 98, 103], ["patients", "SPECIES", 229, 237], ["human", "SPECIES", 98, 103], ["dutasteride", "TREATMENT", 14, 25], ["reducing ACE2", "PROBLEM", 29, 42], ["spike", "PROBLEM", 47, 52], ["RBD internalization", "PROBLEM", 53, 72], ["Androgen imbalance", "PROBLEM", 152, 170], ["androgen regulation", "PROBLEM", 262, 281], ["viral receptor", "TREATMENT", 295, 309], ["co-receptor expression", "TREATMENT", 314, 336], ["increased Spike-RBD entry", "PROBLEM", 348, 373], ["alveolar epithelial cells", "OBSERVATION", 112, 137]]], ["To determine whether androgen plays a role in COVID-19 disease manifestation, we explored the effect of disorders related to androgen imbalance on COVID-19 induced cardiac injury, measured by elevated troponin T levels.", [["cardiac", "ANATOMY", 164, 171], ["COVID-19", "CHEMICAL", 147, 155], ["cardiac injury", "DISEASE", 164, 178], ["androgen", "CHEMICAL", 21, 29], ["androgen", "CHEMICAL", 125, 133], ["COVID-19", "CHEMICAL", 147, 155], ["androgen", "GENE_OR_GENE_PRODUCT", 21, 29], ["androgen", "SIMPLE_CHEMICAL", 125, 133], ["COVID-19", "GENE_OR_GENE_PRODUCT", 147, 155], ["cardiac", "ORGAN", 164, 171], ["troponin T", "GENE_OR_GENE_PRODUCT", 201, 211], ["19 disease manifestation", "PROBLEM", 52, 76], ["disorders", "PROBLEM", 104, 113], ["androgen imbalance", "PROBLEM", 125, 143], ["COVID", "TEST", 147, 152], ["cardiac injury", "PROBLEM", 164, 178], ["elevated troponin T levels", "PROBLEM", 192, 218], ["cardiac", "ANATOMY", 164, 171], ["injury", "OBSERVATION", 172, 178]]], ["We also included the previously described risk factors associated with organ failure32 such as age, BMI, diabetes and hypertension in our data collection (Figure 5A).", [["organ", "ANATOMY", 71, 76], ["diabetes", "DISEASE", 105, 113], ["hypertension", "DISEASE", 118, 130], ["organ", "ORGAN", 71, 76], ["organ failure32", "PROBLEM", 71, 86], ["BMI", "PROBLEM", 100, 103], ["diabetes", "PROBLEM", 105, 113], ["hypertension", "PROBLEM", 118, 130], ["hypertension", "OBSERVATION", 118, 130]]], ["In the de-identified aggregate data from Yale New Haven Hospital, 1577 individuals tested positive for COVID-19 and had serum troponin T measured during the same encounter.", [["serum", "ANATOMY", 120, 125], ["individuals", "ORGANISM", 71, 82], ["serum", "ORGANISM_SUBSTANCE", 120, 125], ["troponin T", "GENE_OR_GENE_PRODUCT", 126, 136], ["serum troponin T", "PROTEIN", 120, 136], ["COVID", "TEST", 103, 108], ["serum troponin T", "TEST", 120, 136]]], ["There was a larger number of males with abnormal serum troponin T levels in both selected age groups (Supplementary Figure 10A).", [["serum", "ANATOMY", 49, 54], ["serum", "ORGANISM_SUBSTANCE", 49, 54], ["troponin T", "GENE_OR_GENE_PRODUCT", 55, 65], ["abnormal serum troponin T levels", "PROBLEM", 40, 72], ["larger", "OBSERVATION_MODIFIER", 12, 18], ["number", "OBSERVATION_MODIFIER", 19, 25], ["abnormal", "OBSERVATION_MODIFIER", 40, 48], ["serum troponin", "OBSERVATION_MODIFIER", 49, 63]]], ["Association analysis in the COVID-19 patients showed that most risk factors are correlated with abnormal levels of troponin T in serum, but the risk factors also correlate with each other (Supplementary Figure 10B).", [["serum", "ANATOMY", 129, 134], ["patients", "ORGANISM", 37, 45], ["troponin T", "GENE_OR_GENE_PRODUCT", 115, 125], ["serum", "ORGANISM_SUBSTANCE", 129, 134], ["troponin T", "PROTEIN", 115, 125], ["patients", "SPECIES", 37, 45], ["Association analysis", "TEST", 0, 20], ["the COVID", "TEST", 24, 33], ["abnormal levels of troponin T in serum", "PROBLEM", 96, 134], ["the risk factors", "PROBLEM", 140, 156]]], ["To account for associations between individual risk factors, we tested multiple multi-variate models (as described in the methods section).", [["individual risk factors", "PROBLEM", 36, 59]]], ["In our final model, prostatic disease increased the odds of having abnormal troponin T by 50.5% (OR=1.505, 95% CI, p-value 0.046), independent of the other risk factors (Figure 5B).Androgen imbalance states are associated with COVID-19 complications in male patientsTo further test the effect of increased androgen on disease manifestations, we analyzed the association between serum androgen levels with disease severity in the UK Biobank (UKBB) (Figure 5C).", [["prostatic", "ANATOMY", 20, 29], ["serum", "ANATOMY", 378, 383], ["prostatic disease", "DISEASE", 20, 37], ["Androgen", "CHEMICAL", 181, 189], ["androgen", "CHEMICAL", 306, 314], ["androgen", "CHEMICAL", 384, 392], ["prostatic", "ORGAN", 20, 29], ["troponin T", "GENE_OR_GENE_PRODUCT", 76, 86], ["Androgen", "SIMPLE_CHEMICAL", 181, 189], ["patients", "ORGANISM", 258, 266], ["androgen", "SIMPLE_CHEMICAL", 306, 314], ["serum", "ORGANISM_SUBSTANCE", 378, 383], ["androgen", "SIMPLE_CHEMICAL", 384, 392], ["patients", "SPECIES", 258, 266], ["prostatic disease", "PROBLEM", 20, 37], ["abnormal troponin T", "PROBLEM", 67, 86], ["CI", "TEST", 111, 113], ["p-value", "TEST", 115, 122], ["Androgen imbalance", "PROBLEM", 181, 199], ["increased androgen on disease manifestations", "PROBLEM", 296, 340], ["serum androgen levels", "TEST", 378, 399], ["disease severity", "PROBLEM", 405, 421], ["prostatic", "ANATOMY", 20, 29], ["disease", "OBSERVATION", 30, 37], ["increased", "OBSERVATION_MODIFIER", 296, 305], ["androgen", "OBSERVATION", 306, 314]]], ["A total of 311,857 individuals in the UKBB passed quality control criteria and were among those with reported COVID-19 testing from the UKBB English recruitment centers.", [["COVID", "TEST", 110, 115]]], ["1,407 individuals were tested for COVID-19, of which 543 (37.5%) had at least one positive test.", [["individuals", "ORGANISM", 6, 17], ["COVID", "TEST", 34, 39]]], ["Of all the individuals who tested positive for COVID-19, 454 individuals (83.6%) were hospitalized, with evidence from their microbiological record of inpatient status (i.e. severe COVID-19; Supplementary Figure 11A).", [["individuals", "ORGANISM", 61, 72], ["COVID", "TEST", 47, 52], ["severe COVID", "PROBLEM", 174, 186]]], ["Quantitative measures for testosterone, sex-hormone binding globulin (SHBG), and free androgen index were first standardized to account for sex differences (Supplementary Figure 11B).", [["testosterone", "CHEMICAL", 26, 38], ["testosterone", "CHEMICAL", 26, 38], ["sex-hormone", "CHEMICAL", 40, 51], ["androgen", "CHEMICAL", 86, 94], ["testosterone", "SIMPLE_CHEMICAL", 26, 38], ["sex-hormone binding globulin", "GENE_OR_GENE_PRODUCT", 40, 68], ["SHBG", "GENE_OR_GENE_PRODUCT", 70, 74], ["sex-hormone binding globulin", "PROTEIN", 40, 68], ["SHBG", "PROTEIN", 70, 74], ["Quantitative measures", "TEST", 0, 21], ["testosterone, sex-hormone binding globulin (SHBG)", "TEST", 26, 75], ["free androgen index", "TEST", 81, 100]]], ["Free androgen index was significantly associated with COVID-19 susceptibility and severity in males (Figure 5D), with no significant effect in females (Supplementary Figure S12), in both adjusted and unadjusted models.", [["androgen", "CHEMICAL", 5, 13], ["androgen", "GENE_OR_GENE_PRODUCT", 5, 13], ["Free androgen index", "TEST", 0, 19], ["COVID", "TEST", 54, 59], ["significant effect in females", "PROBLEM", 121, 150], ["androgen index", "OBSERVATION", 5, 19], ["19 susceptibility", "OBSERVATION_MODIFIER", 60, 77], ["severity", "OBSERVATION_MODIFIER", 82, 90], ["no", "UNCERTAINTY", 118, 120], ["significant", "OBSERVATION_MODIFIER", 121, 132], ["effect", "OBSERVATION_MODIFIER", 133, 139]]], ["In particular, among males who were tested for COVID-19, each standard deviation (SD) increase in free androgen index increased the risk of a positive test (OR=1.22, 95% CI: 1.03\u20131.45, p-value 0.024), as well as severe COVID-19 infection (OR=1.22, 95% CI: 1.02\u20131.46, p-value 0.031), independent of age, Townsend deprivation index, BMI and the first ten principal components of ancestry.", [["infection", "DISEASE", 228, 237], ["androgen", "CHEMICAL", 103, 111], ["androgen", "GENE_OR_GENE_PRODUCT", 103, 111], ["COVID-19", "GENE_OR_GENE_PRODUCT", 219, 227], ["COVID", "TEST", 47, 52], ["free androgen index", "TEST", 98, 117], ["a positive test", "PROBLEM", 140, 155], ["CI", "TEST", 170, 172], ["p-value", "TEST", 185, 192], ["severe COVID-19 infection", "PROBLEM", 212, 237], ["CI", "TEST", 252, 254], ["p-value", "TEST", 267, 274], ["Townsend deprivation index", "TEST", 303, 329], ["BMI", "TEST", 331, 334], ["increase", "OBSERVATION_MODIFIER", 86, 94], ["free androgen index", "OBSERVATION", 98, 117], ["severe", "OBSERVATION_MODIFIER", 212, 218], ["infection", "OBSERVATION", 228, 237]]], ["Similarly, among all male patients from English recruitment centers with available COVID-19 test reporting, each SD increase in free androgen index increased risk of a positive test (OR=1.14, 95% CI: 1.02\u20131.28, p-value 0.027), as well as severe COVID-19 infection (OR=1.15, 95% CI:1.01\u20131.31, p-value 0.037).", [["infection", "DISEASE", 254, 263], ["androgen", "CHEMICAL", 133, 141], ["patients", "ORGANISM", 26, 34], ["androgen", "GENE_OR_GENE_PRODUCT", 133, 141], ["COVID-19", "GENE_OR_GENE_PRODUCT", 245, 253], ["patients", "SPECIES", 26, 34], ["free androgen index", "PROBLEM", 128, 147], ["a positive test", "PROBLEM", 166, 181], ["CI", "TEST", 196, 198], ["p-value", "TEST", 211, 218], ["severe COVID-19 infection", "PROBLEM", 238, 263], ["CI", "TEST", 278, 280], ["p-value", "TEST", 292, 299], ["severe", "OBSERVATION_MODIFIER", 238, 244], ["infection", "OBSERVATION", 254, 263]]], ["In further sensitivity analysis, effects were not mitigated by additional adjustment for prevalent Hypertension and type 2 Diabetes Mellitus (Supplementary Figure 13).", [["Hypertension", "DISEASE", 99, 111], ["type 2 Diabetes Mellitus", "DISEASE", 116, 140], ["further sensitivity analysis", "TEST", 3, 31], ["prevalent Hypertension", "PROBLEM", 89, 111], ["type 2 Diabetes Mellitus", "PROBLEM", 116, 140]]], ["We did not identify any significant associations for Testosterone or SHBG status (Figure 5D, Supplementary Figure 14).DiscussionThere are two important observations in the COVID-19 pandemic: the higher prevalence of severe complications in male individuals and the relative immunity in children.", [["Testosterone", "CHEMICAL", 53, 65], ["Testosterone", "CHEMICAL", 53, 65], ["Testosterone", "SIMPLE_CHEMICAL", 53, 65], ["SHBG", "GENE_OR_GENE_PRODUCT", 69, 73], ["children", "ORGANISM", 286, 294], ["SHBG", "PROTEIN", 69, 73], ["children", "SPECIES", 286, 294], ["Testosterone", "TREATMENT", 53, 65], ["SHBG status", "PROBLEM", 69, 80], ["severe complications", "PROBLEM", 216, 236], ["severe", "OBSERVATION_MODIFIER", 216, 222], ["complications", "OBSERVATION", 223, 236]]], ["Our study identifies a link between male sex hormone signaling and regulation of the SARS-CoV-2 receptor ACE2 and co-receptor TMPRSS2 providing a potential explanation for these observations.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 85, 95], ["ACE2", "GENE_OR_GENE_PRODUCT", 105, 109], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 126, 133], ["SARS-CoV-2 receptor", "PROTEIN", 85, 104], ["ACE2", "PROTEIN", 105, 109], ["co-receptor TMPRSS2", "PROTEIN", 114, 133], ["Our study", "TEST", 0, 9], ["the SARS", "TEST", 81, 89], ["CoV", "TEST", 90, 93], ["co-receptor TMPRSS2", "TREATMENT", 114, 133]]], ["Our results demonstrate that inhibitors of 5 alpha reductases, which dampen androgen signaling, can reduce ACE2 levels and thereby decrease internalization of the viral spike-RBD.", [["androgen", "CHEMICAL", 76, 84], ["5 alpha reductases", "GENE_OR_GENE_PRODUCT", 43, 61], ["androgen", "GENE_OR_GENE_PRODUCT", 76, 84], ["ACE2", "GENE_OR_GENE_PRODUCT", 107, 111], ["5 alpha reductases", "PROTEIN", 43, 61], ["ACE2", "PROTEIN", 107, 111], ["RBD", "PROTEIN", 175, 178], ["inhibitors", "TREATMENT", 29, 39], ["5 alpha reductases", "TREATMENT", 43, 61], ["dampen androgen signaling", "PROBLEM", 69, 94], ["ACE2 levels", "TEST", 107, 118], ["the viral spike", "PROBLEM", 159, 174], ["RBD", "PROBLEM", 175, 178], ["viral spike", "OBSERVATION", 163, 174]]], ["These drugs, commonly prescribed for prostatic disorders, have good safety profiles and show repurposing potential for the treatment of COVID-19.DiscussionThe most lethal complication of COVID-19 is multiorgan failure affecting the lungs, the kidneys and the heart.", [["prostatic", "ANATOMY", 37, 46], ["multiorgan", "ANATOMY", 199, 209], ["lungs", "ANATOMY", 232, 237], ["kidneys", "ANATOMY", 243, 250], ["heart", "ANATOMY", 259, 264], ["prostatic disorders", "DISEASE", 37, 56], ["COVID-19", "CHEMICAL", 187, 195], ["multiorgan failure", "DISEASE", 199, 217], ["COVID-19", "CHEMICAL", 136, 144], ["COVID-19", "CHEMICAL", 187, 195], ["prostatic", "MULTI-TISSUE_STRUCTURE", 37, 46], ["multiorgan", "ORGAN", 199, 209], ["lungs", "ORGAN", 232, 237], ["kidneys", "ORGAN", 243, 250], ["heart", "ORGAN", 259, 264], ["These drugs", "TREATMENT", 0, 11], ["prostatic disorders", "PROBLEM", 37, 56], ["COVID", "TEST", 136, 141], ["COVID", "TEST", 187, 192], ["multiorgan failure affecting the lungs, the kidneys and the heart", "PROBLEM", 199, 264], ["prostatic", "ANATOMY", 37, 46], ["multiorgan failure", "OBSERVATION", 199, 217], ["lungs", "ANATOMY", 232, 237], ["kidneys", "ANATOMY", 243, 250], ["heart", "ANATOMY", 259, 264]]], ["Although there has been tremendous effort towards understanding the biology of SARS-CoV-2 infection at the molecular level, the use of relevant experimental models has been limited.", [["SARS", "DISEASE", 79, 83], ["infection", "DISEASE", 90, 99], ["SARS-CoV-2", "ORGANISM", 79, 89], ["SARS-CoV-2", "SPECIES", 79, 89], ["SARS", "PROBLEM", 79, 83], ["CoV-2 infection", "PROBLEM", 84, 99], ["tremendous", "OBSERVATION_MODIFIER", 24, 34], ["infection", "OBSERVATION", 90, 99]]], ["Modeling and studying pathophysiology with cell types that are not directly affected by SARS-CoV-2 could potentially delay the identification of effective therapeutic targets.", [["cell", "ANATOMY", 43, 47], ["cell", "CELL", 43, 47], ["SARS-CoV-2", "ORGANISM", 88, 98], ["SARS-CoV", "SPECIES", 88, 96], ["cell types", "PROBLEM", 43, 53], ["cell types", "OBSERVATION", 43, 53]]], ["Taking advantage of directed hESC differentiation, we generated scalable cultures of disease-relevant human cardiac cells and performed high-throughput screening to identify drugs that regulate ACE2 expression in these cell types.", [["hESC", "ANATOMY", 29, 33], ["cardiac cells", "ANATOMY", 108, 121], ["cell", "ANATOMY", 219, 223], ["hESC", "CELL", 29, 33], ["human", "ORGANISM", 102, 107], ["cardiac cells", "CELL", 108, 121], ["ACE2", "GENE_OR_GENE_PRODUCT", 194, 198], ["cell", "CELL", 219, 223], ["human cardiac cells", "CELL_TYPE", 102, 121], ["ACE2", "PROTEIN", 194, 198], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 102, 107], ["disease", "PROBLEM", 85, 92], ["relevant human cardiac cells", "PROBLEM", 93, 121], ["throughput screening", "TEST", 141, 161], ["drugs", "TREATMENT", 174, 179], ["cell types", "OBSERVATION", 219, 229]]], ["These experiments underscore the potential of hESC-derived cardiac cells for in-depth investigation of cell-type specific processes and offer a framework for rapid identification and validation of therapeutically-relevant compounds.", [["hESC-derived cardiac cells", "ANATOMY", 46, 72], ["cell", "ANATOMY", 103, 107], ["hESC-derived cardiac cells", "CELL", 46, 72], ["cell", "CELL", 103, 107], ["hESC", "CELL_LINE", 46, 50], ["cardiac cells", "CELL_TYPE", 59, 72], ["rapid identification", "TEST", 158, 178], ["cardiac", "ANATOMY", 59, 66]]], ["Other reports on the use of hESC-derived cell or organoid models highlight the utility of hESC-derived cells in modeling SARS-CoV-2 infection and COVID-19 pathophysiology33.DiscussionResults from our in vitro high-throughput screening of the FDA-approved drugs enable us to develop a novel deep learning strategy to screen millions of drug-like compounds in silico and identify candidates predicted to show superior potency and efficacy.", [["hESC-derived cell", "ANATOMY", 28, 45], ["organoid", "ANATOMY", 49, 57], ["hESC-derived cells", "ANATOMY", 90, 108], ["SARS-CoV-2 infection", "DISEASE", 121, 141], ["hESC-derived cell", "CELL", 28, 45], ["organoid", "CELL", 49, 57], ["hESC-derived cells", "CELL", 90, 108], ["SARS-CoV-2", "ORGANISM", 121, 131], ["hESC", "CELL_LINE", 28, 32], ["hESC-derived cells", "CELL_LINE", 90, 108], ["SARS-CoV", "SPECIES", 121, 129], ["derived cells", "PROBLEM", 95, 108], ["modeling SARS", "TEST", 112, 125], ["CoV", "TEST", 126, 129], ["2 infection", "PROBLEM", 130, 141], ["COVID", "TEST", 146, 151], ["a novel deep learning strategy", "TREATMENT", 282, 312]]], ["The diverse pharmacokinetic properties in these candidates may enable the development of drugs with improved distribution to disease-relevant tissues.", [["tissues", "ANATOMY", 142, 149], ["tissues", "TISSUE", 142, 149], ["drugs", "TREATMENT", 89, 94], ["disease", "PROBLEM", 125, 132], ["diverse", "OBSERVATION_MODIFIER", 4, 11], ["pharmacokinetic properties", "OBSERVATION", 12, 38]]], ["Further experiments are needed to validate these compounds and characterize their pharmacokinetic and pharmacodynamic properties in vitro and in vivo.DiscussionA common characteristic among our validated hit compounds is their ability to target androgen signaling.", [["androgen", "CHEMICAL", 245, 253], ["androgen", "GENE_OR_GENE_PRODUCT", 245, 253], ["these compounds", "TEST", 43, 58]]], ["Analysis of disease outcomes in COVID-19 patients in two independent cohorts revealed a significant association between elevated free androgen and COVID-19 complications pointing to a possible link between androgen-mediated ACE2 regulation and disease severity.", [["androgen", "CHEMICAL", 134, 142], ["androgen", "CHEMICAL", 206, 214], ["patients", "ORGANISM", 41, 49], ["androgen", "SIMPLE_CHEMICAL", 134, 142], ["androgen", "SIMPLE_CHEMICAL", 206, 214], ["ACE2", "GENE_OR_GENE_PRODUCT", 224, 228], ["ACE2", "PROTEIN", 224, 228], ["patients", "SPECIES", 41, 49], ["disease outcomes", "PROBLEM", 12, 28], ["COVID", "TEST", 32, 37], ["elevated free androgen", "PROBLEM", 120, 142], ["COVID-19 complications", "PROBLEM", 147, 169], ["androgen-mediated ACE2 regulation", "TREATMENT", 206, 239], ["disease severity", "PROBLEM", 244, 260], ["disease", "OBSERVATION", 12, 19], ["significant", "OBSERVATION_MODIFIER", 88, 99], ["disease", "OBSERVATION", 244, 251]]], ["Pathway and gene target analysis on compounds that reduce ACE2 levels also highlighted the regulatory roles of peptidase pathways.", [["ACE2", "GENE_OR_GENE_PRODUCT", 58, 62], ["peptidase", "GENE_OR_GENE_PRODUCT", 111, 120], ["ACE2", "PROTEIN", 58, 62], ["gene target analysis", "TEST", 12, 32], ["ACE2 levels", "TEST", 58, 69], ["peptidase pathways", "TREATMENT", 111, 129]]], ["Interestingly, protein interaction maps suggested a possible cross-talk between AR signaling pathways, inflammatory markers and peptidases relevant to the viral receptor and co-receptors, offering insights into alternative pathways involved in ACE2 regulation.DiscussionOur FDA drug screen data revealed that many commonly used medications modulate ACE2 levels and could affect disease severity in COVID-19 patients.", [["AR", "GENE_OR_GENE_PRODUCT", 80, 82], ["ACE2", "GENE_OR_GENE_PRODUCT", 244, 248], ["ACE2", "GENE_OR_GENE_PRODUCT", 349, 353], ["patients", "ORGANISM", 407, 415], ["AR", "PROTEIN", 80, 82], ["inflammatory markers", "PROTEIN", 103, 123], ["peptidases", "PROTEIN", 128, 138], ["viral receptor", "PROTEIN", 155, 169], ["co-receptors", "PROTEIN", 174, 186], ["ACE2", "PROTEIN", 244, 248], ["ACE2", "PROTEIN", 349, 353], ["patients", "SPECIES", 407, 415], ["protein interaction maps", "TEST", 15, 39], ["AR signaling pathways", "PROBLEM", 80, 101], ["inflammatory markers", "PROBLEM", 103, 123], ["peptidases", "PROBLEM", 128, 138], ["the viral receptor and co-receptors", "TREATMENT", 151, 186], ["ACE2 regulation", "TREATMENT", 244, 259], ["FDA drug screen data", "TEST", 274, 294], ["medications", "TREATMENT", 328, 339], ["ACE2 levels", "TEST", 349, 360], ["disease severity", "PROBLEM", 378, 394], ["COVID", "TEST", 398, 403], ["inflammatory", "OBSERVATION_MODIFIER", 103, 115]]], ["Further studies evaluating the relationships between these drugs and disease outcomes will be necessary to assess potential clinical impact and the need to substitute medications that might pose a heightened risk for COVID-19 patients.DiscussionIn conclusion, our results provide key insights into ACE2 regulatory mechanisms, present strong molecular and clinical evidence for the role of androgen signaling in SARS-CoV-2 infection and identify potential therapeutic candidates for the treatment of COVID-19.Cell culture and differentiation. ::: MethodsH9 human embryonic stem cells were maintained and differentiated as described previously10,12.", [["Cell", "ANATOMY", 508, 512], ["embryonic stem cells", "ANATOMY", 562, 582], ["infection", "DISEASE", 422, 431], ["androgen", "CHEMICAL", 389, 397], ["patients", "ORGANISM", 226, 234], ["ACE2", "GENE_OR_GENE_PRODUCT", 298, 302], ["androgen", "GENE_OR_GENE_PRODUCT", 389, 397], ["SARS-CoV-2", "ORGANISM", 411, 421], ["Cell", "CELL", 508, 512], ["human", "ORGANISM", 556, 561], ["embryonic stem cells", "CELL", 562, 582], ["ACE2", "PROTEIN", 298, 302], ["MethodsH9 human embryonic stem cells", "CELL_LINE", 546, 582], ["patients", "SPECIES", 226, 234], ["human", "SPECIES", 556, 561], ["SARS-CoV", "SPECIES", 411, 419], ["human", "SPECIES", 556, 561], ["Further studies", "TEST", 0, 15], ["these drugs", "TREATMENT", 53, 64], ["disease outcomes", "TREATMENT", 69, 85], ["medications", "TREATMENT", 167, 178], ["COVID", "TEST", 217, 222], ["androgen signaling", "PROBLEM", 389, 407], ["SARS", "PROBLEM", 411, 415], ["CoV", "PROBLEM", 416, 419], ["2 infection", "PROBLEM", 420, 431], ["COVID", "TEST", 499, 504], ["Cell culture", "TEST", 508, 520], ["MethodsH9 human embryonic stem cells", "TREATMENT", 546, 582], ["embryonic stem cells", "OBSERVATION", 562, 582]]], ["Briefly, human embryonic stem cells (hESCs) were maintained in mTeSR medium. hESCs were re-plated 72 hours prior to initiating differentiation.", [["embryonic stem cells", "ANATOMY", 15, 35], ["hESCs", "ANATOMY", 37, 42], ["hESCs", "ANATOMY", 77, 82], ["human", "ORGANISM", 9, 14], ["embryonic stem cells", "CELL", 15, 35], ["hESCs", "CELL", 37, 42], ["hESCs", "CELL", 77, 82], ["human embryonic stem cells", "CELL_LINE", 9, 35], ["hESCs", "CELL_TYPE", 37, 42], ["hESCs", "CELL_TYPE", 77, 82], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14], ["hESCs", "TEST", 77, 82], ["embryonic stem cells", "OBSERVATION", 15, 35]]], ["The cardiac differentiation was started with a mesoderm induction cocktail comprised of with 1.5 \u03bcM CHIR99021 (CHIR, Stem-RD), 20 ng/mL BMP4 and 20 ng/mL Activin A in RPMI (Cellgro) supplemented with B27 minus insulin, 2 mM GlutaMAX, 1x NEAA and 1x Normocin (InvivoGen) for 3 days (RPMI+B27 w/o insulin).", [["cardiac", "ANATOMY", 4, 11], ["mesoderm", "ANATOMY", 47, 55], ["CHIR99021", "CHEMICAL", 100, 109], ["Normocin", "CHEMICAL", 249, 257], ["InvivoGen", "CHEMICAL", 259, 268], ["CHIR99021", "CHEMICAL", 100, 109], ["CHIR", "CHEMICAL", 111, 115], ["GlutaMAX", "CHEMICAL", 224, 232], ["Normocin", "CHEMICAL", 249, 257], ["cardiac", "ORGAN", 4, 11], ["CHIR99021", "SIMPLE_CHEMICAL", 100, 109], ["CHIR", "SIMPLE_CHEMICAL", 111, 115], ["BMP4", "GENE_OR_GENE_PRODUCT", 136, 140], ["Activin A", "SIMPLE_CHEMICAL", 154, 163], ["Cellgro", "SIMPLE_CHEMICAL", 173, 180], ["insulin", "GENE_OR_GENE_PRODUCT", 210, 217], ["GlutaMAX", "SIMPLE_CHEMICAL", 224, 232], ["NEAA", "SIMPLE_CHEMICAL", 237, 241], ["Normocin", "SIMPLE_CHEMICAL", 249, 257], ["InvivoGen", "SIMPLE_CHEMICAL", 259, 268], ["insulin", "GENE_OR_GENE_PRODUCT", 295, 302], ["BMP4", "PROTEIN", 136, 140], ["a mesoderm induction cocktail", "TREATMENT", 45, 74], ["Activin A in RPMI (Cellgro)", "TREATMENT", 154, 181], ["B27 minus insulin", "TREATMENT", 200, 217], ["2 mM GlutaMAX", "TREATMENT", 219, 232], ["1x NEAA", "TREATMENT", 234, 241], ["1x Normocin (InvivoGen)", "TREATMENT", 246, 269], ["RPMI", "TEST", 282, 286], ["insulin", "TREATMENT", 295, 302], ["cardiac", "ANATOMY", 4, 11]]], ["Next, cells were treated with 5 \u03bcM XAV939 from day 3\u20136 in RB27-INS.", [["cells", "ANATOMY", 6, 11], ["XAV939", "CHEMICAL", 35, 41], ["cells", "CELL", 6, 11], ["RB27-INS", "CELL", 58, 66]]], ["From day 6 onward, differentiation of cells was carried out in RPMI supplemented with B27, 2 mM GlutaMAX, 1x NEAA and 1x Normocin (RPMI+complete B27).", [["cells", "ANATOMY", 38, 43], ["Normocin", "CHEMICAL", 121, 129], ["GlutaMAX", "CHEMICAL", 96, 104], ["Normocin", "CHEMICAL", 121, 129], ["cells", "CELL", 38, 43], ["GlutaMAX", "SIMPLE_CHEMICAL", 96, 104], ["NEAA", "SIMPLE_CHEMICAL", 109, 113], ["Normocin", "SIMPLE_CHEMICAL", 121, 129], ["B27", "TREATMENT", 86, 89], ["2 mM GlutaMAX", "TREATMENT", 91, 104], ["1x NEAA", "TREATMENT", 106, 113], ["1x Normocin", "TREATMENT", 118, 129]]], ["The protocol is outlined in supplementary Figure 1B.Cell culture and differentiation. ::: MethodsHuman pulmonary alveolar epithelial cells were purchased from Sciencell (cat#3200) and maintained according to the manufacturer\u2019s instructions.High-throughput screening and drug candidate selection. ::: MethodshESC-derived cardiac cells were replated at day 25 of differentiation in 384 well plates.", [["Cell", "ANATOMY", 52, 56], ["pulmonary alveolar epithelial cells", "ANATOMY", 103, 138], ["cardiac cells", "ANATOMY", 320, 333], ["Cell", "CELL", 52, 56], ["MethodsHuman pulmonary alveolar epithelial cells", "CELL", 90, 138], ["MethodshESC-derived cardiac cells", "CELL", 300, 333], ["MethodsHuman pulmonary alveolar epithelial cells", "CELL_TYPE", 90, 138], ["MethodshESC-derived cardiac cells", "CELL_LINE", 300, 333], ["The protocol", "TREATMENT", 0, 12], ["Cell culture", "TEST", 52, 64], ["MethodsHuman pulmonary alveolar epithelial cells", "PROBLEM", 90, 138], ["MethodshESC", "TEST", 300, 311], ["pulmonary", "ANATOMY", 103, 112], ["alveolar", "ANATOMY_MODIFIER", 113, 121], ["epithelial cells", "OBSERVATION", 122, 138], ["cardiac", "ANATOMY", 320, 327]]], ["72 hours after re-plating, the cells were treated with compounds from an FDA-approved chemical library (Selleckchem).", [["cells", "ANATOMY", 31, 36], ["cells", "CELL", 31, 36], ["the cells", "PROBLEM", 27, 36]]], ["24 hours after treatment, cells were fixed stained with ACE2 antibody.", [["cells", "ANATOMY", 26, 31], ["cells", "CELL", 26, 31], ["ACE2", "GENE_OR_GENE_PRODUCT", 56, 60], ["ACE2 antibody", "PROTEIN", 56, 69], ["treatment", "TREATMENT", 15, 24], ["cells", "TEST", 26, 31], ["ACE2 antibody", "TEST", 56, 69]]], ["High-throughput imaging and quantification of fluorescence signals were carried out using the In Cell Analyzer 2000 (GE Healthcare, USA).", [["Cell", "ANATOMY", 97, 101], ["Cell", "CELL", 97, 101], ["throughput imaging", "TEST", 5, 23], ["fluorescence signals", "TEST", 46, 66]]], ["ACE2 signal intensity was normalized to total cell number within each well as measured by DAPI staining.", [["cell", "ANATOMY", 46, 50], ["DAPI", "CHEMICAL", 90, 94], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["cell", "CELL", 46, 50], ["DAPI", "SIMPLE_CHEMICAL", 90, 94], ["ACE2", "PROTEIN", 0, 4], ["ACE2 signal intensity", "TEST", 0, 21], ["DAPI staining", "TEST", 90, 103], ["intensity", "OBSERVATION_MODIFIER", 12, 21], ["total cell", "OBSERVATION_MODIFIER", 40, 50], ["DAPI staining", "OBSERVATION", 90, 103]]], ["Z-score calculation was performed and normalized for each plate.Spike-RBD cell internalization assay. ::: Methods24 hours after replating into 96 well plates, hESC-derived cardiac cells were treated with either vehicle or drug candidates.", [["cell", "ANATOMY", 74, 78], ["hESC", "ANATOMY", 159, 163], ["cardiac cells", "ANATOMY", 172, 185], ["cell", "CELL", 74, 78], ["hESC-derived cardiac cells", "CELL", 159, 185], ["hESC", "CELL_LINE", 159, 163], ["cardiac cells", "CELL_TYPE", 172, 185], ["Z-score calculation", "TEST", 0, 19], ["Spike", "PROBLEM", 64, 69], ["RBD cell internalization assay", "TEST", 70, 100], ["hESC", "TEST", 159, 163], ["RBD cell", "OBSERVATION", 70, 78], ["cardiac cells", "ANATOMY", 172, 185]]], ["After 24 hours, 0.5 \u03bcM/mL human Fc-tagged recombinant spike-RBD protein with (Sino Biological Inc. 40592-V02H) was added to the medium and incubated for 30 minutes.", [["human", "ORGANISM", 26, 31], ["Fc", "GENE_OR_GENE_PRODUCT", 32, 34], ["human Fc", "PROTEIN", 26, 34], ["tagged recombinant spike-RBD protein", "PROTEIN", 35, 71], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 26, 31], ["RBD protein", "TEST", 60, 71]]], ["The cells were subsequently fixed, permeabilized and stained with antibodies against ACE2 and human Fc receptor.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["ACE2", "GENE_OR_GENE_PRODUCT", 85, 89], ["human", "ORGANISM", 94, 99], ["Fc receptor", "GENE_OR_GENE_PRODUCT", 100, 111], ["antibodies", "PROTEIN", 66, 76], ["ACE2", "PROTEIN", 85, 89], ["human Fc receptor", "PROTEIN", 94, 111], ["human", "SPECIES", 94, 99], ["human", "SPECIES", 94, 99], ["antibodies", "TEST", 66, 76], ["ACE2", "TEST", 85, 89], ["human Fc receptor", "TREATMENT", 94, 111]]], ["Image analysis was performed as described above.Immunofluorescence staining. ::: MethodsCells were washed with PBSx3 and fixed with 4% paraformaldehyde for 30 minutes at 4 \u00b0C. Non-specific antigen binding was blocked by treating the cells with PBS+0.5% BSA prior to adding the primary antibodies (ACE2 or TMPRSS2, Proteintech cat#21115\u20131-AP and Novus Biologicals cat# NBP1\u201320984, respectively).", [["cells", "ANATOMY", 233, 238], ["PBSx3", "CHEMICAL", 111, 116], ["BSA", "CHEMICAL", 253, 256], ["NBP1\u201320984", "CHEMICAL", 368, 378], ["PBSx3", "CHEMICAL", 111, 116], ["paraformaldehyde", "CHEMICAL", 135, 151], ["PBSx3", "SIMPLE_CHEMICAL", 111, 116], ["paraformaldehyde", "SIMPLE_CHEMICAL", 135, 151], ["cells", "CELL", 233, 238], ["PBS", "SIMPLE_CHEMICAL", 244, 247], ["BSA", "SIMPLE_CHEMICAL", 253, 256], ["ACE2", "GENE_OR_GENE_PRODUCT", 297, 301], ["primary antibodies", "PROTEIN", 277, 295], ["ACE2", "PROTEIN", 297, 301], ["TMPRSS2", "PROTEIN", 305, 312], ["21115\u20131", "PROTEIN", 330, 337], ["AP", "PROTEIN", 338, 340], ["NBP1", "PROTEIN", 368, 372], ["Image analysis", "TEST", 0, 14], ["Immunofluorescence staining", "TEST", 48, 75], ["MethodsCells", "TREATMENT", 81, 93], ["PBSx3", "TREATMENT", 111, 116], ["4% paraformaldehyde", "TREATMENT", 132, 151], ["Non-specific antigen binding", "PROBLEM", 176, 204], ["PBS", "TEST", 244, 247], ["the primary antibodies", "TEST", 273, 295], ["ACE2", "TEST", 297, 301], ["TMPRSS2", "TEST", 305, 312], ["Proteintech", "TEST", 314, 325], ["AP", "TEST", 338, 340], ["NBP1", "TEST", 368, 372]]], ["Cells were incubated with the primary antibody solution overnight at 4 \u00b0C then washed with PBSx3.", [["Cells", "ANATOMY", 0, 5], ["PBSx3", "CHEMICAL", 91, 96], ["PBSx3", "CHEMICAL", 91, 96], ["Cells", "CELL", 0, 5], ["PBSx3", "SIMPLE_CHEMICAL", 91, 96], ["PBSx3", "PROTEIN", 91, 96], ["the primary antibody solution", "TREATMENT", 26, 55], ["PBSx3", "TREATMENT", 91, 96]]], ["Secondary antibodies and fluorophore conjugated anti human Fc antibody were incubated for 30 minutes at room temperature.", [["human", "ORGANISM", 53, 58], ["antibodies", "PROTEIN", 10, 20], ["fluorophore conjugated anti human Fc antibody", "PROTEIN", 25, 70], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 53, 58], ["Secondary antibodies", "TREATMENT", 0, 20], ["fluorophore conjugated anti human Fc antibody", "TREATMENT", 25, 70]]], ["Finally, cells were washed with PBSx3 and stained with DAPI for nuclear counterstaining.In silico screening: ::: Virtual high-throughput screening dataset. ::: MethodsThe final model described above was used to evaluate 9.2 million compounds from the ZINC15 database.", [["cells", "ANATOMY", 9, 14], ["nuclear", "ANATOMY", 64, 71], ["PBSx3", "CHEMICAL", 32, 37], ["DAPI", "CHEMICAL", 55, 59], ["cells", "CELL", 9, 14], ["PBSx3", "SIMPLE_CHEMICAL", 32, 37], ["DAPI", "SIMPLE_CHEMICAL", 55, 59], ["nuclear", "CELLULAR_COMPONENT", 64, 71], ["PBSx3", "PROTEIN", 32, 37], ["PBSx3", "TREATMENT", 32, 37], ["DAPI", "TREATMENT", 55, 59], ["Methods", "TREATMENT", 160, 167], ["the ZINC15 database", "TEST", 247, 266]]], ["The resulting predictions were variance normalized and the molecules with z-scores below \u22124 for ACE2 expression were selected as hits.", [["ACE2", "GENE_OR_GENE_PRODUCT", 96, 100], ["ACE2", "PROTEIN", 96, 100], ["z-scores", "TEST", 74, 82], ["ACE2 expression", "TEST", 96, 111]]], ["This resulted in 169 potential small molecules.Data visualization: ::: Virtual high-throughput screening dataset. ::: MethodsTo visualize the relationship between the identified hits in a lower dimension, we used Morgan fingerprints to represent all compounds and used UMAPs to project each compound down to 2 dimensions.", [["Methods", "TREATMENT", 118, 125], ["Morgan fingerprints", "TREATMENT", 213, 232], ["UMAPs", "TREATMENT", 269, 274], ["small molecules", "OBSERVATION", 31, 46], ["hits", "OBSERVATION", 178, 182], ["lower dimension", "OBSERVATION_MODIFIER", 188, 203]]], ["For the screened ZINC15 database, we sampled 1 from 1000 compounds for visualization purposes.", [["ZINC15", "DNA", 17, 23], ["visualization purposes", "TEST", 71, 93]]], ["We also used the Morgan fingerprints to cluster in silico and in vitro hits using K-means clustering (number of clusters set to 15).Identification of drug targets in FDA-approved library ::: Predicting drug-protein-pathway interactionsIsomeric SMILES for each drug in the library were acquired from Selleckchem and used to run a similarity ensemble approach (SEA) library search.", [["the Morgan fingerprints", "TREATMENT", 13, 36], ["drug targets", "OBSERVATION", 150, 162]]], ["The SEA predicted targets were filtered, selecting human targets and predicted interaction p-values <0.05, which yielded 2150 predicted proteins targeted by the drug library.Target drug selection: ::: Predicting drug-protein-pathway interactionsThe normalized z-score values reported for all the compounds were first transformed to N(0,1) using the bestNormalize package (v1.4.0) in R (v3.5.1).", [["SEA", "GENE_OR_GENE_PRODUCT", 4, 7], ["human", "ORGANISM", 51, 56], ["SEA", "PROTEIN", 4, 7], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 51, 56], ["interaction p-values", "TEST", 79, 99], ["The normalized z-score values", "TEST", 245, 274]]], ["The treatments with transformed z-scores smaller than \u22121.5 were selected, which resulted in 41 compounds.Target gene selection: ::: Predicting drug-protein-pathway interactionsFor every compound, possible target genes were identified as above.", [["target genes", "DNA", 205, 217], ["The treatments", "TREATMENT", 0, 14], ["transformed z-scores", "TEST", 20, 40], ["target genes", "PROBLEM", 205, 217], ["possible", "UNCERTAINTY", 196, 204], ["target genes", "OBSERVATION", 205, 217]]], ["Weighted combined z-scores were then calculated for each gene by combining normalized z-scores across all treatments.", [["Weighted combined z-scores", "TEST", 0, 26], ["all treatments", "TREATMENT", 102, 116]]], ["The p-values were then calculated based on the combined z-scores and adjusted using p.adjust (method=FDR).", [["The p-values", "TEST", 0, 12], ["the combined z-scores", "TEST", 43, 64], ["p.adjust (method", "TREATMENT", 84, 100]]], ["Using the sum of counts for all other genes and drugs, we performed a Fisher\u2019s exact test to evaluate the degree to which negative z-scores were enrichment among the treatments likely to affect a gene of interest.", [["drugs", "TREATMENT", 48, 53], ["the treatments", "TREATMENT", 162, 176]]], ["As expected, the two p-values, i.e. combined z-score and Fisher\u2019s, are generally correlated (R=0.6, p<1e-200).Gene-set enrichment analysis: ::: Predicting drug-protein-pathway interactionsWe used the combined z-scores across all genes to identify pathways and gene-sets that are associated with changes in ACE2 expression.", [["ACE2", "GENE_OR_GENE_PRODUCT", 306, 310], ["ACE2", "PROTEIN", 306, 310], ["Fisher\u2019s", "TEST", 57, 65], ["R", "TEST", 93, 94], ["the combined z-scores across all genes", "TREATMENT", 196, 234], ["changes in ACE2 expression", "PROBLEM", 295, 321]]], ["For this analysis, we used our iPAGE toolkit34, in conjunction with annotations from MSigDB and Gene Ontology (GO).", [["iPAGE toolkit34", "DNA", 31, 46], ["MSigDB", "DNA", 85, 91], ["this analysis", "TEST", 4, 17], ["our iPAGE toolkit34", "TREATMENT", 27, 46]]], ["The following parameters were set: --ebins=9 --nodups=1 --independence=0.Drug-protein-pathway analysis: ::: Predicting drug-protein-pathway interactionsFor drugs with a normalized z-score <\u22121, drug-protein interactions per biological pathway were analyzed.", [["The following parameters", "TEST", 0, 24], ["--ebins", "TEST", 35, 42], ["drugs", "TREATMENT", 156, 161], ["a normalized z-score", "TEST", 167, 187]]], ["The SEA predicted drug-protein interaction dataset was filtered to exclude drugs with a normalized z-score \u2265\u22121.", [["SEA", "PROTEIN", 4, 7]]], ["Protein pathway gene lists were generated per gene set, comprised of the gene set genes present in the pre-ranked gene list.", [["Protein pathway gene lists", "DNA", 0, 26], ["pre-ranked gene list", "DNA", 103, 123]]], ["For each protein pathway gene list, drug-protein matrices were plotted by the SEA p-value for the interaction.", [["protein pathway gene list", "DNA", 9, 34], ["SEA", "PROTEIN", 78, 81], ["drug-protein matrices", "TREATMENT", 36, 57]]], ["The reported interaction significance scores represent the.Data sources: ::: Single cell sequencing data analysisSingle cell transcriptomics data and associated metadata were obtained from Tissue Stability Cell Atlas (https://www.tissuestabilitycellatlas.org/), Gene Expression Omnibus (GEO; https://www.ncbi.nlm.nih.gov/), and Single Cell Portal (https://singlecell.broadinstitute.org/single_cell).", [["cell", "ANATOMY", 84, 88], ["cell", "ANATOMY", 120, 124], ["cell", "CELL", 84, 88], ["analysisSingle cell", "CELL", 105, 124], ["Single cell sequencing data", "TEST", 77, 104], ["transcriptomics data", "TEST", 125, 145], ["Stability Cell Atlas", "OBSERVATION", 196, 216], ["Portal", "ANATOMY", 340, 346]]], ["Human lung and esophageal datasets containing samples from 5 and 6 previously healthy, post-mortem donors, respectively, were obtained from research published by Madissoon et al.14 A human heart dataset containing samples from 12 previously healthy, post-mortem donors was obtained from research published by Wang et al, GSE10981615.", [["lung", "ANATOMY", 6, 10], ["esophageal", "ANATOMY", 15, 25], ["samples", "ANATOMY", 46, 53], ["heart", "ANATOMY", 189, 194], ["samples", "ANATOMY", 214, 221], ["Human", "ORGANISM", 0, 5], ["lung", "ORGAN", 6, 10], ["esophageal datasets", "CANCER", 15, 34], ["donors", "ORGANISM", 99, 105], ["human", "ORGANISM", 183, 188], ["heart", "ORGAN", 189, 194], ["samples", "CANCER", 214, 221], ["donors", "ORGANISM", 262, 268], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 183, 188], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 183, 188], ["Human lung and esophageal datasets", "PROBLEM", 0, 34], ["post-mortem donors", "TREATMENT", 87, 105], ["post-mortem donors", "TEST", 250, 268], ["lung", "ANATOMY", 6, 10], ["esophageal", "ANATOMY", 15, 25], ["heart", "ANATOMY", 189, 194]]], ["A human colon epithelia dataset containing biopsy samples from 12 healthy individuals were obtained from research published by Smillie et. al.13Lung and esophagus datasets: ::: Quality control: ::: Single cell sequencing data analysisRData objects deposited to Tissue Stability Cell Atlas were pre-filtered by the authors.", [["colon epithelia", "ANATOMY", 8, 23], ["biopsy samples", "ANATOMY", 43, 57], ["13Lung", "ANATOMY", 142, 148], ["esophagus", "ANATOMY", 153, 162], ["cell", "ANATOMY", 205, 209], ["Cell", "ANATOMY", 278, 282], ["human", "ORGANISM", 2, 7], ["colon epithelia", "TISSUE", 8, 23], ["biopsy samples", "CANCER", 43, 57], ["esophagus", "ORGAN", 153, 162], ["cell", "CELL", 205, 209], ["RData objects", "DNA", 234, 247], ["human", "SPECIES", 2, 7], ["human", "SPECIES", 2, 7], ["A human colon epithelia dataset", "TEST", 0, 31], ["biopsy samples", "TEST", 43, 57], ["Single cell sequencing data analysis", "TEST", 198, 234], ["colon", "ANATOMY", 8, 13], ["epithelia", "ANATOMY_MODIFIER", 14, 23], ["esophagus", "ANATOMY", 153, 162], ["Stability Cell Atlas", "OBSERVATION", 268, 288]]], ["Filtering criteria can be found in the methods of Madissoon et al.14 Briefly, cells were excluded if they did not meet all the following criteria: more than 300 and fewer than 5,000 genes detected, fewer than 20,000 UMI, and less than 10% mitochondrial reads.", [["cells", "ANATOMY", 78, 83], ["mitochondrial", "ANATOMY", 239, 252], ["cells", "CELL", 78, 83], ["mitochondrial", "CELLULAR_COMPONENT", 239, 252]]], ["Genes were removed if they were detected in fewer than three cells per tissue.Colon dataset: ::: Quality control: ::: Single cell sequencing data analysisThe gene by cell counts matrix deposited to GEO was pre-filtered by the authors.", [["cells", "ANATOMY", 61, 66], ["tissue", "ANATOMY", 71, 77], ["Colon", "ANATOMY", 78, 83], ["cell", "ANATOMY", 125, 129], ["cell", "ANATOMY", 166, 170], ["cells", "CELL", 61, 66], ["tissue", "TISSUE", 71, 77], ["cell", "CELL", 125, 129], ["cell", "CELL", 166, 170], ["matrix", "CELLULAR_COMPONENT", 178, 184], ["Single cell sequencing data analysis", "TEST", 118, 154], ["cell counts", "OBSERVATION", 166, 177]]], ["Filtering criteria can be found in the methods of Wang et al.15 Briefly, cells were removed if they did not meet all the following criteria: detected at least 500 genes, UMI\u2019s within 2 standard deviations of the mean of log10UMI of all cells, unique read alignment rate at least 50%, and fewer than 72% mitochondrial reads.", [["cells", "ANATOMY", 73, 78], ["cells", "ANATOMY", 236, 241], ["mitochondrial", "ANATOMY", 303, 316], ["cells", "CELL", 73, 78], ["cells", "CELL", 236, 241], ["mitochondrial", "CELLULAR_COMPONENT", 303, 316], ["UMI", "DNA", 170, 173], ["UMI", "TEST", 170, 173], ["alignment rate", "TEST", 255, 269]]], ["Further, cardiomyocytes (CM) from CM-enriched datasets were included if UMIs detected were greater than 10,000.Heart dataset: ::: Quality control: ::: Single cell sequencing data analysisBased on the methods of Smillie et al,13 cells were removed if they did not meet one of the following criteria: minimal expression of 500 genes per cell; nUMIs within two standard deviations from the mean of log10 nUMIs of all cells; unique read alignment rate (# of assigned reads/ # total aligned reads) greater that 50%; and a mitochondrial read percentage of less than 72%.Mitochondrial genes were subsequently removed from the dataset prior to dimensionality reduction.Lung and esophagus datasets: ::: Data integration, dimensionality reduction and cell clustering: ::: Single cell sequencing data analysisBatch correction, data normalization variable gene identification, data scaling, principal component analysis (PCA) and uniform manifold approximation and projection (UMAP) dimensionality reduction was performed by the original authors and included in the RData objects deposited to Tissue Stability Cell Atlas.", [["cardiomyocytes", "ANATOMY", 9, 23], ["CM", "ANATOMY", 25, 27], ["Heart", "ANATOMY", 111, 116], ["cell", "ANATOMY", 158, 162], ["cells", "ANATOMY", 228, 233], ["cell", "ANATOMY", 335, 339], ["cells", "ANATOMY", 414, 419], ["mitochondrial", "ANATOMY", 517, 530], ["Mitochondrial", "ANATOMY", 564, 577], ["Lung", "ANATOMY", 661, 665], ["esophagus", "ANATOMY", 670, 679], ["cell", "ANATOMY", 741, 745], ["cell", "ANATOMY", 769, 773], ["CM", "DISEASE", 25, 27], ["CM", "DISEASE", 34, 36], ["cardiomyocytes", "CELL", 9, 23], ["CM", "CELL", 25, 27], ["CM", "CELL", 34, 36], ["Heart", "ORGAN", 111, 116], ["cell", "CELL", 158, 162], ["cells", "CELL", 228, 233], ["cell", "CELL", 335, 339], ["cells", "CELL", 414, 419], ["mitochondrial", "CELLULAR_COMPONENT", 517, 530], ["Mitochondrial", "CELLULAR_COMPONENT", 564, 577], ["Lung", "ORGAN", 661, 665], ["esophagus", "ORGAN", 670, 679], ["cell", "CELL", 741, 745], ["cell", "CELL", 769, 773], ["cardiomyocytes", "CELL_TYPE", 9, 23], ["500 genes", "DNA", 321, 330], ["Mitochondrial genes", "DNA", 564, 583], ["CM-enriched datasets", "TEST", 34, 54], ["UMIs", "TEST", 72, 76], ["Single cell sequencing data", "TEST", 151, 178], ["the methods", "TEST", 196, 207], ["alignment rate", "TEST", 433, 447], ["a mitochondrial read percentage", "TEST", 515, 546], ["Mitochondrial genes", "PROBLEM", 564, 583], ["dimensionality reduction", "TREATMENT", 636, 660], ["Single cell sequencing data", "TEST", 762, 789], ["data scaling", "TEST", 865, 877], ["principal component analysis", "TEST", 879, 907], ["uniform manifold approximation and projection (UMAP) dimensionality reduction", "TREATMENT", 918, 995], ["cardiomyocytes", "ANATOMY", 9, 23], ["esophagus", "ANATOMY", 670, 679], ["cell clustering", "OBSERVATION", 741, 756], ["Stability Cell Atlas", "OBSERVATION", 1088, 1108]]], ["The original UMAP coordinates generated by the authors were used for any visualizations.Colon Dataset: ::: Data integration, dimensionality reduction and cell clustering: ::: Single cell sequencing data analysisBatch correction by patient sample was performed using the Seurat v3 integration functions.", [["Colon", "ANATOMY", 88, 93], ["cell", "ANATOMY", 154, 158], ["cell", "ANATOMY", 182, 186], ["cell", "CELL", 154, 158], ["cell", "CELL", 182, 186], ["patient", "ORGANISM", 231, 238], ["UMAP coordinates", "DNA", 13, 29], ["patient", "SPECIES", 231, 238], ["any visualizations", "TEST", 69, 87], ["Single cell sequencing data analysis", "TEST", 175, 211], ["patient sample", "TEST", 231, 245], ["cell clustering", "OBSERVATION", 154, 169]]], ["The dataset was split by \u201cSubject\u201d, individual gene matrices were log normalized using a scaling factor of 10,000 and 2,000 variable features were identified per individual gene matrix using variance stabilizing transformation.", [["matrix", "CELLULAR_COMPONENT", 178, 184], ["a scaling factor", "TEST", 87, 103], ["variance stabilizing transformation", "PROBLEM", 191, 226]]], ["2,000 integration anchors were found using the first 30 dimensions of the canonical correlation analysis and individual datasets were integrated using the same number of dimensions.", [["integration anchors", "TREATMENT", 6, 25], ["the canonical correlation analysis", "TEST", 70, 104], ["individual datasets", "TEST", 109, 128]]], ["PCA was performed and UMAP coordinates were found based on the first 20 principal components.Heart Dataset: ::: Data integration, dimensionality reduction and cell clustering: ::: Single cell sequencing data analysisBatch correction by patient sample was performed using mutual nearest neighbor (MNN)36 matching through the \u201cRunFastMNN\u201d function from the SeuratWrappers package.", [["Heart", "ANATOMY", 93, 98], ["cell", "ANATOMY", 159, 163], ["cell", "ANATOMY", 187, 191], ["Heart", "ORGAN", 93, 98], ["cell", "CELL", 159, 163], ["cell", "CELL", 187, 191], ["patient", "ORGANISM", 236, 243], ["UMAP coordinates", "DNA", 22, 38], ["patient", "SPECIES", 236, 243], ["PCA", "TREATMENT", 0, 3], ["the SeuratWrappers package", "TREATMENT", 351, 377], ["cell clustering", "OBSERVATION", 159, 174]]], ["The dataset was log normalized using a scaling factor of 10,000 and 2,000 variable features were identified per individual gene matrix using variance stabilizing transformation.", [["matrix", "CELLULAR_COMPONENT", 128, 134], ["a scaling factor", "TEST", 37, 53]]], ["\u201cRunFastMNN\u201d was performed on the dataset split by \u201cIndividual\u201d and UMAP coordinates were found based on the first 30 MNN dimensions.", [["RunFastMNN", "PROTEIN", 1, 11]]], ["A shared nearest neighbor graph was constructed with the same number of MNN dimensions and clusters were identified using clustering resolution of 0.2.Lung, esophagus and colon datasets: ::: Cell type identification and gene expression analysis: ::: Single cell sequencing data analysisCell type cluster annotations determined by the original authors were available through the metadata downloaded with each dataset.", [["Lung", "ANATOMY", 151, 155], ["esophagus", "ANATOMY", 157, 166], ["colon", "ANATOMY", 171, 176], ["Cell", "ANATOMY", 191, 195], ["cell", "ANATOMY", 257, 261], ["Cell", "ANATOMY", 286, 290], ["Lung, esophagus and colon", "DISEASE", 151, 176], ["MNN", "CANCER", 72, 75], ["Lung", "ORGAN", 151, 155], ["esophagus", "MULTI-TISSUE_STRUCTURE", 157, 166], ["colon", "ORGAN", 171, 176], ["Cell", "CELL", 191, 195], ["cell", "CELL", 257, 261], ["Cell", "CELL", 286, 290], ["Single cell sequencing data analysis", "TEST", 250, 286], ["esophagus", "ANATOMY", 157, 166], ["colon", "ANATOMY", 171, 176]]], ["These original cluster annotations were used for any visualizations.Heart Dataset: ::: Cell type identification and gene expression analysis: ::: Single cell sequencing data analysisClusters were annotated based on cluster specific expression of marker genes identified in the original publication.", [["Heart", "ANATOMY", 68, 73], ["Cell", "ANATOMY", 87, 91], ["cell", "ANATOMY", 153, 157], ["Heart", "ORGAN", 68, 73], ["Cell", "CELL", 87, 91], ["cell", "CELL", 153, 157], ["marker genes", "DNA", 246, 258], ["any visualizations", "TEST", 49, 67], ["Single cell sequencing data analysis", "TEST", 146, 182], ["marker genes", "PROBLEM", 246, 258]]], ["Cluster markers were identified using a Wilcoxon Rank Sum test.Heart Dataset: ::: Cell type identification and gene expression analysis: ::: Single cell sequencing data analysisFollowing cell type annotation, gene dropout values were imputed using adaptively-thresholded low rank approximation (ALRA)37.", [["Heart", "ANATOMY", 63, 68], ["Cell", "ANATOMY", 82, 86], ["cell", "ANATOMY", 148, 152], ["cell", "ANATOMY", 187, 191], ["Heart", "ORGAN", 63, 68], ["Cell", "CELL", 82, 86], ["cell", "CELL", 148, 152], ["cell", "CELL", 187, 191], ["Cluster markers", "TEST", 0, 15], ["a Wilcoxon Rank Sum test", "TEST", 38, 62], ["Single cell sequencing data analysis", "TEST", 141, 177], ["cell type annotation", "TEST", 187, 207], ["gene dropout values", "TEST", 209, 228], ["adaptively-thresholded low rank approximation (ALRA)", "TREATMENT", 248, 300]]], ["The rank-k approximation was automatically chosen for each dataset and all other parameters were set as the default values.", [["all other parameters", "TEST", 71, 91]]], ["The imputed gene expression in shown in all plots and used in all downstream analysis.Gene signature scoring: ::: Single cell sequencing data analysisThe Seurat \u201cAddModuleScore\u201d function was used to score each cell in the datasets for their expression of high confidence drug target genes (Figure 2C) and genes associated with AR signaling (Supplementary Table 3).", [["cell", "ANATOMY", 121, 125], ["cell", "ANATOMY", 210, 214], ["cell", "CELL", 121, 125], ["cell", "CELL", 210, 214], ["Figure 2C", "GENE_OR_GENE_PRODUCT", 290, 299], ["AR", "GENE_OR_GENE_PRODUCT", 327, 329], ["high confidence drug target genes", "DNA", 255, 288], ["Figure 2C", "DNA", 290, 299], ["AR", "PROTEIN", 327, 329], ["all downstream analysis", "TEST", 62, 85], ["Single cell sequencing data analysis", "TEST", 114, 150], ["high confidence drug target genes", "PROBLEM", 255, 288], ["AR signaling", "PROBLEM", 327, 339]]], ["\u201cUpstream AR Activators\u201d were identified through literature search24\u201327, \u201cAR Signaling\u201d genes were taken from the androgen receptor signaling pathway gene ontology term (GO:0030521), and \u201cCommon AR Target Genes\u201d are the common \u201ccore\u201d target genes transcribed by AR activated identified by Jin et. al.28 through comparison of multiple microarray studies.Bulk RNA sequencing analysis. ::: Single cell sequencing data analysisThe bulk RNA sequencing dataset analyzed here was previously reported12.", [["cell", "ANATOMY", 394, 398], ["androgen", "CHEMICAL", 114, 122], ["AR", "GENE_OR_GENE_PRODUCT", 10, 12], ["AR", "GENE_OR_GENE_PRODUCT", 74, 76], ["androgen receptor", "GENE_OR_GENE_PRODUCT", 114, 131], ["AR", "GENE_OR_GENE_PRODUCT", 262, 264], ["cell", "CELL", 394, 398], ["Upstream AR", "PROTEIN", 1, 12], ["search24\u201327", "DNA", 60, 71], ["AR", "PROTEIN", 74, 76], ["androgen receptor signaling pathway gene ontology term", "DNA", 114, 168], ["common \u201ccore\u201d target genes", "DNA", 220, 246], ["AR", "PROTEIN", 262, 264], ["multiple microarray studies", "TEST", 325, 352], ["Bulk RNA sequencing analysis", "TEST", 353, 381], ["Single cell sequencing data analysis", "TEST", 387, 423], ["The bulk RNA sequencing dataset", "TEST", 423, 454]]], ["Briefly, human pluripotent stem cell (H9 with knock-in MYH6:mCherry reporter)-derived cardiomyocytes were prepared as described previously10,12.", [["pluripotent stem cell", "ANATOMY", 15, 36], ["H9", "ANATOMY", 38, 40], ["cardiomyocytes", "ANATOMY", 86, 100], ["human", "ORGANISM", 9, 14], ["pluripotent stem cell", "CELL", 15, 36], ["H9", "CELL", 38, 40], ["cardiomyocytes", "CELL", 86, 100], ["human pluripotent stem cell (H9 with knock-in MYH6:mCherry reporter", "CELL_LINE", 9, 76], ["cardiomyocytes", "CELL_TYPE", 86, 100], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14], ["derived cardiomyocytes", "PROBLEM", 78, 100], ["pluripotent stem cell", "OBSERVATION", 15, 36], ["cardiomyocytes", "ANATOMY", 86, 100]]], ["Reporter tagged cardiomyocytes were isolated from the negative fraction of the culture by FACS sorting.", [["cardiomyocytes", "ANATOMY", 16, 30], ["cardiomyocytes", "CELL", 16, 30], ["cardiomyocytes", "CELL_TYPE", 16, 30], ["Reporter tagged cardiomyocytes", "PROBLEM", 0, 30], ["the culture", "TEST", 75, 86], ["cardiomyocytes", "ANATOMY", 16, 30]]], ["Both the purified cardiomyocytes and negative fractions were prepared and sent for bulk RNA sequencing.", [["cardiomyocytes", "ANATOMY", 18, 32], ["cardiomyocytes", "CELL", 18, 32], ["purified cardiomyocytes", "CELL_TYPE", 9, 32], ["bulk RNA sequencing", "TEST", 83, 102], ["cardiomyocytes", "ANATOMY", 18, 32], ["negative fractions", "OBSERVATION", 37, 55]]], ["Gene expression between the cardiomyocytes and non-cardiomyocytes was compared by averaging the read count per gene and normalizing by the average read count of GAPDH.Protein-protein interaction network construction. ::: Single cell sequencing data analysisProtein-protein interaction network analysis was performed using the Search Tool for the Retrieval of Interacting Genes (STRING) database.", [["cardiomyocytes", "ANATOMY", 28, 42], ["non-cardiomyocytes", "ANATOMY", 47, 65], ["cell", "ANATOMY", 228, 232], ["cardiomyocytes", "CELL", 28, 42], ["non-cardiomyocytes", "CELL", 47, 65], ["GAPDH", "GENE_OR_GENE_PRODUCT", 161, 166], ["cell", "CELL", 228, 232], ["cardiomyocytes", "CELL_TYPE", 28, 42], ["non-cardiomyocytes", "CELL_TYPE", 47, 65], ["GAPDH", "PROTEIN", 161, 166], ["Interacting Genes", "DNA", 359, 376], ["Gene expression between the cardiomyocytes and non-cardiomyocytes", "PROBLEM", 0, 65], ["GAPDH", "PROBLEM", 161, 166], ["Protein", "TEST", 167, 174], ["Single cell sequencing data analysis", "TEST", 221, 257], ["Protein", "TEST", 257, 264], ["protein interaction network analysis", "TEST", 265, 301], ["cardiomyocytes", "ANATOMY", 28, 42]]], ["The minimum required interaction score was set to 0.7 corresponding to high confidence with the edge thickness indicating the degree of data support from the following active interaction sources: textmining, experiments, databases, co-expression, neighborhood, gene fusion and co-occurrence.Signaling pathway illustration. ::: Single cell sequencing data analysisSEA predicted drug-protein interactions were connected by lines.", [["cell", "ANATOMY", 334, 338], ["cell", "CELL", 334, 338], ["data support", "TREATMENT", 136, 148], ["Single cell sequencing data", "TEST", 327, 354], ["drug-protein interactions", "TREATMENT", 377, 402]]], ["Lines were dashed if the MaxTC score was below 1.", [["MaxTC", "PROTEIN", 25, 30], ["Lines", "TREATMENT", 0, 5], ["the MaxTC score", "TEST", 21, 36]]], ["Proteins corresponding with the 30 significantly enriched genes from 2C were highlighted in yellow.", [["Proteins", "TEST", 0, 8]]], ["Adobe Illustrator 24.1 was used for visualization.Transcriptional changes associated with AR down-regulation. ::: Single cell sequencing data analysisWe used an existing AR ChIP-seq dataset generated in LNCaP cells to identify direct transcriptional targets of AR.", [["cell", "ANATOMY", 121, 125], ["LNCaP cells", "ANATOMY", 203, 214], ["AR", "GENE_OR_GENE_PRODUCT", 90, 92], ["cell", "CELL", 121, 125], ["LNCaP cells", "CELL", 203, 214], ["AR", "GENE_OR_GENE_PRODUCT", 261, 263], ["AR", "PROTEIN", 90, 92], ["AR ChIP-seq dataset", "DNA", 170, 189], ["LNCaP cells", "CELL_LINE", 203, 214], ["AR", "PROTEIN", 261, 263], ["visualization", "TEST", 36, 49], ["Transcriptional changes", "PROBLEM", 50, 73], ["AR down", "PROBLEM", 90, 97], ["Single cell sequencing data analysisWe", "TEST", 114, 152], ["an existing AR ChIP", "TREATMENT", 158, 177], ["LNCaP cells", "TREATMENT", 203, 214], ["AR", "PROBLEM", 261, 263]]], ["We downloaded processed peaks from the Gene Expression Omnibus (GSM3148987) and lifted the peaks from hg19 over to hg38.", [["hg38", "DNA", 115, 119]]], ["We then used annotatePeak function (package ChIPseeker v1.8) to identify peaks 5kb downstream or upstream of transcription start sites (TSS).", [["5kb downstream", "DNA", 79, 93], ["transcription start sites", "DNA", 109, 134], ["TSS", "DNA", 136, 139], ["annotatePeak function (package ChIPseeker v", "TREATMENT", 13, 56]]], ["The genes with AR binding to this 10kb window around their TSS were selected as direct AR-bound targets.Transcriptional changes associated with AR down-regulation. ::: Single cell sequencing data analysisWe also used an RNA-seq dataset generated using RNA-mediated knockdown of AR (SRR7120653, SRR7120649, SRR7120646, and SRR7120642).", [["cell", "ANATOMY", 175, 179], ["AR", "GENE_OR_GENE_PRODUCT", 15, 17], ["AR", "GENE_OR_GENE_PRODUCT", 87, 89], ["AR", "GENE_OR_GENE_PRODUCT", 144, 146], ["cell", "CELL", 175, 179], ["AR", "GENE_OR_GENE_PRODUCT", 278, 280], ["AR", "PROTEIN", 15, 17], ["10kb window", "DNA", 34, 45], ["TSS", "DNA", 59, 62], ["AR", "PROTEIN", 87, 89], ["AR", "PROTEIN", 144, 146], ["AR", "PROTEIN", 278, 280], ["AR binding", "PROBLEM", 15, 25], ["Transcriptional changes", "PROBLEM", 104, 127], ["AR down", "PROBLEM", 144, 151], ["Single cell sequencing data analysisWe", "TEST", 168, 206], ["an RNA", "TEST", 217, 223], ["RNA", "TEST", 252, 255], ["AR", "PROBLEM", 278, 280]]], ["We downloaded raw fastq files and aligned them to the transcriptome (gencode.v28) using Salmon (v0.14.1 using --validateMappings and -l ISR flags).", [["fastq files", "DNA", 18, 29], ["Mappings", "TEST", 120, 128]]], ["We then used DESeq2 (1.22.2) to compare gene expression changes in response to AR knockdown.", [["AR", "GENE_OR_GENE_PRODUCT", 79, 81], ["AR", "PROTEIN", 79, 81], ["DESeq2", "TREATMENT", 13, 19], ["gene expression changes", "PROBLEM", 40, 63], ["AR knockdown", "TREATMENT", 79, 91]]], ["We then used the AR-bound gene-set from the previous step to assess how the AR targets respond to its down-regulation.", [["AR", "GENE_OR_GENE_PRODUCT", 17, 19], ["AR", "GENE_OR_GENE_PRODUCT", 76, 78], ["AR", "PROTEIN", 17, 19], ["AR targets", "DNA", 76, 86]]], ["For this, we used our iPAGE tool34, which uses mutual information (MI) and an associated z-score to assess the enrichment/depletion patterns of a gene-set across gene expression modulations.", [["iPAGE tool34", "DNA", 22, 34], ["our iPAGE tool34", "TREATMENT", 18, 34], ["MI", "PROBLEM", 67, 69], ["an associated z-score", "PROBLEM", 75, 96], ["the enrichment/depletion patterns", "PROBLEM", 107, 140], ["a gene-set across gene expression modulations", "TREATMENT", 144, 189], ["expression modulations", "OBSERVATION", 167, 189]]], ["To visualize this data, we included a volcano plat, with genes of interest shown in red.", [["volcano plat", "DNA", 38, 50], ["a volcano plat", "TEST", 36, 50], ["red", "OBSERVATION", 84, 87]]], ["For this analysis, we divided log-fold changes into nine equally populated bins, which were also included along with the patterns of enrichment and depletion across the data.Yale New Haven Hospital patient dataset. ::: Single cell sequencing data analysisEPIC\u2019s SlicerDicer feature was used to collect the Yale New Haven Hospital (YNHH) electronic health record anonymous aggregate-level data.", [["cell", "ANATOMY", 226, 230], ["patient", "ORGANISM", 198, 205], ["cell", "CELL", 226, 230], ["patient", "SPECIES", 198, 205], ["this analysis", "TEST", 4, 17], ["Single cell sequencing data", "TEST", 219, 246], ["enrichment", "OBSERVATION", 133, 143]]], ["Using this feature, a total of 8657 patients had a COVID-19 ICD-10 diagnosis code at YNHH during November 28, 2019-April 28 2020 time period.", [["patients", "ORGANISM", 36, 44], ["COVID-19 ICD-10 diagnosis code", "DNA", 51, 81], ["patients", "SPECIES", 36, 44], ["a COVID-19 ICD", "TREATMENT", 49, 63]]], ["Among them, 1577 patients had a Troponin T checked during the same encounter and were selected for subsequent analysis.", [["patients", "ORGANISM", 17, 25], ["Troponin T", "GENE_OR_GENE_PRODUCT", 32, 42], ["Troponin T", "PROTEIN", 32, 42], ["patients", "SPECIES", 17, 25], ["a Troponin T", "TEST", 30, 42], ["subsequent analysis", "TEST", 99, 118]]], ["Out of 1577 patients, 787 were female and 790 were male.Yale New Haven Hospital patient dataset. ::: Single cell sequencing data analysisNext, we focused on males above age 40 for subsequent risk factor analysis.", [["cell", "ANATOMY", 108, 112], ["patients", "ORGANISM", 12, 20], ["patient", "ORGANISM", 80, 87], ["cell", "CELL", 108, 112], ["patients", "SPECIES", 12, 20], ["patient", "SPECIES", 80, 87], ["Single cell sequencing data analysis", "TEST", 101, 137], ["subsequent risk factor analysis", "PROBLEM", 180, 211]]], ["Risk factors associated with disease outcome, including age, BMI, status of hypertensive disorder, status of diabetes mellitus disorder and prostate disease were collected as dichotomized variables during data download.", [["prostate", "ANATOMY", 140, 148], ["hypertensive disorder", "DISEASE", 76, 97], ["diabetes mellitus disorder", "DISEASE", 109, 135], ["prostate disease", "DISEASE", 140, 156], ["prostate disease", "CANCER", 140, 156], ["Risk factors", "PROBLEM", 0, 12], ["disease outcome", "PROBLEM", 29, 44], ["BMI", "PROBLEM", 61, 64], ["hypertensive disorder", "PROBLEM", 76, 97], ["diabetes mellitus disorder", "PROBLEM", 109, 135], ["prostate disease", "PROBLEM", 140, 156], ["prostate", "ANATOMY", 140, 148]]], ["Variable cutoffs were set as follows: age, 40\u201365y vs. 65+ y, BMI, <30 vs. >=30, troponin T <0.01 ng/ml vs. >=0.01 ng/ml.", [["troponin T", "GENE_OR_GENE_PRODUCT", 80, 90], ["Variable cutoffs", "TEST", 0, 16], ["BMI", "TEST", 61, 64], ["troponin T", "TEST", 80, 90]]], ["Diabetes, hypertension and prostatic disease were binary originally and were collected as a visit diagnosis.", [["prostatic", "ANATOMY", 27, 36], ["Diabetes", "DISEASE", 0, 8], ["hypertension", "DISEASE", 10, 22], ["prostatic disease", "DISEASE", 27, 44], ["prostatic", "ORGAN", 27, 36], ["Diabetes", "PROBLEM", 0, 8], ["hypertension", "PROBLEM", 10, 22], ["prostatic disease", "PROBLEM", 27, 44], ["hypertension", "OBSERVATION", 10, 22], ["prostatic", "ANATOMY", 27, 36], ["disease", "OBSERVATION", 37, 44]]], ["Appropriate SNOMED-CT (systematized nomenclature of medicine\u2013clinical terms) were used to include or exclude patients according to their pre-existing conditions.", [["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["Appropriate SNOMED-CT", "TEST", 0, 21]]], ["The following terms were used to identify patients with pre-existing conditions in the database: \u201cdisorders of glucose metabolism\u201d to select the patients with any form of the Diabetes Mellitus, \u201cHypertensive disorder\u201d to select the patients with any form of hypertension and \u201chyperplasia of prostate or Neoplasm of Prostate\u201d to select patients with disorders of prostate gland.", [["prostate", "ANATOMY", 291, 299], ["Neoplasm", "ANATOMY", 303, 311], ["Prostate", "ANATOMY", 315, 323], ["prostate gland", "ANATOMY", 362, 376], ["glucose", "CHEMICAL", 111, 118], ["Diabetes Mellitus", "DISEASE", 175, 192], ["Hypertensive disorder", "DISEASE", 195, 216], ["hypertension", "DISEASE", 258, 270], ["hyperplasia", "DISEASE", 276, 287], ["disorders of prostate gland", "DISEASE", 349, 376], ["glucose", "CHEMICAL", 111, 118], ["patients", "ORGANISM", 42, 50], ["glucose", "SIMPLE_CHEMICAL", 111, 118], ["patients", "ORGANISM", 145, 153], ["patients", "ORGANISM", 232, 240], ["prostate", "CANCER", 291, 299], ["Prostate\u201d", "CANCER", 315, 324], ["patients", "ORGANISM", 335, 343], ["prostate gland", "MULTI-TISSUE_STRUCTURE", 362, 376], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 145, 153], ["patients", "SPECIES", 232, 240], ["patients", "SPECIES", 335, 343], ["pre-existing conditions", "PROBLEM", 56, 79], ["glucose metabolism", "PROBLEM", 111, 129], ["the Diabetes Mellitus", "PROBLEM", 171, 192], ["Hypertensive disorder", "PROBLEM", 195, 216], ["hypertension", "PROBLEM", 258, 270], ["\u201chyperplasia of prostate", "PROBLEM", 275, 299], ["Neoplasm of Prostate", "PROBLEM", 303, 323], ["disorders of prostate gland", "PROBLEM", 349, 376], ["Diabetes", "OBSERVATION", 175, 183], ["hypertension", "OBSERVATION", 258, 270], ["hyperplasia", "OBSERVATION", 276, 287], ["prostate", "ANATOMY", 291, 299], ["Neoplasm", "OBSERVATION", 303, 311], ["Prostate", "ANATOMY", 315, 323], ["prostate gland", "ANATOMY", 362, 376]]], ["The study was in accordance with Institutional Review Board policy.Yale New Haven Hospital patient dataset. ::: Single cell sequencing data analysisA total of 681 subjects exist in this dataset with 239 high troponin and 442 low troponin cases.", [["cell", "ANATOMY", 119, 123], ["patient", "ORGANISM", 91, 98], ["cell", "CELL", 119, 123], ["troponin", "GENE_OR_GENE_PRODUCT", 208, 216], ["troponin", "GENE_OR_GENE_PRODUCT", 229, 237], ["troponin", "PROTEIN", 208, 216], ["patient", "SPECIES", 91, 98], ["The study", "TEST", 0, 9], ["Single cell sequencing data analysis", "TEST", 112, 148], ["this dataset", "TEST", 181, 193], ["high troponin", "TEST", 203, 216], ["low troponin cases", "PROBLEM", 225, 243]]], ["The interdependence of all variables was explored through their correlation matrix (Supplementary Figure 10B) and pairwise Fisher\u2019s exact tests.", [["exact tests", "TEST", 132, 143]]], ["To find the optimal model, we used a backward selection approach.", [["a backward selection approach", "TREATMENT", 35, 64]]], ["We started with a logistic regression model with troponin as response and all the other variables and their pairwise interaction terms as covariates.", [["troponin", "GENE_OR_GENE_PRODUCT", 49, 57], ["troponin", "PROTEIN", 49, 57], ["troponin", "TEST", 49, 57]]], ["Odds of having abnormal troponin T in the baseline group (40\u201365y, no prostate disease, low BMI, no diabetes, no hypertension, n=58) was 0.038.UK Biobank dataset. ::: Single cell sequencing data analysisIndividual-level longitudinal phenotypic data from the UK Biobank, a large-scale population-based cohort with genotype and phenotype data in approximately 500,000 volunteer participants recruited from 2006\u20132010 was used39.", [["prostate", "ANATOMY", 69, 77], ["cell", "ANATOMY", 173, 177], ["prostate disease", "DISEASE", 69, 85], ["low BMI", "DISEASE", 87, 94], ["diabetes", "DISEASE", 99, 107], ["hypertension", "DISEASE", 112, 124], ["troponin T", "GENE_OR_GENE_PRODUCT", 24, 34], ["prostate", "CANCER", 69, 77], ["cell", "CELL", 173, 177], ["troponin T", "PROTEIN", 24, 34], ["participants", "SPECIES", 375, 387], ["abnormal troponin T", "PROBLEM", 15, 34], ["prostate disease", "PROBLEM", 69, 85], ["low BMI", "PROBLEM", 87, 94], ["diabetes", "PROBLEM", 99, 107], ["hypertension", "PROBLEM", 112, 124], ["Single cell sequencing data analysis", "TEST", 166, 202], ["Individual", "TEST", 202, 212], ["a large-scale population", "TREATMENT", 269, 293], ["phenotype data", "TEST", 325, 339], ["no", "UNCERTAINTY", 66, 68], ["prostate", "ANATOMY", 69, 77], ["disease", "OBSERVATION", 78, 85], ["large", "OBSERVATION_MODIFIER", 271, 276]]], ["Baseline assessments were conducted at 22 assessment centers across the UK using touch screen questionnaire, computer assisted verbal interview, physical tests, and sample collection including for DNA.", [["DNA", "CELLULAR_COMPONENT", 197, 200], ["Baseline assessments", "TEST", 0, 20], ["touch screen", "TEST", 81, 93], ["physical tests", "TEST", 145, 159], ["sample collection", "TEST", 165, 182], ["DNA", "PROBLEM", 197, 200]]], ["Additional details regarding the study protocol are described online (www.ukbiobank.ac.uk).UK Biobank dataset. ::: Single cell sequencing data analysisOf 488,377 individuals genotyped in the UK Biobank, we used data for 311,857 participants from English recruiting centers where COVID-19 testing was reported in the UK Biobank, as done previously40.", [["cell", "ANATOMY", 122, 126], ["cell", "CELL", 122, 126], ["participants", "SPECIES", 228, 240], ["the study protocol", "TEST", 29, 47], ["Single cell sequencing data analysisOf", "TEST", 115, 153]]], ["Additionally, we further filtered to individuals with white British ancestry consenting to genetic analyses, with genotypic-phenotypic sex concordance, without sex aneuploidy, and removed one individual from each pair of 1st or 2nd degree relatives selected randomly.", [["aneuploidy", "DISEASE", 164, 174], ["genetic analyses", "TEST", 91, 107]]], ["Secondary use of the data was approved by the Massachusetts General Hospital institutional review board (protocol 2013P001840) and facilitated through UK Biobank Application 7089.UK Biobank androgen indices and phenotypic covariates: ::: Single cell sequencing data analysisFree androgen index was calculated in the UK Biobank by using total testosterone and sex hormone-binding globulin (SHBG) as in the equation: Free androgen index= 100*(total Testoterone/SHBG).", [["cell", "ANATOMY", 245, 249], ["testosterone", "CHEMICAL", 342, 354], ["androgen", "CHEMICAL", 190, 198], ["androgen", "CHEMICAL", 279, 287], ["testosterone", "CHEMICAL", 342, 354], ["androgen", "CHEMICAL", 420, 428], ["UK", "GENE_OR_GENE_PRODUCT", 179, 181], ["cell", "CELL", 245, 249], ["testosterone", "SIMPLE_CHEMICAL", 342, 354], ["sex hormone-binding globulin", "GENE_OR_GENE_PRODUCT", 359, 387], ["SHBG", "GENE_OR_GENE_PRODUCT", 389, 393], ["SHBG", "GENE_OR_GENE_PRODUCT", 459, 463], ["sex hormone-binding globulin", "PROTEIN", 359, 387], ["SHBG", "PROTEIN", 389, 393], ["SHBG", "PROTEIN", 459, 463], ["UK Biobank androgen indices", "TEST", 179, 206], ["Single cell sequencing data analysis", "TEST", 238, 274], ["Free androgen index", "TEST", 274, 293], ["total testosterone", "TREATMENT", 336, 354], ["sex hormone", "TEST", 359, 370], ["SHBG", "TEST", 389, 393], ["Free androgen index", "TEST", 415, 434], ["total Testoterone/SHBG", "TREATMENT", 441, 463]]], ["Testosterone (nmol/L), SHBG (nmol/L), and free androgen index (unitless) phenotypes were observed to have varying distributions by sex, with outliers.", [["Testosterone", "CHEMICAL", 0, 12], ["Testosterone", "CHEMICAL", 0, 12], ["androgen", "CHEMICAL", 47, 55], ["Testosterone", "SIMPLE_CHEMICAL", 0, 12], ["SHBG", "GENE_OR_GENE_PRODUCT", 23, 27], ["androgen", "GENE_OR_GENE_PRODUCT", 47, 55], ["SHBG", "PROTEIN", 23, 27], ["Testosterone (nmol/L)", "TREATMENT", 0, 21], ["SHBG (nmol/L)", "TEST", 23, 36], ["free androgen index", "TEST", 42, 61], ["phenotypes", "PROBLEM", 73, 83]]], ["Sex-specific extreme outliers for each phenotype were identified and excluded by adjusting the traditional box and whisker upper and lower bounds, accounting for skewness in the phenotypic data identified using the Robustbase package in R (setting range=3) (https://cran.r-project.org/web/packages/robustbase/robustbase.pdf).", [["upper", "ORGANISM_SUBDIVISION", 123, 128], ["each phenotype", "PROBLEM", 34, 48], ["skewness", "PROBLEM", 162, 170], ["the Robustbase package", "TREATMENT", 211, 233]]], ["After excluding extreme outliers, we performed inverse rank normalization of each phenotype by sex to a mean of 0 and SD 1 for use in analysis (Supplementary Figure 11B).UK Biobank androgen indices and phenotypic covariates: ::: Single cell sequencing data analysisDefinitions for phenotypic covariates included in sensitivity analysis are included in Supplementary Table 4.", [["cell", "ANATOMY", 236, 240], ["androgen", "CHEMICAL", 181, 189], ["UK", "GENE_OR_GENE_PRODUCT", 170, 172], ["cell", "CELL", 236, 240], ["extreme outliers", "PROBLEM", 16, 32], ["UK Biobank androgen indices", "TEST", 170, 197], ["Single cell sequencing data analysisDefinitions", "TEST", 229, 276], ["phenotypic covariates", "PROBLEM", 281, 302], ["sensitivity analysis", "TEST", 315, 335]]], ["In brief, hypertension was defined by self-reported hypertension and billing codes for essential hypertension, hypertensive disease with and without heart failure, hypertensive heart and renal diseases, and secondary hypertension.", [["heart", "ANATOMY", 149, 154], ["heart", "ANATOMY", 177, 182], ["renal", "ANATOMY", 187, 192], ["hypertension", "DISEASE", 10, 22], ["hypertension", "DISEASE", 52, 64], ["hypertension", "DISEASE", 97, 109], ["hypertensive disease", "DISEASE", 111, 131], ["heart failure", "DISEASE", 149, 162], ["hypertensive", "DISEASE", 164, 176], ["heart and renal diseases", "DISEASE", 177, 201], ["hypertension", "DISEASE", 217, 229], ["heart", "ORGAN", 149, 154], ["heart", "ORGAN", 177, 182], ["renal", "ORGAN", 187, 192], ["hypertension", "PROBLEM", 10, 22], ["hypertension", "PROBLEM", 52, 64], ["essential hypertension", "PROBLEM", 87, 109], ["hypertensive disease", "PROBLEM", 111, 131], ["heart failure", "PROBLEM", 149, 162], ["hypertensive heart", "PROBLEM", 164, 182], ["renal diseases", "PROBLEM", 187, 201], ["secondary hypertension", "PROBLEM", 207, 229], ["hypertension", "OBSERVATION", 10, 22], ["hypertension", "OBSERVATION", 52, 64], ["hypertension", "OBSERVATION", 97, 109], ["hypertensive", "OBSERVATION_MODIFIER", 111, 123], ["disease", "OBSERVATION", 124, 131], ["without", "UNCERTAINTY", 141, 148], ["heart", "ANATOMY", 149, 154], ["failure", "OBSERVATION", 155, 162], ["hypertensive", "OBSERVATION", 164, 176], ["heart", "ANATOMY", 177, 182], ["renal", "ANATOMY", 187, 192], ["diseases", "OBSERVATION", 193, 201], ["secondary", "OBSERVATION_MODIFIER", 207, 216], ["hypertension", "OBSERVATION", 217, 229]]], ["Type 2 diabetes was defined by billing codes for non-insulin-dependent diabetes mellitus or self-reported type 2 diabetes.", [["Type 2 diabetes", "DISEASE", 0, 15], ["non-insulin", "DISEASE", 49, 60], ["diabetes mellitus", "DISEASE", 71, 88], ["type 2 diabetes", "DISEASE", 106, 121], ["Type 2 diabetes", "PROBLEM", 0, 15], ["non-insulin-dependent diabetes mellitus", "PROBLEM", 49, 88], ["type 2 diabetes", "PROBLEM", 106, 121], ["diabetes", "OBSERVATION", 7, 15], ["diabetes", "OBSERVATION", 113, 121]]], ["Enlarged prostate was defined by combining self-reported enlarged prostate and billing codes for prostatic hyperplasia.UK Biobank COVID-19 case/control models: ::: Single cell sequencing data analysisCOVID-19 phenotypes used in the present analysis are from UK Biobank downloaded on May 2, 2020 and include combined nose/throat swabs and lower respiratory samples analyzed using PCR.", [["prostate", "ANATOMY", 9, 17], ["prostate", "ANATOMY", 66, 74], ["prostatic", "ANATOMY", 97, 106], ["cell", "ANATOMY", 171, 175], ["nose", "ANATOMY", 316, 320], ["throat swabs", "ANATOMY", 321, 333], ["lower respiratory samples", "ANATOMY", 338, 363], ["prostatic hyperplasia", "DISEASE", 97, 118], ["prostate", "CANCER", 9, 17], ["prostate", "CANCER", 66, 74], ["prostatic hyperplasia", "PATHOLOGICAL_FORMATION", 97, 118], ["cell", "CELL", 171, 175], ["nose", "ORGANISM_SUBDIVISION", 316, 320], ["Enlarged prostate", "PROBLEM", 0, 17], ["enlarged prostate", "PROBLEM", 57, 74], ["prostatic hyperplasia", "PROBLEM", 97, 118], ["COVID", "TEST", 130, 135], ["Single cell sequencing data", "TEST", 164, 191], ["analysisCOVID", "TEST", 192, 205], ["combined nose/throat swabs", "TEST", 307, 333], ["lower respiratory samples", "TEST", 338, 363], ["PCR", "TEST", 379, 382], ["prostate", "ANATOMY", 9, 17], ["enlarged", "OBSERVATION_MODIFIER", 57, 65], ["prostate", "ANATOMY", 66, 74], ["prostatic", "ANATOMY", 97, 106], ["hyperplasia", "OBSERVATION", 107, 118], ["throat", "ANATOMY", 321, 327], ["lower respiratory", "ANATOMY", 338, 355]]], ["Four case/control definitions were used in analysis to iterate over COVID-19 susceptibility and severity across both tested individuals and all individuals with reported COVID-19 testing from the UK Biobank English recruitment centers40.", [["COVID", "TEST", 68, 73], ["COVID", "TEST", 170, 175]]], ["COVID+ cases were defined as any individual with at least one positive test.", [["COVID", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["Severe COVID+ cases were defined as any individual with at least one positive test who also had evidence from their microbiological record that they were hospitalized inpatient.", [["COVID", "DISEASE", 7, 12], ["Severe COVID+ cases", "PROBLEM", 0, 19], ["cases", "OBSERVATION", 14, 19]]], ["Additionally, individuals with COVID-19 of unknown severity were excluded from the Severe COVID+ analyses.", [["COVID", "TEST", 31, 36], ["unknown severity", "PROBLEM", 43, 59], ["the Severe COVID+ analyses", "PROBLEM", 79, 105]]], ["Thus, the four definitions were as follows: for individuals tested with COVID: comparing 1) COVID+ vs. COVID\u2212 test results, 2) Severe COVID+ vs. COVID\u2212; and for all white British individuals from the UK Biobank English recruitment centers with available COVID-test reporting: 3) COVID+ vs. All, 4) Severe COVID+ vs. All.UK Biobank statistical models: ::: Single cell sequencing data analysisAssociation of the three androgen indices (Free androgen index, testosterone, and SHBG) with COVID-19 across the four case/control definitions was performed using logistic regression in R-3.5.", [["cell", "ANATOMY", 362, 366], ["testosterone", "CHEMICAL", 455, 467], ["androgen", "CHEMICAL", 416, 424], ["androgen", "CHEMICAL", 439, 447], ["testosterone", "CHEMICAL", 455, 467], ["cell", "CELL", 362, 366], ["androgen", "SIMPLE_CHEMICAL", 439, 447], ["testosterone", "SIMPLE_CHEMICAL", 455, 467], ["SHBG", "GENE_OR_GENE_PRODUCT", 473, 477], ["COVID", "PROTEIN", 103, 108], ["SHBG", "PROTEIN", 473, 477], ["COVID\u2212 test results", "TEST", 103, 122], ["Severe COVID+ vs. COVID\u2212", "PROBLEM", 127, 151], ["Severe COVID", "PROBLEM", 298, 310], ["Single cell sequencing data", "TEST", 355, 382], ["the three androgen indices", "TEST", 406, 432], ["Free androgen index", "TEST", 434, 453], ["testosterone", "TEST", 455, 467], ["SHBG", "TEST", 473, 477], ["COVID", "TEST", 484, 489], ["logistic regression", "TEST", 554, 573]]], ["Three main association models were used for analysis: 1) an unadjusted model, 2) a sparsely adjusted model using age, normalized Townsend deprivation index (a marker of socioeconomic status), and the first ten principal components of genetic ancestry, and 3) a fully adjusted model that additionally adjusted for normalized body mass index (BMI).", [["body", "ANATOMY", 324, 328], ["body", "ORGANISM_SUBDIVISION", 324, 328], ["normalized Townsend deprivation index", "PROBLEM", 118, 155], ["normalized body mass index", "PROBLEM", 313, 339]]], ["Analyses were performed across males and females as well as separately by sex.", [["Analyses", "TEST", 0, 8]]], ["Several additional sensitivity analyses were performed to assess for the robustness of associations.", [["Several additional sensitivity analyses", "TEST", 0, 39]]], ["In particular, analyses were performed additionally adjusting for prevalent hypertension and prevalent type 2 diabetes, showing consistent associations.Statistical methods: ::: Single cell sequencing data analysisExperiments were carried out in a minimum of 3 biological replicates unless specified otherwise.", [["cell", "ANATOMY", 184, 188], ["hypertension", "DISEASE", 76, 88], ["type 2 diabetes", "DISEASE", 103, 118], ["cell", "CELL", 184, 188], ["prevalent hypertension", "PROBLEM", 66, 88], ["prevalent type 2 diabetes", "PROBLEM", 93, 118], ["Single cell sequencing data analysis", "TEST", 177, 213], ["diabetes", "OBSERVATION", 110, 118]]], ["Two-tailed student\u2019s t-test was performed to compare treatment groups unless otherwise indicated in the methods section or legends.", [["t-test", "TEST", 21, 27], ["treatment groups", "TREATMENT", 53, 69]]], ["Error bars in s represent standard error of the mean.", [["standard error", "OBSERVATION", 26, 40]]]], "85d7df32a52adc5699ba4cce08fd366119194f28": [["1 This unprecedented health event places massive pressure on health care systems worldwide, in addition to severe negative social and economic impact.", [["massive pressure on health care systems", "TREATMENT", 41, 80], ["massive", "OBSERVATION_MODIFIER", 41, 48], ["pressure", "OBSERVATION_MODIFIER", 49, 57], ["severe", "OBSERVATION_MODIFIER", 107, 113], ["negative", "OBSERVATION", 114, 122]]], ["Although there is no direct effect of COVID-19 on the urinary tract from a urological point of view, 2 this does not mean urologists will not get involved.", [["urinary tract", "ANATOMY", 54, 67], ["COVID-19", "CHEMICAL", 38, 46], ["COVID-19", "CHEMICAL", 38, 46], ["urinary tract", "ORGANISM_SUBDIVISION", 54, 67], ["COVID", "TEST", 38, 43], ["no", "UNCERTAINTY", 18, 20], ["urinary tract", "ANATOMY", 54, 67]]]], "PMC4572045": [["IntroductionPrimary immunodeficiency diseases (PIDs) are a heterogeneous group of more than 200 disorders that result from a large number of different genetic abnormalities affecting the innate and adaptive immune systems [1].", [["IntroductionPrimary immunodeficiency diseases", "DISEASE", 0, 45], ["PIDs", "DISEASE", 47, 51], ["IntroductionPrimary immunodeficiency diseases", "PROBLEM", 0, 45], ["200 disorders", "PROBLEM", 92, 105], ["different genetic abnormalities", "PROBLEM", 141, 172], ["heterogeneous", "OBSERVATION_MODIFIER", 59, 72], ["large", "OBSERVATION_MODIFIER", 125, 130], ["number", "OBSERVATION_MODIFIER", 131, 137]]], ["It has been estimated that there are about 250,000 patients in the United States who have been diagnosed with PID, and many others still to be identified [2].", [["PID", "DISEASE", 110, 113], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["PID", "PROBLEM", 110, 113]]], ["Worldwide, PIDs are more common than generally thought [3, 4].", [["PIDs", "DISEASE", 11, 15]]], ["Antibody deficiencies account for more than half (50.9 %) of all immunodeficiency disorders [4].", [["immunodeficiency disorders", "DISEASE", 65, 91], ["Antibody deficiencies", "PROBLEM", 0, 21], ["all immunodeficiency disorders", "PROBLEM", 61, 91]]], ["This heterogeneous group of disorders is characterized by impaired antibody production leading to low quantity and/or quality of antibodies [5].", [["antibodies", "PROTEIN", 129, 139], ["This heterogeneous group of disorders", "PROBLEM", 0, 37], ["impaired antibody production", "PROBLEM", 58, 86], ["low quantity and/or quality of antibodies", "PROBLEM", 98, 139], ["heterogeneous", "OBSERVATION_MODIFIER", 5, 18], ["impaired", "OBSERVATION_MODIFIER", 58, 66], ["antibody production", "OBSERVATION", 67, 86], ["low quantity", "OBSERVATION_MODIFIER", 98, 110]]], ["Unfortunately, these disorders are likely to go undiagnosed for years, delaying initiation of appropriate therapy [6].IntroductionMany types of PID involving antibody deficiency can be effectively managed by administering immunoglobulin (Ig).", [["PID involving antibody deficiency", "DISEASE", 144, 177], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 222, 236], ["Ig", "GENE_OR_GENE_PRODUCT", 238, 240], ["immunoglobulin", "PROTEIN", 222, 236], ["Ig", "PROTEIN", 238, 240], ["these disorders", "PROBLEM", 15, 30], ["appropriate therapy", "TREATMENT", 94, 113], ["PID", "PROBLEM", 144, 147], ["antibody deficiency", "PROBLEM", 158, 177], ["immunoglobulin (Ig", "TREATMENT", 222, 240], ["antibody deficiency", "OBSERVATION", 158, 177]]], ["In this context, Ig therapy has been shown to significantly decrease the risk of infections and improve quality of life [7\u201310].", [["infections", "DISEASE", 81, 91], ["Ig", "GENE_OR_GENE_PRODUCT", 17, 19], ["Ig therapy", "TREATMENT", 17, 27], ["infections", "PROBLEM", 81, 91], ["infections", "OBSERVATION", 81, 91]]], ["Early diagnosis and treatment lead to better clinical outcomes with decreased risk for morbidity and mortality [6, 11\u201314].IntroductionTo improve early diagnosis of PID, several initiatives starting with awareness campaigns have been introduced [15, 16].", [["PID", "DISEASE", 164, 167], ["treatment", "TREATMENT", 20, 29], ["morbidity", "PROBLEM", 87, 96], ["PID", "PROBLEM", 164, 167], ["awareness campaigns", "TREATMENT", 203, 222]]], ["Development of newborn screening programs for severe combined immunodeficiency (SCID) changed the paradigm for detecting PID from that of identifying patients after they suffer infectious complications from their disease to that of prospectively screening large populations before the manifestations of their disease become clinically apparent [17\u201323].", [["immunodeficiency", "DISEASE", 62, 78], ["SCID", "DISEASE", 80, 84], ["PID", "DISEASE", 121, 124], ["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 150, 158], ["newborn screening programs", "TREATMENT", 15, 41], ["severe combined immunodeficiency (SCID", "PROBLEM", 46, 84], ["PID", "PROBLEM", 121, 124], ["infectious complications", "PROBLEM", 177, 201], ["their disease", "PROBLEM", 207, 220], ["prospectively screening large populations", "PROBLEM", 232, 273], ["their disease", "PROBLEM", 303, 316]]], ["Currently, the US Department of Health and Human Services recommends screening for SCID in all newborns by detecting T cell receptor excision circles (TREC) [24].", [["T cell", "ANATOMY", 117, 123], ["SCID", "DISEASE", 83, 87], ["Human", "ORGANISM", 43, 48], ["newborns", "ORGANISM", 95, 103], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 117, 132], ["T cell receptor", "PROTEIN", 117, 132], ["Human", "SPECIES", 43, 48], ["screening", "TEST", 69, 78], ["SCID", "PROBLEM", 83, 87]]], ["The platform for TREC testing employs the dried blood spot obtained from neonates for the purpose of congenital disease testing.", [["blood", "ANATOMY", 48, 53], ["congenital disease", "DISEASE", 101, 119], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["TREC testing", "TEST", 17, 29], ["the dried blood spot", "TEST", 38, 58], ["congenital disease testing", "PROBLEM", 101, 127]]], ["The detection of severe B cell disorders, such as X-linked agammaglobulinemia, has also been proposed through this vehicle through detection of the B cell receptor genetic recombination product [25, 26].IntroductionWhile these approaches can and do detect the most severe forms of PID, the vast majority of conditions and patients will not be identified via these modalities.IntroductionTo raise awareness and increase the index of suspicion for PID in general, various lists of suggestive signs and symptoms have been proposed [2, 27\u201329].", [["B cell", "ANATOMY", 24, 30], ["B cell", "ANATOMY", 148, 154], ["B cell disorders", "DISEASE", 24, 40], ["agammaglobulinemia", "DISEASE", 59, 77], ["PID", "DISEASE", 281, 284], ["PID", "DISEASE", 446, 449], ["B cell", "CELL", 24, 30], ["B cell receptor", "GENE_OR_GENE_PRODUCT", 148, 163], ["patients", "ORGANISM", 322, 330], ["B cell receptor genetic recombination product", "PROTEIN", 148, 193], ["patients", "SPECIES", 322, 330], ["severe B cell disorders", "PROBLEM", 17, 40], ["X-linked agammaglobulinemia", "PROBLEM", 50, 77], ["the B cell receptor genetic recombination product", "TREATMENT", 144, 193], ["PID", "PROBLEM", 281, 284], ["PID", "PROBLEM", 446, 449], ["suggestive signs", "PROBLEM", 479, 495], ["symptoms", "PROBLEM", 500, 508], ["severe", "OBSERVATION_MODIFIER", 17, 23], ["B cell disorders", "OBSERVATION", 24, 40], ["agammaglobulinemia", "OBSERVATION", 59, 77]]], ["These include recurrent respiratory tract infections (otitis media, sinusitis, bronchitis, pneumonia), gastrointestinal infections, recurrent/chronic diarrhea, meningitis and/or sepsis, and autoimmunity [2].", [["respiratory tract", "ANATOMY", 24, 41], ["gastrointestinal", "ANATOMY", 103, 119], ["respiratory tract infections", "DISEASE", 24, 52], ["otitis media", "DISEASE", 54, 66], ["sinusitis", "DISEASE", 68, 77], ["bronchitis", "DISEASE", 79, 89], ["pneumonia", "DISEASE", 91, 100], ["gastrointestinal infections", "DISEASE", 103, 130], ["diarrhea", "DISEASE", 150, 158], ["meningitis", "DISEASE", 160, 170], ["sepsis", "DISEASE", 178, 184], ["autoimmunity", "DISEASE", 190, 202], ["tract", "ORGANISM_SUBDIVISION", 36, 41], ["gastrointestinal", "ORGANISM_SUBDIVISION", 103, 119], ["recurrent respiratory tract infections", "PROBLEM", 14, 52], ["otitis media", "PROBLEM", 54, 66], ["sinusitis", "PROBLEM", 68, 77], ["bronchitis", "PROBLEM", 79, 89], ["pneumonia", "PROBLEM", 91, 100], ["gastrointestinal infections", "PROBLEM", 103, 130], ["recurrent/chronic diarrhea", "PROBLEM", 132, 158], ["meningitis", "PROBLEM", 160, 170], ["sepsis", "PROBLEM", 178, 184], ["autoimmunity", "PROBLEM", 190, 202], ["recurrent", "OBSERVATION_MODIFIER", 14, 23], ["respiratory tract", "ANATOMY", 24, 41], ["infections", "OBSERVATION", 42, 52], ["otitis", "OBSERVATION", 54, 60], ["sinusitis", "OBSERVATION", 68, 77], ["bronchitis", "OBSERVATION", 79, 89], ["pneumonia", "OBSERVATION", 91, 100], ["gastrointestinal", "ANATOMY", 103, 119], ["infections", "OBSERVATION", 120, 130], ["chronic", "OBSERVATION_MODIFIER", 142, 149], ["diarrhea", "OBSERVATION", 150, 158], ["meningitis", "OBSERVATION", 160, 170], ["sepsis", "OBSERVATION", 178, 184]]], ["Some patients having these manifestations may have hypogammaglobulinemia.", [["hypogammaglobulinemia", "DISEASE", 51, 72], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["these manifestations", "PROBLEM", 21, 41], ["hypogammaglobulinemia", "PROBLEM", 51, 72], ["hypogammaglobulinemia", "OBSERVATION", 51, 72]]], ["Because immunoglobulin levels are abnormal in many PIDs, it is recommended that the initial evaluation of such patients should start with quantitation of serum IgG, IgM, and IgA [2, 6, 30].IntroductionNevertheless, the under-diagnosis and substantial diagnostic delays in identifying antibody deficiencies suggest that there continues to be significant barriers to obtaining this important screening test early in the course of disease.", [["serum", "ANATOMY", 154, 159], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 8, 22], ["PIDs", "CANCER", 51, 55], ["patients", "ORGANISM", 111, 119], ["serum", "ORGANISM_SUBSTANCE", 154, 159], ["IgG", "GENE_OR_GENE_PRODUCT", 160, 163], ["IgM", "GENE_OR_GENE_PRODUCT", 165, 168], ["IgA", "GENE_OR_GENE_PRODUCT", 174, 177], ["immunoglobulin", "PROTEIN", 8, 22], ["serum IgG", "PROTEIN", 154, 163], ["IgM", "PROTEIN", 165, 168], ["IgA", "PROTEIN", 174, 177], ["patients", "SPECIES", 111, 119], ["immunoglobulin levels", "TEST", 8, 29], ["abnormal", "PROBLEM", 34, 42], ["the initial evaluation", "TEST", 80, 102], ["serum IgG", "TEST", 154, 163], ["IgM", "TEST", 165, 168], ["IgA", "TEST", 174, 177], ["substantial diagnostic delays", "PROBLEM", 239, 268], ["antibody deficiencies", "PROBLEM", 284, 305], ["this important screening test", "TEST", 375, 404], ["disease", "PROBLEM", 428, 435], ["antibody deficiencies", "OBSERVATION", 284, 305]]], ["In an attempt to decrease one barrier to screening, we developed a simpler targeted screening tool that can be implemented in primary care or specialty clinics to facilitate the timely diagnosis of hypogammaglobulinemia.", [["hypogammaglobulinemia", "DISEASE", 198, 219], ["hypogammaglobulinemia", "PROBLEM", 198, 219], ["hypogammaglobulinemia", "OBSERVATION", 198, 219]]], ["To do this, we developed a dried blood spot assay for measurement of serum Ig levels that correlates with results obtained using the standard nephelometry assay, remains stable during transport by regular mail service, and permits the collection of samples in any clinical setting.Samples ::: MethodsAll samples were drawn from 107 healthy individuals (50 males and 57 females) ranging in age from 11 months to 57 years, each of whom or their parents/guardians signed consent forms.", [["blood", "ANATOMY", 33, 38], ["serum", "ANATOMY", 69, 74], ["samples", "ANATOMY", 304, 311], ["blood", "ORGANISM_SUBSTANCE", 33, 38], ["serum", "ORGANISM_SUBSTANCE", 69, 74], ["Ig", "GENE_OR_GENE_PRODUCT", 75, 77], ["Ig", "PROTEIN", 75, 77], ["a dried blood spot assay", "TEST", 25, 49], ["serum", "TEST", 69, 74], ["Ig levels", "TEST", 75, 84], ["the standard nephelometry assay", "TEST", 129, 160], ["the collection of samples", "TEST", 231, 256], ["Methods", "TREATMENT", 293, 300], ["All samples", "TEST", 300, 311], ["stable", "OBSERVATION_MODIFIER", 170, 176]]], ["Blood samples (both venous blood draws and DBS) were obtained simultaneously at the same visit from healthy individuals.", [["Blood samples", "ANATOMY", 0, 13], ["venous blood", "ANATOMY", 20, 32], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["venous blood", "MULTI-TISSUE_STRUCTURE", 20, 32], ["Blood samples", "TEST", 0, 13], ["both venous blood draws", "TEST", 15, 38], ["DBS", "TEST", 43, 46]]], ["Drops of blood were applied to collection cards (IDBS Spot Saver Card, ID Biological Systems, Greenville, SC, USA) (Fig. 1) after performing finger capillary puncture using a lancet.", [["blood", "ANATOMY", 9, 14], ["finger capillary", "ANATOMY", 141, 157], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["Drops of blood", "TREATMENT", 0, 14], ["collection cards", "TEST", 31, 47], ["finger capillary puncture", "TEST", 141, 166], ["blood", "ANATOMY", 9, 14], ["capillary puncture", "OBSERVATION", 148, 166]]], ["The circles on the collection card were entirely saturated.", [["circles", "OBSERVATION_MODIFIER", 4, 11], ["saturated", "OBSERVATION_MODIFIER", 49, 58]]], ["The collection cards were allowed to dry on a flat surface for approximately 3 h at room temperature (18 \u00b0C to 25 \u00b0C), and then were transported to the laboratory inside a polyethylene bag that was contained in a sealed envelope.", [["surface", "ANATOMY", 51, 58], ["polyethylene", "CHEMICAL", 172, 184], ["polyethylene", "CHEMICAL", 172, 184], ["a flat surface", "TREATMENT", 44, 58], ["a polyethylene bag", "TREATMENT", 170, 188], ["collection", "OBSERVATION", 4, 14], ["polyethylene bag", "OBSERVATION", 172, 188]]]], "PMC7120971": [["IntroductionHealth care workers (HCWs) have a crucial role to play in responses to chemical, biological, radiological, nuclear and explosive (CBRNE) events.", [["nuclear", "ANATOMY", 119, 126], ["nuclear", "CELLULAR_COMPONENT", 119, 126]]], ["The Black Death (bubonic plague) swept through Medieval Europe on various occassions, leading to debate over whether physicians and other public officials had a duty to remain with the sick (Luther 1527).", [["Death", "DISEASE", 10, 15], ["bubonic", "DISEASE", 17, 24], ["The Black Death", "PROBLEM", 0, 15], ["Black", "OBSERVATION_MODIFIER", 4, 9]]], ["During the 1918 influenza pandemic, many nurses and others who volunteered to care for the infected themselves contracted the deadly influenza (Godderis and Rossiter 2013).", [["influenza pandemic", "DISEASE", 16, 34], ["influenza", "DISEASE", 133, 142]]], ["After the 1995 Aum Shinrokyo Sarin attacks, 10% of hospital HCWs involved in treating exposed patients ended up needing to be treated themselves because patients\u2019 clothes exposed them to Sarin (Rebera and Rafalowski 2014).", [["patients", "ORGANISM", 94, 102], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 94, 102], ["patients", "SPECIES", 153, 161]]], ["In the 2002\u20132003 SARS outbreak, approximately 30% of all cases occurred in HCWs; in Toronto, about half of the cases were in HCWs, three of whom died (Malm et al. 2008).", [["SARS", "DISEASE", 17, 21]]], ["Towards the end of the Ebola virus disease outbreak in West Africa, 898 cases of Ebola infection had occurred in HCWs, of whom 518 died (Statista 2015).", [["Ebola virus disease", "DISEASE", 23, 42], ["Ebola infection", "DISEASE", 81, 96], ["Ebola virus", "ORGANISM", 23, 34], ["Ebola", "ORGANISM", 81, 86], ["Ebola virus", "SPECIES", 23, 34], ["Ebola virus", "SPECIES", 23, 34], ["Ebola infection", "PROBLEM", 81, 96], ["Ebola virus", "OBSERVATION", 23, 34], ["Ebola", "OBSERVATION_MODIFIER", 81, 86], ["infection", "OBSERVATION", 87, 96]]], ["The lethality of the virus is well-known, but the HCWs were disproportionately impacted.", [["HCWs", "ORGANISM", 50, 54], ["The lethality of the virus", "PROBLEM", 0, 26], ["lethality", "OBSERVATION", 4, 13], ["virus", "OBSERVATION", 21, 26], ["disproportionately", "OBSERVATION_MODIFIER", 60, 78], ["impacted", "OBSERVATION", 79, 87]]], ["Liberia was worst hit, where 8.07% of its health workforce died from the virus, compared to 0.11% of its general population (Evans et al. 2015).", [["the virus", "PROBLEM", 69, 78]]], ["Not only did caring for patients put HCWs at risk of physical disease and death, but some who survived faced stigmatisation and discrimination afterwards (OHCHR 2014).IntroductionYet possibly the most egregious example of the risks HCWs find themselves exposed to has been in the ongoing war in Syria.", [["physical disease", "DISEASE", 53, 69], ["death", "DISEASE", 74, 79], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["physical disease", "PROBLEM", 53, 69], ["death", "PROBLEM", 74, 79]]], ["These resulted in 677 injuries and 261 deaths, with one quarter of the victims being HCWs.", [["injuries", "DISEASE", 22, 30], ["deaths", "DISEASE", 39, 45]]], ["As a result, health care services are being divided between locations and staff numbers on site are kept to a minimum to reduce the impact of individual attacks.IntroductionHCWs who respond to CBRNE events typically put themselves in harm\u2019s way to an increasing degree compared to responders to other disasters that do not involve infectious agents or contaminants.", [["individual attacks", "PROBLEM", 142, 160], ["CBRNE events", "PROBLEM", 193, 205], ["infectious agents", "TREATMENT", 331, 348]]], ["Disaster responders typically choose to enter disaster zones, and usually have specialised training to prepare for such events.", [["such events", "PROBLEM", 115, 126]]], ["This chapter will not focus on such responders, but on HCWs who find themselves in the midst of a CBRNE event.", [["a CBRNE event", "PROBLEM", 96, 109]]], ["The ethical question is whether HCWs have a duty to care for any and all patients in the event of a CBRNE crisis.", [["CBRNE", "DISEASE", 100, 105], ["HCWs", "ORGANISM", 32, 36], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["a CBRNE crisis", "PROBLEM", 98, 112]]], ["In other words, are HCWs obliged to accept the risks that accompany caring for patients after a CBRNE event?", [["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["a CBRNE event", "PROBLEM", 94, 107]]], ["In recent years, \u2018the issue of duty to care has emerged as a matter of paramount concern among health care professionals, hospital administrators, public policy makers, and bioethicists\u2019 (Ruderman et al. 2006, 2).The Current SituationBefore proceeding to examine the ethical issues involved, this discussion must be prefaced by the finding that many HCWs accept the risks of their work and diligently care for their patients in spite of the dangers involved.", [["HCWs", "ORGANISM", 350, 354], ["patients", "ORGANISM", 416, 424], ["patients", "SPECIES", 416, 424]]], ["The heroism apparent during the Ebola outbreak led Time to declare these HCWs the 2014 Person of the Year (Von Drehle and Baker 2014).", [["Ebola", "DISEASE", 32, 37]]], ["A report into the SARS outbreak in Toronto found that, \u2018Workers generally showed heroism and altruism in the face of danger during the SARS outbreak\u2019 (University of Toronto 2005, 10).", [["SARS", "DISEASE", 18, 22], ["SARS", "DISEASE", 135, 139], ["heroism", "PROBLEM", 81, 88]]], ["The Toronto report continued that \u2018some balked at caring for people infected with SARS, and a few were dismissed for failing to report for duty.", [["SARS", "DISEASE", 82, 86], ["people", "ORGANISM", 61, 67], ["people", "SPECIES", 61, 67], ["SARS", "PROBLEM", 82, 86]]], ["Post-SARS, many health care workers raised concerns about the level of protection to themselves and their families.", [["SARS", "DISEASE", 5, 9]]], ["Some even left the profession\u2019 (University of Toronto 2005, 10).The Current SituationCBRNE crises lead to ethical challenges that involve individual and societal decisions.", [["ethical challenges", "TREATMENT", 106, 124], ["left", "ANATOMY_MODIFIER", 10, 14]]], ["On an individual level, workers have to balance their ethical duties towards their patients and the public with those towards themselves and their own health, and their duties towards their families and other dependants.", [["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91]]], ["The societal level is seen most clearly by the devastation brought by Ebola onto the healthcare workforce in the affected countries.", [["Ebola", "DISEASE", 70, 75], ["Ebola", "ORGANISM", 70, 75]]], ["These systems started with woefully inadequate healthcare workforces, and the deaths of so many HCWs from Ebola have left the systems even more debilitated.", [["deaths", "DISEASE", 78, 84], ["Ebola", "DISEASE", 106, 111], ["Ebola", "ORGANISM", 106, 111]]], ["Although Ebola was directly devastating in many ways, an additional 25,000 deaths may occur each year because of the deaths of so many HCWs in these countries (Evans et al. 2015).", [["Ebola", "DISEASE", 9, 14], ["deaths", "DISEASE", 75, 81], ["deaths", "DISEASE", 117, 123], ["Ebola", "ORGANISM", 9, 14], ["Ebola", "PROBLEM", 9, 14], ["Ebola", "OBSERVATION", 9, 14], ["devastating", "OBSERVATION_MODIFIER", 28, 39]]], ["A healthcare system, and society more broadly, must somehow balance its ethical duty to care for those presently sick while knowing that this can increase the risks to the long-term health of the people in their societies who will require care in the future.The Current SituationWith the constant risk of an incurable pathological agent appearing, the growing fear of an imminent pandemic, and the threat of terrorists obtaining nuclear materials, the importance of reflecting on the duty to care and other ethical challenges associated with CBRNE has been noted (and was one of the impetuses for the two projects than contributed to this book).", [["CBRNE", "DISEASE", 542, 547], ["people", "ORGANISM", 196, 202], ["people", "SPECIES", 196, 202], ["an incurable pathological agent", "PROBLEM", 305, 336], ["an imminent pandemic", "PROBLEM", 368, 388], ["incurable", "OBSERVATION_MODIFIER", 308, 317]]], ["Ethical decision-makingskills are needed to address such issues.", [["such issues", "PROBLEM", 52, 63]]], ["Yet in spite of the acknowledged importance of such topics, the Toronto SARS report found that \u2018There is currently a vacuum in this field\u2019 (University of Toronto 2005, 10).", [["SARS", "DISEASE", 72, 76], ["vacuum", "OBSERVATION", 117, 123]]], ["In the US, for example, the 2009 H1N1 flu pandemic led to several calls to develop pandemic readiness plans.", [["flu", "DISEASE", 38, 41], ["H1N1 flu pandemic", "SPECIES", 33, 50], ["pandemic readiness plans", "TREATMENT", 83, 107]]], ["Some US states have pandemic plans, but few address the duty to care explicitly.", [["pandemic plans", "TREATMENT", 20, 34]]], ["Louisiana, the state most directly hit by Hurricane Katrina, is one that does, defining the duty to care as \u2018the obligation of health care professionals to care for patients at all times\u2019 (Louisiana Department of Health & Hospitals 2014, 10).", [["patients", "ORGANISM", 165, 173], ["patients", "SPECIES", 165, 173]]], ["It notes that during pandemics HCWs will have to balance their duty to individual patients with that to all patients.", [["HCWs", "ORGANISM", 31, 35], ["patients", "ORGANISM", 82, 90], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 82, 90], ["patients", "SPECIES", 108, 116]]], ["As noted above, the duty to care usually refers to individual patients.", [["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70]]], ["During a crisis, like a CBRNE event, a balance may be needed between the duty to care for individuals and for society as a whole.", [["a crisis", "PROBLEM", 7, 15], ["a CBRNE event", "PROBLEM", 22, 35]]], ["HCWs may see their duty not to harm patients as obliging them to avoid contagious or contaminated patients because of the risk that they could pick up the agent and pass it on to others unknowingly.", [["HCWs", "ORGANISM", 0, 4], ["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 98, 106], ["contagious", "PROBLEM", 71, 81]]], ["While the duty to care is a long-standing ethical principle in healthcare, it raises many ethical challenges that require further careful reflection and analysis.Healthcare Readiness for CBRNESome discussion has occurred around the readiness of current healthcare systems for emergency responses to CBRNE.", [["a long-standing ethical principle in healthcare", "TREATMENT", 26, 73], ["further careful reflection and analysis", "TEST", 122, 161]]], ["The guidance states that \u2018Effective human resource management is essential to ensure adequate staff capacity and the continuity of operations during any incident that increases the demand for human resources\u2019 (WHO Regional Office for Europe 2011, 17).", [["human", "ORGANISM", 36, 41], ["human", "ORGANISM", 192, 197], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 192, 197], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 192, 197], ["Effective human resource management", "TREATMENT", 26, 61], ["operations", "TREATMENT", 131, 141]]], ["Instead, the focus is on policy and management preparation.Healthcare Readiness for CBRNEA systematic review examined qualitative research into nurses\u2019 preparations for ethical issues in public health emergencies and disasters.", [["management preparation", "TREATMENT", 36, 58]]], ["The authors identified \u2018a failure to directly address the issue of ethical considerations in planning, preparedness, and response to public health emergencies and disasters by nurses\u2019 (Johnstone and Turale 2014, 73).", [["\u2018a failure", "PROBLEM", 23, 33]]], ["The American Nurses Association (2017) acknowledged the conflict between nurses\u2019 duty to care for patients and their own right to self-preservation, and the challenge of finding the right balance.", [["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["right", "ANATOMY_MODIFIER", 182, 187]]], ["The American College of Chest Physicians (CHEST) has a prominent role in preparing US doctors who will be at the front line of any respiratory pandemic.", [["respiratory pandemic", "DISEASE", 131, 151], ["any respiratory pandemic", "PROBLEM", 127, 151], ["Chest", "ANATOMY", 24, 29], ["CHEST", "ANATOMY", 42, 47], ["respiratory", "ANATOMY", 131, 142], ["pandemic", "OBSERVATION", 143, 151]]], ["They issued a Consensus Statement on the ethical issues of caring for patients during pandemics and disasters.", [["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78]]], ["This Statement does not address the duty to care (Biddison et al. 2014).Healthcare Readiness for CBRNEWith little explicit emphasis on the duty to care in crisis situations, HCWs may not be aware of their obligations or have reflected on how they might respond during a CBRNE crisis.", [["CBRNE", "DISEASE", 270, 275], ["a CBRNE crisis", "PROBLEM", 268, 282]]], ["Some surveys have asked HCWs if they would report for work in the event of different types of crises.", [["crises", "PROBLEM", 94, 100]]], ["In a survey in the US, roughly half of the HCWs who responded stated they likely would not report to work during an influenza pandemic (Balicer et al. 2006).", [["influenza pandemic", "DISEASE", 116, 134], ["HCWs", "ORGANISM", 43, 47], ["an influenza pandemic", "PROBLEM", 113, 134]]], ["Another survey of Emergency Department workers in Chicago asked whether people would work additional hours to help victims of different types of CBRNE events.", [["CBRNE", "DISEASE", 145, 150], ["people", "ORGANISM", 72, 78], ["people", "SPECIES", 72, 78], ["CBRNE events", "PROBLEM", 145, 157]]], ["Among these HCWs, 98% said they would accept extra work after an airplane crash, 85% after a radioactive bomb, and 54% after the release of a biological agent (Masterson et al. 2009).Healthcare Readiness for CBRNEThese types of studies have weaknesses because they ask people\u2019s opinions about hypothetical situations when they are not in a disaster.", [["people", "ORGANISM", 269, 275], ["people", "SPECIES", 269, 275], ["a biological agent", "TREATMENT", 140, 158], ["studies", "TEST", 228, 235], ["weaknesses", "PROBLEM", 241, 251]]], ["However, the on-going nature of a pandemic and the lethality of agents like Ebola, sarin and radioactivity, may lead some to question whether their duty to care applies to those patients.Healthcare Readiness for CBRNEChanges to the nature of healthcare are also important to consider here.", [["Ebola", "DISEASE", 76, 81], ["sarin", "CHEMICAL", 83, 88], ["Ebola", "ORGANISM", 76, 81], ["sarin", "SIMPLE_CHEMICAL", 83, 88], ["patients", "ORGANISM", 178, 186], ["Ebola", "SPECIES", 76, 81], ["patients", "SPECIES", 178, 186], ["a pandemic", "PROBLEM", 32, 42], ["the lethality of agents", "TREATMENT", 47, 70], ["Ebola", "PROBLEM", 76, 81]]], ["Arguments are made to view healthcare organisations as businesses, patients as consumers, and HCWs as employees contracted to deliver a service.", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75]]], ["As such approaches come to infuse the ethos of healthcare, they may inadvertently impact responses to CBRNE crises.", [["CBRNE crises", "PROBLEM", 102, 114]]], ["Sheri Fink\u2019s investigation into Hurricane Katrina included an exploration of some of the corporate decision-making that interferred with patient care and rescue (Fink 2013).", [["patient", "ORGANISM", 137, 144], ["patient", "SPECIES", 137, 144], ["an exploration", "TEST", 59, 73]]], ["This sort of approach can lead to a focus on contractual obligations towards workers and patients, which may not address obligations to society as a whole.", [["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97]]], ["As will be discussed more below, a contractual approach has particular limitations when altruism and sacrifice are required, which is usually the situation when the duty to care is invoked.The Traditional ViewGranted the limitations of the surveys cited above, the possibility that a significant proportion of the healthcare workforce might not show up in the aftermath of a CBRNE crisis is of concern.", [["CBRNE", "DISEASE", 375, 380], ["a CBRNE crisis", "PROBLEM", 373, 387]]], ["The book examines many of the same ethical issues that challenged the responders to Ebola virus disease.So the Plague defied all Medicine; the very Physicians were seized with it, \u2026 This was the Case of several Physicians, even some of them the most eminent; \u2026 it rather is to their Praise, that they ventured their Lives so far as even to lose them in the Service of Mankind; They endeavoured to do good, and to save the Lives of others (Defoe 1969, 35\u20136).This traditional view is that doctors and nurses will lay down their lives for their patients and the good of society.", [["Ebola virus disease", "DISEASE", 84, 103], ["Ebola virus", "ORGANISM", 84, 95], ["patients", "ORGANISM", 542, 550], ["Ebola virus", "SPECIES", 84, 95], ["patients", "SPECIES", 542, 550], ["Ebola virus", "SPECIES", 84, 95], ["Ebola virus disease", "PROBLEM", 84, 103], ["Ebola virus", "OBSERVATION", 84, 95]]], ["Those who stayed to take care of Ebola patients, or came to offer what they could, acted upon this view (Von Drehle 2014).", [["Ebola", "DISEASE", 33, 38], ["Ebola", "ORGANISM", 33, 38], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47]]], ["In battle-torn Syria, the White Helmets formed a volunteer group to provide aid and rescue to those injured by chemical and explosive devices.", [["chemical and explosive devices", "TREATMENT", 111, 141], ["torn", "OBSERVATION_MODIFIER", 10, 14], ["Syria", "OBSERVATION", 15, 20]]], ["Martin Luther gave similar advice to those facing the Black Death: \u2018paid public servants such as city physicians, city clerks and constables, or whatever their titles, should not flee unless they furnish capable substitutes who are acceptable to their employer\u2019 (Luther 1527, 477).Changing Professional EthicsThis view was explicitly called for in earlier professional ethics codes.", [["Death", "DISEASE", 60, 65]]], ["By the 1970s such strong statements about the duty to care in the face of infectious risks had disappeared from most codes (Ruderman et al. 2006).Changing Professional EthicsThe traditional obligation that a doctor should accept the risks of practicing medicine has faded.", [["practicing medicine", "TREATMENT", 242, 261], ["infectious", "OBSERVATION", 74, 84]]], ["Different reasons have been given for this, including the general belief that infectious diseases had been overpowered, as least in those countries with access to effective antibiotics (Ruderman et al. 2006).", [["infectious diseases", "DISEASE", 78, 97], ["infectious diseases", "PROBLEM", 78, 97], ["effective antibiotics", "TREATMENT", 163, 184], ["infectious", "OBSERVATION", 78, 88]]], ["The arrival in the 1980s of HIV and AIDS, especially at first when little was known about its transmission and less about its treatment, led to further weakening of the meaning of the duty to care.", [["HIV and", "DISEASE", 28, 35], ["AIDS", "DISEASE", 36, 40], ["HIV", "SPECIES", 28, 31], ["HIV", "SPECIES", 28, 31], ["HIV", "PROBLEM", 28, 31], ["its treatment", "TREATMENT", 122, 135]]], ["SARS, H1N1 and Ebola raised further questions about what the duty to care implies, both ethically and practically.", [["SARS", "DISEASE", 0, 4], ["Ebola", "DISEASE", 15, 20], ["Ebola", "ORGANISM", 15, 20], ["SARS", "PROBLEM", 0, 4], ["H1N1", "PROBLEM", 6, 10], ["Ebola", "PROBLEM", 15, 20]]], ["In response, nurses in Liberia went on strike during the Ebola outbreak because of low wages and the lack of personal protective equipment (PPE) that guards against infectious diseases like Ebola (Agence France-Presse 2014).", [["Ebola", "DISEASE", 57, 62], ["infectious diseases", "DISEASE", 165, 184], ["Ebola", "DISEASE", 190, 195], ["Ebola", "ORGANISM", 190, 195], ["infectious diseases", "PROBLEM", 165, 184]]], ["Likewise, nurses in the US protested, and some went on strike, to express concern over the lack of preparation and protective equipment for Ebola in their hospitals (Skinner and Johnson 2014).Changing Professional EthicsIn the 1800s, a doctor knew that caring for some patients entailed serious risks.", [["Ebola", "DISEASE", 140, 145], ["Ebola", "ORGANISM", 140, 145], ["patients", "ORGANISM", 269, 277], ["patients", "SPECIES", 269, 277]]], ["Many HCWs have died, and continue to die, in the service of their patients.", [["HCWs", "ORGANISM", 5, 9], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74]]], ["As one doctor noted during Ebola, many HCWs \u2018found themselves \u201cfighting a forest fire with spray bottles.\u201d", [["Ebola", "DISEASE", 27, 32], ["Ebola", "ORGANISM", 27, 32], ["spray bottles", "TREATMENT", 91, 104]]], ["They will be summarised here, but are discussed in more detail with an extensive bibliography by Malm et al. (2008).Ethical JustificationThe first is that HCWs consent to take on certain risks as they go through their professional training.", [["HCWs", "ORGANISM", 155, 159]]], ["Risks are part of all forms of practice, and can arise physically, such as from needle-sticks, using certain equipment, lifting patients, etc., and also emotionally, such as from watching patients suffer and even die.", [["patients", "ORGANISM", 128, 136], ["patients", "ORGANISM", 188, 196], ["patients", "SPECIES", 128, 136], ["patients", "SPECIES", 188, 196], ["certain equipment", "TREATMENT", 101, 118]]], ["Training should make people aware of these risks and therefore HCWs consent to accept these risks as part of professional practice.", [["people", "ORGANISM", 21, 27], ["people", "SPECIES", 21, 27]]], ["This is especially the case when someone works in infectious diseases, but applies to all HCWs.", [["infectious diseases", "DISEASE", 50, 69], ["infectious diseases", "PROBLEM", 50, 69], ["infectious", "OBSERVATION", 50, 60]]], ["The criticism of this argument is that SARS, H1N1 and Ebola have changed healthcare practice.", [["SARS", "DISEASE", 39, 43], ["H1N1", "DISEASE", 45, 49], ["Ebola", "DISEASE", 54, 59], ["Ebola", "ORGANISM", 54, 59], ["SARS", "PROBLEM", 39, 43], ["H1N1", "PROBLEM", 45, 49]]], ["Risks from serious infectious diseases did not exist for many HCWs trained in earlier years, and hence people have not in any realistic way consented to take on some of the risks that exist today.Ethical JustificationThe second approach uses an analogy to argue that HCW give implied consent to certain risks.", [["infectious diseases", "DISEASE", 19, 38], ["people", "ORGANISM", 103, 109], ["people", "SPECIES", 103, 109], ["serious infectious diseases", "PROBLEM", 11, 38], ["serious", "OBSERVATION_MODIFIER", 11, 18], ["infectious", "OBSERVATION", 19, 29]]], ["The criticism of this argument is that even if accepted in principle, it does not necessarily entail that all HCWs have a duty to care for all patients, particularly those who put HCWs at higher risk.", [["HCWs", "ORGANISM", 110, 114], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151]]], ["For example, someone with training in infectious diseases may have a duty to care for infected patients, but this does not imply that a psychiatric nurse has the same duty to those patients.", [["infectious diseases", "DISEASE", 38, 57], ["psychiatric", "DISEASE", 136, 147], ["patients", "ORGANISM", 95, 103], ["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 181, 189], ["infectious diseases", "PROBLEM", 38, 57], ["infectious", "OBSERVATION", 38, 48]]], ["Thus, the duty to care should be limited to those who have relevant training and experience in the conditions that ail the patient.Ethical JustificationThe third argument is that someone with specialised knowledge, training and skills has an additional responsibility to use that knowledge to help those in need of that expertise.", [["patient", "ORGANISM", 123, 130], ["patient", "SPECIES", 123, 130], ["relevant training", "TREATMENT", 59, 76]]], ["By their own training, HCWs are better able to care for such patients in ways that reduce their own risks.", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69]]], ["They also have easier access to the necessary protective equipment.", [["the necessary protective equipment", "TREATMENT", 32, 66]]], ["As a result of such contributions from society, HCWs should reciprocate by taking care of patients who are in need.", [["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98]]], ["Some claim that the respect or status once given HCWs no longer exists, and in some places HCWs do not receive a commensurate salary.Ethical JustificationThe fifth approach is that many HCWs take professional oaths or accept ethics codes and these often commit them to a duty to care.", [["HCWs", "ORGANISM", 186, 190]]], ["People entering a professional may view oaths as symbolic rather than a serious commitment to specific ethical values.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["The Ebola fighters regularly mentioned that they wanted to help their neighbours and their communities (Von Drehle 2014).", [["Ebola", "ORGANISM", 4, 9]]], ["Public health crises and CBRNE events remind us of the need to consider relationships and communities within ethics.", [["Public health crises", "PROBLEM", 0, 20], ["CBRNE events", "PROBLEM", 25, 37]]], ["At the same time, such approaches do not provide clear mechanisms for balancing the duties HCWs have to the variety of people they are in relationships with: family, neighbours, colleagues, patients.", [["people", "ORGANISM", 119, 125], ["patients", "ORGANISM", 190, 198], ["people", "SPECIES", 119, 125], ["patients", "SPECIES", 190, 198]]], ["Guidance is needed on how to balance such conflicting obligations to various parties.WHO GuidanceThe World Health Organization (WHO) developed general guidance on the ethical issues in public health responses to pandemic influenza (WHO 2007).", [["influenza", "DISEASE", 221, 230], ["pandemic influenza", "PROBLEM", 212, 230]]], ["What was stated after SARS remains the case today: \u2018the time to address the ethical duty to provide care is at hand \u2013 before the arrival of the next public health emergency\u2019 (Ruderman et al. 2006, 6).WHO GuidanceThe guidance notes that the duty to care can be addressed in terms of moral, professional, contractual or legal obligations.", [["SARS", "DISEASE", 22, 26], ["legal obligations", "OBSERVATION", 318, 335]]], ["Rather than taking a rigid legalistic approach, the guidance offers some flexibility.", [["a rigid legalistic approach", "TREATMENT", 19, 46]]], ["These should take account of differences in expertise and skills possessed by various HCWs, although as needs develop, people may be asked to work beyond their usual responsibilities.", [["people", "ORGANISM", 119, 125], ["people", "SPECIES", 119, 125]]], ["Reasonable accomodations should also be made for those whose own health changes their risk, such as those who may be immunocompromised or pregnant.", [["immunocompromised", "PROBLEM", 117, 134]]], ["These include providing training for pandemics, implementing appropriate preventive measures, and having available the necessary equipment to respond adequately, such as personal protective equipment (PPE).", [["pandemics", "TREATMENT", 37, 46], ["appropriate preventive measures", "TREATMENT", 61, 92]]], ["When people become ill or injured through their work, treatment should be provided, as well as access to psychosocial support.", [["people", "ORGANISM", 5, 11], ["people", "SPECIES", 5, 11], ["treatment", "TREATMENT", 54, 63], ["psychosocial support", "TREATMENT", 105, 125]]], ["To uphold the duty to not harm, employers and governments should educate HCWs on their ethical obligation to reduce the spread of infection if they become ill.WHO GuidanceThese recommendations are applicable for HCWs responding to many CBRNE events.", [["infection", "DISEASE", 130, 139], ["infection", "PROBLEM", 130, 139], ["many CBRNE events", "PROBLEM", 231, 248], ["infection", "OBSERVATION", 130, 139]]], ["However, they were published in 2007 and their uptake has been relatively slow.", [["relatively", "OBSERVATION_MODIFIER", 63, 73], ["slow", "OBSERVATION_MODIFIER", 74, 78]]], ["For example, a CBRNE readiness survey was sent to all hospitals in Belgium and the results published in 2014.", [["a CBRNE readiness survey", "TEST", 13, 37]]], ["Seventy two percent of the hospitals responded, with 11% stating they had decontamination facilities close to the emergency department entrance, and 6% reported having appropriate PPE available for those doing triage and decontamination.", [["decontamination", "TREATMENT", 221, 236]]], ["At the same time, almost three-quarters of the facilities expressed the belief that they were ready for CBRNE events.", [["CBRNE events", "PROBLEM", 104, 116]]], ["The researchers concluded that \u2018There are serious gaps in hospital preparedness for CBRN incidents in Belgium\u2019 (Mortelmans et al. 2014, 300).WHO GuidanceMuch further work is needed to engage with HCWs on the duty to treat and the practical obligations this entails.", [["CBRN", "DISEASE", 84, 88], ["serious", "OBSERVATION_MODIFIER", 42, 49]]], ["In his study of trust in the helping professions, Edmund Pellegrino finds that contractual agreements tend to lead to \u2018ethical minimalism\u2019 (1991, 79).", [["minimalism", "DISEASE", 127, 137]]], ["\u2018The professional\u2019s necessity to efface self-interest will be blunted since legalistic and contractual relationships call upon the participants to protect their own interest, not that of the other party\u2014except to the extent the contract requires.", [["participants", "SPECIES", 131, 143]]], ["In CBRNE crises, going the extra mile is exactly what needs to be encouraged, and this requires a return to traditional professional values and what are called ethical virtues: the personal character traits that lead people to strive for ethical ideals.Ethical Virtues and the\u00a0Duty to CareWhen the duty to care is seen as based on ethical virtues, as opposed to on legal or contractual obligations, HCWs will be guided by their personal integrity and consciences on how to balance this duty with their other duties.", [["people", "ORGANISM", 217, 223], ["people", "SPECIES", 217, 223]]], ["Concerns have been raised that this may lead to many HCWs failing to report for work during CBRNE events.", [["work during CBRNE events", "PROBLEM", 80, 104]]], ["A small amount of research has been conducted on the factors that motivate people to work during CBRNE events.", [["people", "ORGANISM", 75, 81], ["people", "SPECIES", 75, 81], ["small", "OBSERVATION_MODIFIER", 2, 7], ["amount", "OBSERVATION_MODIFIER", 8, 14]]], ["In one study, the leading motivational factor was a sense of duty to their profession, but other factors included concern for their family\u2019s health, personal safety and child care (Masterson et al. 2009).", [["one study", "TEST", 3, 12]]], ["These are very personal factors, rather than ones based on professional and legal obligations.Ethical Virtues and the\u00a0Duty to CareWhen interviewed for Time\u2019s 2014 Person of the Year award, Ebola virus disease responders did not refer to regulatory or professional codes.", [["Ebola virus disease", "DISEASE", 189, 208], ["Ebola virus", "ORGANISM", 189, 200], ["Ebola virus", "SPECIES", 189, 200], ["Ebola virus", "SPECIES", 189, 200], ["Ebola virus disease", "PROBLEM", 189, 208]]], ["Some survived Ebola and said \u2018It looked like God gave me a second chance to help others\u2019 (Gibbs 2014).Ethical Virtues and the\u00a0Duty to CareWays of communicating these personal ethical virtues need to be developed and included in the training of HCWs, especially those more likely to be involved in CBRNE events.", [["Ebola", "DISEASE", 14, 19], ["Ebola", "ORGANISM", 14, 19], ["CBRNE", "CANCER", 297, 302], ["Ebola", "OBSERVATION", 14, 19]]], ["Stories about courage, heroism and fear in the face of life\u2019s dangers have been used throughout human history to encourage reflection on the sorts of character traits that are necessary to deal with life\u2019s risks.", [["human", "ORGANISM", 96, 101], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101]]], ["The real-life stories of responders such as those recounted in the Ebola issue of Time can be used to foster the development of virtues like courage and volunteerism in the face of CBRNE risks (Von Drehle 2014).Ethical Virtues and the\u00a0Duty to Care", [["Ebola", "DISEASE", 67, 72]]]], "PMC7374136": [["IntroductionThe epidemic of novel coronavirus disease 2019 (COVID-19) has captured intense attention nationwide and globally.", [["coronavirus disease", "DISEASE", 34, 53], ["COVID-19", "CHEMICAL", 60, 68], ["coronavirus", "ORGANISM", 34, 45], ["novel coronavirus disease", "PROBLEM", 28, 53], ["COVID", "TEST", 60, 65], ["coronavirus disease", "OBSERVATION", 34, 53]]], ["This disease has widely and rapidly spread in China and several other countries.", [["This disease", "PROBLEM", 0, 12], ["disease", "OBSERVATION", 5, 12], ["widely", "OBSERVATION_MODIFIER", 17, 23], ["rapidly", "OBSERVATION_MODIFIER", 28, 35], ["spread", "OBSERVATION_MODIFIER", 36, 42]]], ["COVID-19 pneumonia is highly contagious, spreading mainly through contact and droplets, and the general population is susceptible.", [["pneumonia", "DISEASE", 9, 18], ["COVID", "TEST", 0, 5], ["pneumonia", "PROBLEM", 9, 18], ["pneumonia", "OBSERVATION", 9, 18], ["highly", "OBSERVATION_MODIFIER", 22, 28], ["contagious", "OBSERVATION_MODIFIER", 29, 39]]], ["Since the middle of December 2019, person-to-person transmission of COVID-19 has occurred among close contacts.", [["COVID-19", "CHEMICAL", 68, 76], ["COVID-19", "DNA", 68, 76], ["person", "SPECIES", 35, 41], ["person", "SPECIES", 45, 51], ["middle", "ANATOMY_MODIFIER", 10, 16]]], ["According to the official website of the National Health Commission, as of February 23, 2020, 49,824 people have been confirmed to have COVID-19 infections, and 635,531 have come into close contact with confirmed COVID-19 patients in mainland China [1].", [["infections", "DISEASE", 145, 155], ["people", "ORGANISM", 101, 107], ["patients", "ORGANISM", 222, 230], ["people", "SPECIES", 101, 107], ["patients", "SPECIES", 222, 230], ["COVID", "TEST", 136, 141]]], ["A close contact is defined as a person who has not taken effective protection and has close contact (within 1 m) with confirmed and suspected patients 2 days before symptom onset in suspected and confirmed patients or 2 days before samples of asymptomatic infection are taken [2].", [["samples", "ANATOMY", 232, 239], ["infection", "DISEASE", 256, 265], ["patients", "ORGANISM", 142, 150], ["patients", "ORGANISM", 206, 214], ["person", "SPECIES", 32, 38], ["patients", "SPECIES", 142, 150], ["patients", "SPECIES", 206, 214], ["asymptomatic infection", "PROBLEM", 243, 265], ["asymptomatic", "OBSERVATION_MODIFIER", 243, 255], ["infection", "OBSERVATION", 256, 265]]], ["There has been no doubt that close contacts are more likely to contract COVID-19.IntroductionChina has made unprecedented efforts in identifying and quarantining close contacts of confirmed patients to control the infection and cut off transmission routes [3].", [["infection", "DISEASE", 214, 223], ["COVID-19", "CHEMICAL", 72, 80], ["patients", "ORGANISM", 190, 198], ["patients", "SPECIES", 190, 198], ["COVID", "TEST", 72, 77], ["the infection", "PROBLEM", 210, 223], ["no doubt", "UNCERTAINTY", 15, 23], ["more likely", "UNCERTAINTY", 48, 59], ["infection", "OBSERVATION", 214, 223]]], ["Quarantine refers to separating and restricting the movement of people who are exposed to a contagious disease to see if they become sick, thus reducing their risk of infecting others [4], whereas isolation means separating infected people from those who do not get the infection.", [["Quarantine", "CHEMICAL", 0, 10], ["infection", "DISEASE", 270, 279], ["people", "ORGANISM", 64, 70], ["people", "ORGANISM", 233, 239], ["people", "SPECIES", 64, 70], ["people", "SPECIES", 233, 239], ["a contagious disease", "PROBLEM", 90, 110], ["the infection", "PROBLEM", 266, 279], ["infection", "OBSERVATION", 270, 279]]], ["Quarantine is considered to be the first principle of infectious disease control.", [["Quarantine", "CHEMICAL", 0, 10], ["Quarantine", "CHEMICAL", 0, 10], ["Quarantine", "TREATMENT", 0, 10], ["infectious disease control", "TREATMENT", 54, 80], ["infectious", "OBSERVATION", 54, 64]]], ["The primary purpose of quarantine is to prevent transmission of an infectious agent from those potentially incubating the disease [5].", [["quarantine", "TREATMENT", 23, 33], ["an infectious agent", "PROBLEM", 64, 83], ["the disease", "PROBLEM", 118, 129], ["infectious", "OBSERVATION", 67, 77]]], ["There are different types of quarantine for preventing infectious diseases.", [["infectious diseases", "DISEASE", 55, 74], ["quarantine", "TREATMENT", 29, 39], ["infectious diseases", "PROBLEM", 55, 74], ["different types", "OBSERVATION_MODIFIER", 10, 25], ["infectious", "OBSERVATION", 55, 65]]], ["In Singapore, video monitoring of people quarantined at home was common during the severe acute respiratory syndrome (SARS) outbreak [6].", [["acute respiratory syndrome", "DISEASE", 90, 116], ["SARS", "DISEASE", 118, 122], ["people", "ORGANISM", 34, 40], ["people", "SPECIES", 34, 40], ["video monitoring", "TEST", 14, 30], ["the severe acute respiratory syndrome", "PROBLEM", 79, 116], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["respiratory syndrome", "OBSERVATION", 96, 116]]], ["Individuals with exposure to SARS were instructed not to leave their homes or have visitors in Toronto [7].", [["SARS", "DISEASE", 29, 33]]], ["A prospective cohort study from Korea reported that quarantine types included single-room quarantine, cohort quarantine, and self-imposed quarantine for persons exposed to patients with confirmed Middle East respiratory syndrome (MERS) infections [8].", [["Middle East respiratory syndrome (MERS) infections", "DISEASE", 196, 246], ["persons", "ORGANISM", 153, 160], ["patients", "ORGANISM", 172, 180], ["persons", "SPECIES", 153, 160], ["patients", "SPECIES", 172, 180], ["Middle East respiratory syndrome (MERS)", "SPECIES", 196, 235], ["A prospective cohort study", "TEST", 0, 26], ["Middle East respiratory syndrome (MERS) infections", "PROBLEM", 196, 246], ["respiratory syndrome", "OBSERVATION", 208, 228]]], ["In China, close contacts of COVID-19 patients were quarantined at home or in medical quarantine centers that were remodeled by small and medium-sized hotels or hostels to temporarily house close contacts of COVID-9 patients or cured COVID-19 patients and to control the spread of COVID-19.", [["COVID-9", "CHEMICAL", 207, 214], ["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 215, 223], ["patients", "ORGANISM", 242, 250], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 215, 223], ["patients", "SPECIES", 242, 250], ["COVID", "TEST", 280, 285], ["small", "OBSERVATION_MODIFIER", 127, 132]]], ["Although quarantine measures are designed to protect an individual's physical health from infectious diseases, it is necessary to consider the mental health of those subject to such restrictions.IntroductionMany studies have investigated the psychological experience of quarantined individuals during major infectious disease outbreaks.", [["infectious diseases", "DISEASE", 90, 109], ["infectious disease", "DISEASE", 307, 325], ["quarantine measures", "TREATMENT", 9, 28], ["infectious diseases", "PROBLEM", 90, 109], ["Many studies", "TEST", 207, 219], ["quarantined individuals", "PROBLEM", 270, 293], ["major infectious disease outbreaks", "PROBLEM", 301, 335], ["infectious", "OBSERVATION_MODIFIER", 307, 317]]], ["A recent review reported that quarantine for preventing infectious diseases had adverse psychological outcomes, such as posttraumatic stress disorder (PTSD), anger and confusion, which can lead to long-term negative psychological effects [9].", [["infectious diseases", "DISEASE", 56, 75], ["posttraumatic stress disorder", "DISEASE", 120, 149], ["PTSD", "DISEASE", 151, 155], ["anger", "DISEASE", 158, 163], ["confusion", "DISEASE", 168, 177], ["infectious diseases", "PROBLEM", 56, 75], ["adverse psychological outcomes", "PROBLEM", 80, 110], ["posttraumatic stress disorder", "PROBLEM", 120, 149], ["PTSD", "PROBLEM", 151, 155], ["anger", "PROBLEM", 158, 163], ["confusion", "PROBLEM", 168, 177], ["long-term negative psychological effects", "PROBLEM", 197, 237]]], ["Specifically, during the SARS outbreak, Cava et al. [10] adopted a descriptive, qualitative design to explore the experience of home quarantine of individuals affected by SARS in Toronto.", [["SARS", "DISEASE", 25, 29], ["SARS", "DISEASE", 171, 175], ["Cava", "ANATOMY", 40, 44]]], ["The 21 participants described their experience during the quarantine, including feeling stigmatized, feeling rejected and blamed, or feeling bored, and the subtheme of coping ran through the quarantine process.", [["participants", "SPECIES", 7, 19]]], ["Another study assessed the psychological effects of quarantine among 129 individuals who were self-quarantined during the SARS epidemic.", [["SARS", "DISEASE", 122, 126], ["individuals", "ORGANISM", 73, 84], ["Another study", "TEST", 0, 13], ["the SARS epidemic", "PROBLEM", 118, 135]]], ["This study found that symptoms of PTSD and depression were observed in 28.9% and 31.2% of participants [7].", [["PTSD", "DISEASE", 34, 38], ["depression", "DISEASE", 43, 53], ["participants", "SPECIES", 90, 102], ["This study", "TEST", 0, 10], ["symptoms", "PROBLEM", 22, 30], ["PTSD", "PROBLEM", 34, 38], ["depression", "PROBLEM", 43, 53]]], ["The interview results of Cava et al. [6] reported that respondents exposed to someone with suspected SARS were quarantined at home for 10 days, they had feelings of fear or denial about their risk of being infected by SARS, and they showed high compliance with the quarantine order.", [["SARS", "DISEASE", 101, 105], ["SARS", "DISEASE", 218, 222], ["respondents", "ORGANISM", 55, 66], ["SARS", "PROBLEM", 101, 105], ["SARS", "PROBLEM", 218, 222], ["Cava", "ANATOMY", 25, 29], ["infected", "OBSERVATION", 206, 214]]], ["Wang et al. [11] adopted a cross-sectional study design to investigate whether being quarantined to contain H1N1 flu transmission was correlated with negative psychological effects and found quarantine did not have immediate negative psychological consequences among 176 undergraduate students who were quarantined as close contacts for 7 days.", [["flu", "DISEASE", 113, 116], ["H1N1 flu", "SPECIES", 108, 116], ["a cross-sectional study", "TEST", 25, 48], ["H1N1 flu transmission", "PROBLEM", 108, 129]]], ["The reason may be the lower morbidity and mortality rate during the H1N1 outbreak than the SARS outbreak.", [["H1N1", "DISEASE", 68, 72], ["SARS", "DISEASE", 91, 95], ["the lower morbidity", "PROBLEM", 18, 37], ["mortality rate", "TEST", 42, 56], ["the H1N1 outbreak", "PROBLEM", 64, 81], ["the SARS outbreak", "PROBLEM", 87, 104], ["lower", "OBSERVATION_MODIFIER", 22, 27], ["morbidity", "OBSERVATION", 28, 37]]], ["The COVID-19 patients and suspected patients are populations who must be quarantined.", [["patients", "ORGANISM", 13, 21], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 36, 44]]], ["Zhou et al. [12] explored the psychological experience and coping strategies of COVID-19 patients during the quarantine period through their comments.", [["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97]]], ["Huang et al. [13] introduced psychological self-help methods to suspected patients, such as accepting their own negative emotions and positively changing their perceptions about facing COVID-19.", [["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82]]], ["Xiang et al. [14] reported that patients with confirmed or suspected cases expressed fear of the consequences of COVID-19 infection, and others in quarantine felt bored, lonely, and angry.", [["infection", "DISEASE", 122, 131], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["COVID-19 infection", "PROBLEM", 113, 131], ["infection", "OBSERVATION", 122, 131]]], ["Quarantining close contacts of COVID-19 has been the primary community control measure available.", [["COVID-19", "CHEMICAL", 31, 39], ["COVID-19", "DNA", 31, 39], ["COVID", "TREATMENT", 31, 36]]], ["In the initial stage of the COVID-19 outbreak in China, Wang et al. [15] found that more than half of the general public assessed the psychological impact as moderate to severe, and approximately one-third reported moderate to severe anxiety.", [["anxiety", "DISEASE", 234, 241], ["moderate to severe anxiety", "PROBLEM", 215, 241], ["moderate", "OBSERVATION_MODIFIER", 158, 166], ["severe", "OBSERVATION_MODIFIER", 170, 176], ["moderate", "OBSERVATION_MODIFIER", 215, 223], ["severe", "OBSERVATION_MODIFIER", 227, 233], ["anxiety", "OBSERVATION", 234, 241]]], ["Therefore, people who had a history of contact with COVID-19 patients may suffer from greater stress.", [["people", "ORGANISM", 11, 17], ["patients", "ORGANISM", 61, 69], ["people", "SPECIES", 11, 17], ["patients", "SPECIES", 61, 69], ["greater stress", "PROBLEM", 86, 100]]], ["These people are more prone to various psychological and mental problems.", [["people", "ORGANISM", 6, 12], ["people", "SPECIES", 6, 12], ["various psychological and mental problems", "PROBLEM", 31, 72]]], ["However, there is no known information on the quarantine experience of close contacts in the current epidemic situation of COVID-19.IntroductionTo fill the gaps in the literature, we conducted a qualitative descriptive study to explore the quarantine experiences of close contacts during the quarantine in China.", [["COVID", "TEST", 123, 128], ["a qualitative descriptive study", "TEST", 193, 224], ["no", "UNCERTAINTY", 18, 20]]], ["They also may help to understand how to provide humanistic quarantine care in the health care delivery system.Design ::: MethodsExisting quantitative methods do not sufficiently take into account the perceptions and experiences of close contacts, but a qualitative descriptive design allows for an understanding of their experience [16] and is employed when a research study aims to discover and describe a process, a phenomenon, or the perspectives and views of the participants [17,18].", [["participants", "SPECIES", 467, 479], ["humanistic quarantine care", "TREATMENT", 48, 74], ["MethodsExisting quantitative methods", "TREATMENT", 121, 157], ["a research study", "TEST", 358, 374]]], ["Because a qualitative approach would yield a more detailed, in-depth and comprehensive description of the quarantine experience of the participants, a descriptive qualitative method was employed to explore the quarantine experience of close contacts of COVID-19 patients.", [["patients", "ORGANISM", 262, 270], ["participants", "SPECIES", 135, 147], ["patients", "SPECIES", 262, 270]]], ["Qualitative descriptive studies employ the principles of naturalistic enquiry or investigate a phenomenon in its natural state as much as possible [16,19].", [["Qualitative descriptive studies", "TEST", 0, 31], ["a phenomenon", "PROBLEM", 93, 105]]], ["In terms of quality assurance, the reporting of this study was consistent with the consolidated criteria for reporting qualitative research [20].Objectives ::: MethodsThe purpose of this study was to gain a better understanding of the quarantine experiences of close contacts during the quarantine.Objectives ::: MethodsOur two main research questions are as follows:1.How did your emotions change during the quarantine?2.What strategies did you adopt or what support did you receive to cope with your emotional changes during the quarantine?", [["this study", "TEST", 48, 58], ["Methods", "TREATMENT", 160, 167], ["this study", "TEST", 182, 192], ["your emotions change", "PROBLEM", 377, 397], ["your emotional changes", "PROBLEM", 497, 519]]]]}